VOLUME 16
2026 978-3-928383-98-1
16th European Biotechnology Guide
Proven Expertise and Customized End-To-End Solutions for Your Products Clinical & Commercial
Over 100 years of trusted Drug Substance Cell Culture / Microbial: 200L – 800L – 2000L and Fill-Finish Solutions • •
• •
Oncolytic Viruses
Drug Substance Manufacturing
Drug Product Manufacturing
Recombinant Proteins Monoclonal Antibodies
Process Development
Vaccines
• •
Gene & Immune Therapeutics
Science & Industry
Biosimilars
Labeling & Packaging
European Biotechnology Guide
Quality Control & Analytics
Seamless project integration and a reliable supply chain – powered by our expert transfer team. Contact us
IDT Biologika Dessau-Rosslau, Germany
www.idt-biologika.com
2026
Proud to be part of the SK bioscience family.
Publication Partners
European Biotechnology Guide Science & Industry
© Knowbio GbmH, Berlin 2026 European Biotechnology Science & Industry Guide 2026 (Vol. 16) Published by: Knowbio GmbH Jacobsenweg 61 13509 Berlin, Germany Tel. +49-30-264921-0 service@knowb.io www.knowb.io Editor: Joachim Eeckhout Executive Producer: Andreas Macht Production: Martina Willnow Graphic Design: Michaela Reblin/Martina Willnow Printed at: PIEREG Druckcenter Berlin GmbH This book is protected by copyright. All rights including those regarding translation, reprinting and reproduction reserved. No part of this book covered by the copyright hereon may be processed, reproduced, and proliferated in any form or by any means (graphic, electronic, or mechanical, including photocopying, recording, taping, or via information storage and retrieval systems, and the Internet). The copyright for the printed photos is held by the presented companies. ISBN: 978-3-928383-98-1
Editorial
Europe invents. Now it must scale. Europe’s biotech story going into 2026 is not one of shrinking ambition but one of sharpening focus. After a year in which European Healthcare & Life Sciences venture funding reached €9.903bn (with Biotech/Pharma taking €4.599bn)1, capital proved available, but increasingly conditional: strong science, clear differentiation, and a believable path to scale. The deal tape reinforced that selectivity. European life sciences transactions surged in Q3 2025 (with mega-deals such as MSD’s $10 bn acquisition of Verona Pharma and Genmab’s $8 bn acquisition of Merus) before cooling again in Q4 – a pattern that looks less like “boom and bust” and more like a market separating signal from noise. The good news is that Europe’s innovation engine kept turning. In 2025, the EMA recommended 104 medicines for EU marketing authorisation2, including 38 with a new active substance and 41 biosimilars, a powerful mix of breakthrough science and cost-relief through competition. And the clinical trials system is becoming more predictable: in Q4 2025, the EU Clinical Trials Information System (the European Union’s centralized clinical trial portal) averaged 211 new trial applications per month, with a median 108 days from submission to decision3. Early 2026 didn’t start quietly either: at its January 2026 meeting, EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended six new medicines for approval, alongside nine extensions of therapeutic indications.
Joachim Eeckhout CEO
So why does 2026 feel like a make‑or‑break year? Because Europe’s chronic weakness is no longer a quiet inconvenience; it’s the headline. In February 2026, leading investors launched the European Life Sciences Coalition, pointing out that Europe accounts for just 7% of global life sciences VC and that most EU biotech IPOs in recent years chose to list outside the EU. The early-year funding pulse underlines the point: Europe raised only $141.4m across five private biotech rounds in January 2026, a sharp drop from $978.3m across 11 rounds in January 20254. This isn’t a lack of ideas; it’s a bottleneck in scaling. If European biotech wants to succeed in 2026, the next months should be about turning policy intent into deployable capital and faster execution. The EU’s 2025 Life Sciences Strategy (backed by €10bn+ annually) and the European Biotech Act package point to the right levers: investment pilots with the European Investment Bank, quicker multi‑country trials, regulatory sandboxes, and serious support for biomanufacturing and advanced therapies. Add instruments like EIC STEP Scale Up (with €10–30m tickets and a €300m 2026 budget), and the pieces are on the table. The test for 2026 is straightforward: can Europe finance fewer projects, but take more of them all the way from data to clinic to factory to patients? If it can, the narrative changes from “Europe invents, others scale” to a far more strategic one: Europe builds companies of global consequence, on European soil, with European capital. Three watchpoints will reveal whether the shift is real: more European growth rounds that keep headquarters and manufacturing in-region; faster, more harmonised clinical development across countries; and sustained dealmaking that rewards quality biology, not hype. Europe has always had the science. 2026 is the year it has to prove it can scale it.
1 FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 12/2025 2
Human medicine in 2025, EMA
Monitoring the European clinical trials environment, A deliverable of the ACT EU Priority Action 2 October-December 2025, EMA 3
4
Labiotech.eu’s fundraising tracker
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
2|3
Connecting Life Science Innovation With a Global Audience. We combine strategic communication and marketing with the power of leading life science media brands.
Life
scie nces med ia
Built on experience. Focused on what’s next.
Knowbio GmbH I Lessingstr. 12 I 16552 Mühlenbecker Land I www.knowb.io
Content
Editorial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3
Hochschule Campus Wien HCW . . . . . . . . . .
. . .
72
IDT Biologika GmbH . . . . . . . . . . . . . . . . . . . .
. . .
74
Immunic Therapeutics . . . . . . . . . . . . . . . . . .
. . .
76
Introduction . . . . . . . . . . . . . . . . . . . . . . . .
7
Intravacc B.V . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
78
Prefaces of Cooperation Partners . .
13
iOmx Therapeutics AG . . . . . . . . . . . . . . . . . .
. . .
80
BIO Deutschland e. V. . . . . . . . . . . . . . . . . . . . . . ....
14
IZB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
82
BIOTECH AUSTRIA . . . . . . . . . . . . . . . . . . . . . . ....
15
Kupando GmbH . . . . . . . . . . . . . . . . . . . . . . .
. . .
84
Hungarian Biotechnology Association . . . . . . . . ....
16
Lipotype . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
86
Medicon Valley Alliance . . . . . . . . . . . . . . . . . . . . ....
17
Maiwald GmbH . . . . . . . . . . . . . . . . . . . . . . . .
. . .
88
Microcoat Biotechnologie GmbH . . . . . . . . . .
. . .
90
Profiles. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19
Microsynth AG . . . . . . . . . . . . . . . . . . . . . . . .
. . .
92
360 law Firm . . . . . . . . . . . . . . . . . . . . . . . . . .
20
Navigo Proteins GmbH . . . . . . . . . . . . . . . . . .
. . .
94
. . .
96
. . . .
3PBIOVIAN . . . . . . . . . . . . . . . . . . . . . . .
. . . .
22
Navigo Pure . . . . . . . . . . . . . . . . . . . . . . . . . .
ABclonal Germany GmbH. . . . . . . . . . . . . . . .
. . .
24
Neovii Biotech GmbH . . . . . . . . . . . . . . . . . . .
. . .
98
Absea Biotechnology GmbH . . . . . . . . . . . . .
. . .
26
New England Biolabs GmbH . . . . . . . . . . . . .
. . .
100
. . .
102
ACIB GmbH . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
28
Northway Biotech | UAB Biopharma . . . . . . .
AiCuris Anti-infective Cures AG . . . . . . . . . . .
. . .
30
Omicron-Laserage® Laserprodukte GmbH . .
. . .
104
. . .
106
AIT Austrian Institute of Technology GmbH . .
. . .
32
Pharmahungary™ Group . . . . . . . . . . . . . . . .
Axolabs LGC Limited . . . . . . . . . . . . . . . . . . .
. . .
34
PlasmidFactory . . . . . . . . . . . . . . . . . . . . . . . .
. . .
108
Biaffin GmbH & Co KG . . . . . . . . . . . . . . . . . .
. . .
36
ProBioGen . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
110
. . .
112
Bioengineering AG . . . . . . . . . . . . . . . . . . . . .
. . .
38
ProJect Pharmaceutics GmbH . . . . . . . . . . . .
Biomay AG . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
40
Promega Corporation . . . . . . . . . . . . . . . . . . .
. . .
114
BioNTech . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
42
PSM Saar GmbH . . . . . . . . . . . . . . . . . . . . . .
. . .
116
. . .
118
Boehringer Ingelheim . . . . . . . . . . . . . . . . . . .
. . .
44
QUANTRO Therapeutics GmbH . . . . . . . . . . .
CeGat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
46
Rentschler Biopharma SE . . . . . . . . . . . . . . .
. . .
120
. . .
122
Collaborative Drug Discovery . . . . . . . . . . . . .
. . .
48
Richter- Biologics . . . . . . . . . . . . . . . . . . . . . .
Comprei . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
50
SciRhom . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
124
CZ Vaccines . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . .
52
Valicare GmbH . . . . . . . . . . . . . . . . . . . . . . . .
. . .
126
. . .
128
DC Advisory Daiwa Corporate Advisroy . . . . .
. . .
54
Vetter Pharma International GmbH. . . . . . . . .
Enzymicals AG . . . . . . . . . . . . . . . . . . . . . . . .
. . .
56
x-act Cologne . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
130
EVONIK Operations GmbH . . . . . . . . . . . . . .
. . .
58
YMC Europe . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
132
Yumab GmbH . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
134
Evotec SE . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
60
FGK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
62
Formycon AG . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
64
Start ups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
136
Galimedix Therapeutics, Inc. . . . . . . . . . . . . .
. . .
66
Loop Lab Bio GmbH. . . . . . . . . . . . . . . . . . .
. . .
137
Health Capital Berlin-Brandenburg . . . . . . . . .
. . . .
68
Oligo Peptide Service Technology GmbH . . .
. . .
138
70
RIANA Therapeutics GmbH . . . . . . . . . . . . . .
. . .
139
HistologiX . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
4|5
Engage with customers all over Europe Europe is a common research area and, for the industry, it represents a huge unified market with more than 500 million potential customers. The magazine European Biotechnology has been both monitoring and shaping this economic area for 24 years now. Together, we can keep improving. Join us!
Annual subscription €120 Please order online: european-biotechnology.com
Knowbio GmbH I Jacobsenweg 61 I 13509 Berlin I www.knowb.io
Introduction
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
6|7
European biotech in 2025: the year the market re-learned how to scale Europe entered 2025 with a familiar contradiction: world-class science and clinical execution, but a capital market that still rewards certainty over ambition. Across the year, that tension produced a “two speed” market. Platforms with credible differentiation (especially in oncology, ADCs, immunology, radiopharma and next gen vaccines) could raise large rounds and attract global buyers. At the same time, many companies outside the top tier faced down rounds, extended runways, or “quiet” strategic reviews. What changed versus 2023–2024 wasn’t that risk suddenly became cheap again. It was that buyers and investors became more willing to pay for derisking. In practice, Europe’s best companies increasingly competed on three attributes: (1) quality of early human data, (2) manufacturing readiness (for complex modalities), and (3) a narrative that survived stricter diligence. The result was a year where Europe looked less like a peripheral R&D outpost and more like a set of specialised, interconnected clusters feeding a global deal machine. Financing: Bigger tickets, tighter filters In 2025, total venture financing for European Healthcare & Life Sciences reached €9.903bn, with Biotech/Pharma taking 46% (€4.599bn)1. Oncology remained the largest biotech indication (30% of biotech/pharma volume). The headline number matters, but the composition matters more: capital concentrated around fewer “must own” stories, while the middle of the market faced tougher valuation negotiations and more selective investors. Quarterly deal data shows how uneven the year really was. In Q1 2025, KPMG estimated that the total VC & growth capital deal value reached ~US$2.4bn; Q2 jumped to ~US$5.6bn; Q3 surged to ~US$20.3bn (an anomaly due to CapVest’s majority stake in STADA, a consumer healthcare and generics specialist at an estimated deal value over US$11 billion); and Q4 cooled to ~US$5.2bn2. This pattern – quiet start, mid year lift, Q3 spike, then normalisation – matches what many founders ex-
perienced: long fundraising cycles, punctuated by short windows where real appetite returned. Behind the numbers, three funding dynamics defined 2025: › “Platform premium” over “single asset premium”. Investors consistently preferred modality platforms (ADC tech, bispecific discovery engines, radiopharma supply chains) over one-shot Phase II bets, unless the Phase II dataset was unusually clean and commercial. This helped explain why certain European companies raised very large rounds even as the median venture round remained tough. › Syndicates widened geographically but narrowed institutionally. The most competitive rounds increasingly combined a small set of repeat specialist investors with selective crossover participation. › Structured financing and “balance sheet engineering” became normal. Debt, royalty deals, and milestone-based tranches were no longer “last resort” options but a strategic choice to avoid punitive equity pricing and to bridge to catalysts. A few financings illustrate the market’s barbell shape. Verdiva Bio’s US$410m Series A in Q1 (GLP 1/metabolic focus) and Tubulis’ $400m raise in Q4 (next generation ADC platform) were among the biggest private rounds of the year. At the same time, month-to-month monitor data suggests that many of the year’s “top deals” were still sub €100m. In other words, Europe’s financing engine worked in 2025, but it worked best at the extremes: either very big, globally resonant stories, or disciplined rounds sized for clear milestones. Q2 also showed that “non-dilutive” remained available for specific theses. We can point to the $262.5m debt financing for ITM Isotope Technologies Munich (radiopharma) as a good example. Dealmaking: Europe as both hunter and hunted If 2025 had a signature, it was the return of mega deals around European targets and, importantly,
80 70 60
1057 12,20 820
33,50
6,90
17,50
5,20
705
50
6,70 8,60
40 30
700 570 7,10
8,00 11,60
48,70
50,20 33,00
20
37,10
26,80
10 0
2021 M&A
2022 IPOs / follow-ons
2023 VC & growth capital
2024 Nb of deals
2025
Fig. 1: Life sciences deals in Europe
the rise of European buyers. The year’s M&A wasn’t just US pharma “shopping Europe”; it increasingly included European champions consolidating strategically.
Source: KPMG European Life Sciences Deals Overview
Q1 set the tone with targeted technology buys. AstraZeneca agreed to acquire Belgium based EsoBiotec for up to US$1bn to advance in vivo cell therapy delivery, an example of big pharma paying for platform optionality rather than a single late stage asset. In oncology, Japan’s Taiho moved on Switzerland’s Araris Biotech for $400m upfront plus potential milestones of up to $740m; the strategic logic was clear: access to an ADC conjugation approach aimed at improved stability and tolerability. Q2 reminded the market that “strategic consolidation” can be as important as new R&D. BioNTech’s agreement to acquire CureVac in an all-stock deal (implied value around $1.25bn) has been seen as a high-profile European-to-European combination, aimed at strengthening mRNA capabilities and creating a more scaled platform for oncology and infectious disease programmes. Q3 was the breakout quarter. KPMG estimated European M&A value at $21.1bn in Q3, led by MSD’s
$10bn acquisition of Verona Pharma (commercial respiratory foothold via a first-in-class dual PDE3/4 inhibitor) and Genmab’s $8bn acquisition of Merus (late-stage bispecific oncology asset with Phase 3 ambitions). The same quarter also featured Sanofi’s agreement to acquire UK vaccine biotech Vicebio for up to $1.6bn, and Sandoz’s move to buy Evotec’s Toulouse biologics manufacturing site in a $350m transaction; evidence that “control of manufacturing” is becoming part of Europe’s competitive story, not just a cost center. Q4 didn’t replicate Q3’s headline mega deals, but it reinforced that strategic buying remained open when the fit was tight. Alkermes’ ~$2.4bn acquisition of Avadel (narcolepsy), Ipsen’s $1bn acquisition of ImCheck (immuno oncology), and AstraZeneca’s acquisition of SixPeaks Bio for up to $300m (metabolic / obesity-related antibody–peptide conjugation). Two strategic themes cut across these deals: › De risked differentiation wins. Buyers paid for latestage confidence (Verona), for “clean” oncology assets with clear path to market (Merus), or for platforms that could unlock multiple programmes (EsoBiotec, Vicebio). In a market still skeptical of long-duration risk, the fastest way to value was to reduce the number of things that can go wrong. 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
8|9
Europe’s IPO market remained dormant in 2025, but public capital became a meaningful “second channel” through follow-ons and alternative listings. KPMG noted a steady drumbeat of sizeable follow-on offerings (e.g., Abivax’s ~US$650m follow-on in Q3 and multiple Q4 raises above US$75m). In other words, public investors were willing to fund companies with a clear catalyst path and sufficient liquidity, even if the classic “IPO window” never fully reopened.
› Europe’s buyers are learning to play of fense. Genmab and BioNTech, in particular, are signaling a direction of travel. European companies with real cash generation or credible balance sheets increasingly act as consolidators, not only licensors. For the ecosystem, this matters: local acquirers can keep talent, programmes and manufacturing anchored in Europe while still operating globally.
Rank
Company (HQ)
Headquarter
Original amount
Standardised EUR amount
Round type
Date (2025)
Focus
1
Abivax
France
US$650M
€575M
Public offering
July
Chronic inflammatory diseases
2
Isomorphic Labs
U.K.
US$600M
€531M
Private round
March
AI drug discovery/design
3
MoonLake Immunotherapeutics
Switzerland
Up to US$500M
€442M
Non-dilutive debt
April
Inflammation / immunology
4
Verdiva Bio
U.K. / U.S.A.
US$411M
€305M
Series A
January
Cardiometabolic / obesity
5
uniQure
Netherlands
US$345M
€364M
Public offering
September
Gene therapy
6
Tubulis
Germany
€308M
€308M
Series C
October
ADC platform
7
ITM
Germany
Up to US$262.5M
€232M
Non-dilutive debt
May
Radiopharma
8
Centessa Pharmaceuticals
U.K. / U.S.A.
US$250M
€221M
Public offering
November
Neurological disorders & immuno-oncology
9
Pharvaris
Switzerland
US$175M
€155M
Public offering
July
Hereditary angioedema
10
Bavarian Nordic
Denmark
US$160M
€142M
Non-dilutive asset sale
June
Vaccines
11
Hemab Therapeutics
Denmark / U.S.A.
US$157M
€139M
Series C
October
Bleeding disorders
12
AAVantgarde Bio
Italy / U.K.
US$141M
€124M
Series B
November
Ocular gene therapy
13
Draig Therapeutics
U.K.
US$140M
€119M
Series A
June
Neuropsychiatric disorders
14
SpliceBio
Spain
US$135M
€106M
Series B
June
Stargardt disease & genetic medicines
15
CellCentric
U.K. / U.S.A.
US$120M
€125M
Series C
May
Oncology
16
Oculis
Switzerland
US$110M
€97M
Public offering
October
Ophthalmology / neuroophthalmology
17
Granite Bio
Switzerland
US$100M
€88M
Series A/B combined
April
Immunology
18
NUCLIDIUM
Switzerland / Germany
CHF 79M
€84M
Series B
July
Radiopharma
19
Actithera
Norway
US$75.5M
€67M
Series A
July
Radiopharma
20
Maxion Therapeutics
U.K.
US$72M
€64M
Series A
March
Ion channels/GPCR targets
Table 1: Top 20 largest biotech funding rounds in 2025
A key implication for European management teams: fundraising strategy has to be multi-track. In 2025, the strongest companies prepared to raise privately, publicly, or via strategic partnerships, then took whichever route priced best when timing aligned. This is increasingly a core competence, not a niceto-have.
Picture: © Habibur Rahaman - Freepik.com
Geography: A network of specialised clusters Europe’s biotech market is often described as fragmented. In 2025, that fragmentation increasingly looked like specialization. Rather than one dominant hub, Europe functions as a network of clusters with distinct comparative advantages and the year’s biggest deals often connected them. DACH (Germany, Switzerland, Austria) continued to excel in deep tech therapeutics, translational science, and industrial execution. Switzerland remained a magnet for oncology and platform companies. Germany’s ecosystem showed how quickly platforms can scale when paired with global capital (BioNTech’s consolidation move on CureVac; Tubulis’ large raise). Basel’s pharma gravitational pull still matters, but more activity now sits around Zurich, Munich and Berlin as engineering-heavy biology expands. The U.K. & Ireland remained Europe’s most liquid “interface” with U.S. capital markets and global pharma. The UK’s ability to produce assets that are both clinically advanced and commercially viable
showed up in Vicebio’s acquisition by Sanofi and Verona’s acquisition by MSD. In 2025, the UK’s role wasn’t just discovery; it was de-risking: companies that can generate decisive Phase II/III evidence and package it for global buyers. Benelux continued to punch above its weight in biologics engineering and cross-border company building. The Genmab-Merus combination is an emblematic intra-European consolidation: Danish capital and commercial experience buying Dutch late-stage oncology strength. Belgium’s role in advanced therapies was reinforced by EsoBiotec’s acquisition, which also highlights how smaller geographies can produce platform technologies attractive to the largest buyers. The Nordics remained strong in immunology, enabling tech, and capital-efficient execution. Denmark’s presence is obvious via Genmab and December’s top financing (Sidera Bio). Sweden and Finland continued to contribute deep science and device/diagnostics capability, of ten as par t of broader European syndicates. France and Southern Europe continued to build depth, especially in biologics manufacturing, vaccines, and medtech/robotics. The Evotec–Sandoz Toulouse transaction illustrates how manufacturing capacity in Europe can be repositioned as strategic infrastructure. Meanwhile, clusters in Paris-Saclay and Barcelona increasingly look like “talent engines” 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
10 | 11
Rank
Acquirer → Target
Acquirer HQ
Target HQ
Announced (2025)
Original deal value
Standardised EUR deal value
Acquired asset
1
Novartis → Avidity Biosciences
Switzerland
U.S.A.
October
$12.0B
€10.62B
RNA delivery to muscle
2
MSD (Merck & Co.) → Verona Pharma
U.S.A.
U.K.
July
$10.0B
€8.85B
COPD inhaled drug
3
Sanofi → Blueprint Medicines
France
U.S.A.
June
$9.5B
€8.41B
Allergy/inflammation and oncology/ hematology
4
Genmab → Merus
Denmark
Netherlands
September
$8.0B
€7.08B
Bispecific antibodies
5
Novo Nordisk → Akero Therapeutics
Denmark
U.S.A.
October
$5.2B
€4.60B
MASH
6
Merck KGaA → SpringWorks Therapeutics
Germany
U.S.A.
April
$3.9B
€3.45B
Oncology + rare disease
7
Roche → 89bio
Switzerland
U.S.A.
September
$3.5B
€3.10B
MASH
8
Novartis → Anthos Therapeutics
Switzerland
U.S.A.
February
$3.1B
€2.74B
FXI inhibition mAb
9
Nordic Capital / Permira → Bavarian Nordic
Sweden / U.K.
Denmark
July
$3.0B
€2.65B
Vaccines
10
Alkermes → Avadel
Ireland
Ireland
November
$2.1B
€2.37B
Narcolepsy
11
Sanofi → Dren Bio asset (DR-0201)
France
U.S.A.
March
$1.9B
€1.68B
Myeloid engager for deep B-cell depletion
12
Novartis → Regulus Therapeutics
Switzerland
U.S.A.
April
$1.7B
€1.50B
microRNA therapeutics
13
Sanofi → Vicebio
France
U.K.
July
$1.6B
€1.42B
Respiratory vaccines
14
Novartis → Tourmaline Bio
Switzerland
U.S.A.
September
$1.4B
€1.24B
Anti-IL-6 mAb
15
BioNTech → CureVac
Germany
Germany
June
$1.25B
€1.11B
mRNA
16
GSK → IDRx
U.K.
U.S.A.
January
$1.15B
€1.02B
Precision oncology
17
Taiho Pharmaceutical → Araris Biotech
Japan
Switzerland
March
$1.14B
€1.01B
Next-gen ADC conjugation platform
18
AstraZeneca → EsoBiotec
U.K.
Belgium
March
$1.0B
€0.88B
In-vivo CAR-T
19
Ipsen → ImCheck Therapeutics
France
France
October
€1.0B
€1.00B
Immuno-oncology
20
Sanofi → Vigil Neuroscience
France
U.S.A.
May
$0.6B
€0.53B
Neuroinflammation
Table 2: Top 20 largest biotech M&A deals in 2025
that feed pan-European teams rather than purely local companies. The practical takeaway: in 2025, Europe’s competitive advantage was less about “one winner city” and more about the ability to stitch capabilities together: science in one hub, engineering in another, trials across multiple countries, and financing syndicated internationally. What 2025 sets up for the European biotech story 2025 did not “solve” Europe’s biotech financing gap, but it clarified the playbook for winning in the current regime. European biotech performed best when it combined differentiated science with credible execution, used capital efficiently, and kept multiple financing/exit pathways open. The year’s mega deals demonstrated that global buyers will
pay for European assets when risk is reduced and that Europ ean champions are increasingly willing to buy, not just sell. If 2024 was about survival, 2025 was about selection. The companies that emerged stronger are those that treated the market as it is, not as it was: a market that prices proof, platform leverage, and operational readiness. That’s a tougher standard, but it’s also how European biotech becomes a market that can scale.
Joachim Eeckhout
1
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 12/2025
2
European Life Sciences Deals Overview Q4 2025, KPMG
Our Cooperation Partners
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
12 | 13
Unlocking Economic Growth through Biotechnology German biotechnology sent a positive signal in 2025. With equity financing of approximately €1.79 billion, the industry held its ground in a challenging environment. Although total financing volume was around 7% below 2024, the strong momentum in the second half demonstrated the sector’s resilience and long-term potential. Capital market developments were particularly notable. Listed companies increased their financing proceeds, raising €1.2 billion – a 20% increase from 2024. At the same time, venture capital investment declined to €593 million. This divergence highlights how differentiated the market has become and underscores the importance of strengthening capabilities for growth financing to ensure that promising innovations reach commercial scale.
Investment in biotechnology is investment in innovation, highly skilled employment and economic resilience. The sector is not a niche industry. It is a strategic growth driver with substantial potential to strengthen prosperity and public health. This company guide demonstrates the diversity, research intensity and entrepreneurial ambition of Germany’s biotechnology ecosystem. By working together, we can ensure that scientific excellence translates into sustainable economic strength, and that innovative ideas become solutions to the major challenges of our time.
The steady number of seed rounds in 2025 is encouraging for the future and reflects the scientific excellence of Germany’s research landscape. Yet the scale-up phase remains a critical bottleneck. It is during the transition from early development to international expansion that companies decide whether to grow in Europe or relocate abroad. The international comparison is stark: while €593 million in venture capital was invested in Germany throughout the year, biotechnology companies in the United States raised more than €14 billion in the first nine months of 2025 alone.
To secure technological sovereignty and long-term value creation in Europe, we must act decisively. This includes more competitive tax policies, consistent reduction of administrative burdens, rapid implementation of growth and scale-up funds, effective execution of the High-Tech Agenda Germany, and timely implementation of the European Biotech Act.
For more information: Roland Sackers President of BIO Deutschland e. V. Schützenstraße 6a 10117 Berlin info@biodeutschland.org → www.biodeutschland.org
Picture: © QIAGEN
Access to capital markets is essential, but it is not sufficient. The industry’s business models range from therapeutic and diagnostic development to contract research, manufacturing, sustainable food and biobased materials. Each segment requires competitive and reliable framework conditions.
Austria’s Biotech: United. Innovative. Impactful. Biotechnology thrives on exchange, collaboration and trust. Creating the right formats for meaningful dialogue is therefore at the heart of what BIOTECH AUSTRIA stands for. As we enter our sixth year, we are proud to contribute to the European Biotechnology Guide 2026 and to highlight the strength and maturity of Austria’s biotech community.
All of this takes place in a highly supportive environment. Austria’s inclusion of biotechnology as a key industry in the Industrial Strategy 2035, a dynamic start up and scale up landscape, strong public agencies such as FFG, aws, ABA and regional business agencies, and the excellence of universities and research institutes provide fertile ground for growth and ambition.
BIOTECH AUSTRIA is the independent association representing the Austrian biotechnology sector. Our role is to connect, convene and give a strong, coherent voice to the ecosystem. We bring together companies, researchers, investors, institutions and public stakeholders, and provide structured platforms where ideas can develop into action.
At the same time, the sector is entering a decisive phase. Upcoming initiatives such as the EU Biotech Act, discussions on regulatory simplification, access to infrastructure, and the availability of competitive scale up financing will shape Europe’s ability to translate scientific excellence into global impact. For many companies, bridging the gap from early innovation to industrial and commercial scale remains a central challenge. Addressing these issues requires close coordination between industry, policymakers, investors and public institutions. Biotechnology is a long term endeavour, built on collaboration and confidence in innovation. With engaged members, effective formats and a clear commitment to dialogue, BIOTECH AUSTRIA looks ahead with optimism — ready to help shape the next chapter of European biotechnology.
A cornerstone of our work are our Working Groups, Task Forces and Policy Groups. These member driven formats enable focused exchange on key topics such as regulation, financing, manufacturing, talent and sustainability. They combine technical expertise with practical experience and feed directly into our policy positions and recommendations, ensuring that the perspectives of the biotech community are heard and understood at national and European level.
Equally important are our community and visibility formats. The Biotech Austria Circle offers a trusted space for strategic discussion among senior leaders, fostering long term relationships and shared understanding across the ecosystem. Our Annual Biotech Summit Austria has become a flagship event, bringing together national and international stakeholders to discuss trends, challenges and opportunities shaping the future of biotechnology. These events are designed not only to inform, but to inspire, connect and strengthen the sense of a shared mission.
For more information: Peter Llewellyn-Davies President, BIOTECH AUSTRIA biotechaustria.org
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
14 | 15
Positioning Hungary within the global biotech landscape The Hungarian Biotechnology Association is entering a new phase of development, with strengthened strategic focus and expanded activity aimed at enhancing Hungary’s visibility and integration within the international life sciences community. Hungary has a strong scientific tradition and a growing biotech sector spanning drug discovery, medical technology, diagnostics, and translational research. However, the ecosystem has remained fragmented, with limited international representation and coordination. Our Association is working to change this.
Building a connected biotech community
A strengthened platform for collaboration The Hungarian Biotechnology Association is evolving into an open, collaborative platform, shaped by its members. With clear strategic focus and active governance, the Association aims to be a trusted partner for international stakeholders looking to engage and collaborate. We welcome connections with clusters, companies, investors, and institutions interested in engaging with Hungary’s evolving biotech landscape.
Contact www.linkedin.com/company/hungarianbiotech info@biotechhungary.hu
Our mission is to act as a catalyst for the Hungarian biotech ecosystem by connecting industry, academia, investors, and policymakers. We aim to provide a professional platform that supports collaboration, knowledge exchange, and international engagement.
Enabling international integration Hungarian biotech companies and research groups offer strong expertise in areas such as oncology, CNS therapeutics, advanced diagnostics, and medical device innovation. Strengthening their presence at leading partnering events and international platforms is essential for accelerating collaboration and investment opportunities.
For more information: Zita Sepsi Managing Director Szilánk köz 3., 6724 Szeged, Hungary +36205023606 zita.sepsi@hungarianbiotech.org
MEDICON VALLEY ALLIANCE – YOUR GATEWAY TO THE NORDICS Medicon Valley Alliance (MVA) is a leading non-profit membership organisation with more than 300 members. It is dedicated to fostering both collaboration and innovation within the life sciences sector across the Medicon Valley region, which spans eastern Denmark and southern Sweden, and collaboration between the Medicon Valley life science ecosystem and other leading European/international life science hubs. Established in 1997, MVA brings together universities, hospitals, companies, and regional governments, creating a dynamic network that drives growth in biotechnology, pharmaceuticals, and medical technology. Its mission is to facilitate cross-border partnerships, promote knowledge sharing, and support the commercialisation of research, ultimately strengthening the region’s global competitiveness in health and life sciences.
Who and why MVA’s membership comprises a diverse group of stakeholders, including start-ups, established enterprises, academic institutions, and public organisations. This diversity forms the backbone of the alliance, ensuring a rich environment for interdisciplinary collaboration. Members benefit from access to numerous networking events, conferences, and workshops organised throughout the year, which provide opportunities to connect with industry leaders, researchers, and policymakers. These events are designed to foster innovation, initiate joint projects, and enable members to stay abreast of the latest trends and regulatory changes affecting the sector. One of the key benefits of MVA membership is the ability to tap into the alliance’s extensive network. This connectivity makes it easier for organisations to find partners for research, development, and commercialisation projects. The shared resources and expertise available within the alliance reduce barriers to entry for smaller companies, helping them scale more rapidly and effectively. Larger enterprises gain access to cutting-edge research and emerging technologies, while academic institutions and hospitals find industrial partners for clinical trials and translational research. Members of Medicon Valley Alliance also enjoy enhanced visibility within the international life sciences community. MVA actively promotes its members through
international delegations, marketing initiatives, and participation in global conferences. This exposure facilitates access to new markets, investors, and strategic partners, boosting growth and innovation. The alliance’s advocacy work ensures that the interests of its members are represented in regional and national policy discussions, contributing to a supportive business environment and favourable regulatory frameworks.
A buzzing meeting and market place Beyond networking and advocacy, MVA provides members with tailored services such as market intelligence, industry reports, and matchmaking support. These services help organisations navigate complex business landscapes, identify emerging opportunities, and make informed strategic decisions. The alliance also coordinates thematic working groups that address critical issues such as clinical trials, regulatory affairs, and digital health, enabling members to collaborate on solutions and share best practices. Membership in Medicon Valley Alliance is a strategic investment for any organisation seeking to thrive in the life sciences sector. The combination of collaborative opportunities, access to resources, visibility, and advocacy makes MVA an indispensable partner for growth and innovation. Whether a start-up looking to scale, an established company seeking new markets, or an academic institution pursuing collaborative research, MVA offers unparalleled support in advancing the ambitions of its members and contributing to the region’s reputation as a global hub for health and life sciences.
For more information: David Munis Zepernick Director Member Engagement and Communication, Medicon Valley Alliance Arne Jacobsens Allé 15, 2, DK 2300 Copenhagen +45 24 98 16 68, dz@mva.org → www.mva.org 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
16 | 17
Profiles
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
18 | 19
Name › 360 Law Firm Address/P.O. Box › Lautrupsgade 7 Postal Code/City › DK-2100 Country › Denmark Telephone › +45-69-16-63-60 Email › info@360-lawfirm.com Website › www.360-lawfirm.com Social Media › I Number of Employees › 21 Founded (year) › 2020 Areas of Activity › Legal services, business advisory, entering and establishing companies in the Nordic Region, work permits
360 Law Firm – Your Partner for Biotech and Life Science Expansion into Denmark and the Nordics 360 Law Firm provides comprehensive, 360-degree legal and business advice to help international companies in biotechnology, life sciences, pharmaceuticals, and medical technology establish, grow, and thrive in Denmark and across the Nordic region. Our clients also include organisations in clean technology, infrastructure, energy, and broader technology sectors.
What Sets Us Apart Our ability to combine deep legal expertise with an extensive network that strengthens your business is what sets us apart from your normal law firm. Our clients don’t just receive legal guidance – they gain access to connections that create real value and a dedicated business partner.
Networking as Part of the Solution At 360 Law Firm, we view networking as a core part of our solution. We’re not just legal experts; we engage with our clients’ businesses and the industries they operate in. Legal advice alone is no longer enough – it must be contextualised within your business and the broader environment. Our network development is a collective effort across the firm. The team collaborates closely with embassies, business promotion organisations, and industry leaders to create cross-border relationships that drive growth. From professional networks we co-founded to global industry collaborations, our connections turn legal support from a cost into an investment in your business development. Every member of the team contributes, ensuring our clients benefit from a wide, multi-layered network tailored to their specific needs.
Member of
360 L AW FIRM
A Dedicated Partner for Your Business When you work with 360 Law Firm, you receive a dedicated contact person – a single point of contact who knows your business, your organisation, and your ambitions. This means you gain a strategic partner, not just a lawyer for problem-solving. We actively engage with your team to support business development, help you navigate the regulatory landscape, and leverage our network to create opportunities. Our approach ensures that legal advice is aligned with your strategy, providing value far beyond conventional legal services.
More than Problem Solvers We’re not just problem solvers; we foster development. This is why large international organisations choose us, even when compared with much larger firms. Discover how 360 Law Firm can help you enter and grow in Denmark and the Nordics, with access to both expert advice and an invaluable network. Visit us at www.360-lawfirm.com or call us at +45 69 16 63 60.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
20 | 21
Name › 3PBIOVIAN Manufacturing site Address/P.O. Box › Polígono Mocholi, Plaza Cein, 1 Postal Code/City › 31110 Noáin Country › Spain Manufacturing site Address/P.O. Box › Tykistökatu 6A, Biocity Postal Code/City › 20520 Turku Country › Finland Commercial office Address/P.O. Box › 53 State Street, Suites 503 504 Postal Code/City › 02109 Boston Country › MA (USA) Contact Person › Timothy Scott Gomez (Director of Business Development) Telephone › +34-948-34-64-80 +35-8-50-3650973 Email › businessdevelopment@3pbiovian.com Website › www.3pbiovian.com Social Media › I Number of Employees › 550+ Areas of Activity › | Biotechnology | Biomedicine | CDMO | GMP | Biologics | Recombinant Proteins | Advanced Therapies | Viral Vectors | Plasmid DNA | Fill & Finish
Affinity in the making 3PBIOVIAN is a globally operating Contract Development and Manufacturing Organisation (CDMO), providing unparalleled end-to-end development and manufacturing services for biologics and advanced therapies. Collaboration is at the core of how we work. We partner closely with our clients, adapting to their unique needs and guiding them through every stage: from clinical development and trials to commercial production. Our client-oriented approach ensures seamless project execution and efficient progression. Our service offering spans multiple platforms, including microbial and mammalian expression systems, adenoviruses, adeno-associated viruses (AAV), our exclusive AAVion® Platform, plasmid DNA and cell therapy. With a diverse range of bioreactor sizes,we offer flexible production scaling to meet the needs of biopharmaceutical companies worldwide Leveraging decades of expertise and extensive capabilities, we position ourselves as a leading pan-European independent biologics CDMO, dedicated to advancing therapies that address patients’ unmet clinical needs, making advanced biologics and tomorrow’s life transforming therapies.
GMP certified 3PBIOVIAN offers GMP manufacturing services for microbial and mammalian protein expression platforms, viral vector production for adenoviruses and AAVs, cell therapy, and plasmid DNA production.
Summary of services › Plasmid DNA production › Cell line development › GMP cell banking and Virus Seed Stock production › Process development and optimisation › Technology transfer › Analytical methods development, qualification, and validation
3PBIOVIAN
› Scale-up and cGMP manufacturing › Formulation development › Fill and Finish › Quality Assurance (QA) and Quality Control (QC) › Drug Substance (DS) & Drug Product (DP) release
GMP manufacturing capacities › Mammalian, single use bioreactors: 50L, 200L, 400L, 2000L › Microbial, stainless-steel bioreactors: 10L, 100L, 200L, 500L, 1000L › Viral Vector manufacturing: • Adherent: Up to 500 m2 • Suspension: 10L, 25L, 50L and 200L › Plasmid DNA, stainless steel bioreactors: 25L, 40L, 200L
Our manufacturing sites Our manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland, seamlessly support the diverse needs of our clients, covering everything from pre-clinical and clinical supply to full-scale commercial manufacturing. In Turku, Finland, our manufacturing site boasts a workforce of around 200 employees and spans 5,100 m2, with an on-going expansion to 6,300 m2 within the GeneCity manufacturing facility. Our facilities feature dedicated capacities for GMP manufacturing, analytical methods development, quality control services, and fully automated aseptic fill-and-finish processes. In Pamplona, Spain, our manufacturing facility employs +350 people and encompasses an expansive area of 10,500 m2. It houses GMP manufacturing capabilities, state-of-the-art equipment and advanced technology for analytical method development and quality control assessments. Our flexible facilities, certified by EMA and inspected by the FDA, are continually expanding to accommodate the evolving landscape of cutting-edge biopharmaceutical manufacturing requirements.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
22 | 23
Name › ABclonal Germany GmbH Address/P.O. Box › Emanuel-Leutze-Straße 8 Postal Code/City › 40547 Dusseldorf Country › Germany Contact Person › Dr. Jing Lu Telephone › +49-211-1584-9841 Email › info@abclonal.com Website › abclonal.com Social Media › F I I Number of Employees › ~900 globally Founded (year) › 2022 for the Germany branch; 2011 for the parent company Type of Laboratory › ISO 9001 and ISO13485 certified Areas of Activity › | Develop and manufacture high quality reagents, including antibodies, recombinant proteins, molecular enzymes and NGS library preparation kits for research, IVD, CRO, and CDMO. | CRO service for antibody discovery, engineering, and production using hybridoma, single B cell, or phage display strategies. | CRO service for recombinant protein expression and peptide synthesis External › | The Michael J.Fox Foundation Collaborations | YCharOS | mAb3D Atlas | Histologix Ltd | Chimera Biotec GmbH
ABclonal Germany GmbH – Your European Partner in Global Life Sciences Innovation ABclonal is an innovative growth company aiming to provide reliable and cost-effective products and s ervices for both basic and translational research in cutting edge biomedical science. Innovation is our DNA, with worldwide R&D centres focusing on technical innovation and product development for protein science and molecular biology. ABclonal Germany GmbH, a strategic branch of A Bclonal Technology Co., Ltd., embodies the global vision and scientific excellence of its parent company while delivering localised expertise to researchers, biotech companies, and healthcare institutions across Europe. As part of ABclonal’s international network – supported by R&D, production, and commercial hubs spanning North America, Asia, and Europe – we are committed to advancing life sciences innovation worldwide.
Global Strength, Local Precision Leveraging ABclonal’s global infrastructure, ABclonal Germany provides European clients with direct a ccess to cutting-edge solutions in biological reagents, molecular enzymes, NGS automation, and antibody discovery services.
Why Partner with ABclonal Germany? › Trusted Globally, Rooted Locally: Join 100,000+ international customers who rely on ABclonal’s products, backed by our German team’s commitment to responsiveness and regulatory excellence. › End-to-End Solutions: From research antibodies to diagnostic materials, we provide products validated for global reproducibility, with logistics optimised for European timelines. › Sustainability & Compliance: Aligned with EU regulations and sustainability goals, we prioritise ethical practices and eco-friendly innovation.
ABCLONAL
Our Milestones
SMab™ Rabbit Recombinant Monoclonal Antibodies Novel Targets
MultiApplication
Lot-to-Lot Consistency
Ultra Sensitivity
High Specificity
Cross-Species Reactivity
› Antibody Production Services ABclonal was founded with a strong focus on providing customised antibody production services. Our mission has always been to enhance life science research by delivering better, high-quality antibodies. › Every Protein Should Have an Antibody We launched the Human Genome Antibody Project, aiming to document and generate an antibody for every protein encoded in the human genome. By utilising recombinant protein antigens, we have successfully developed over 20,000 rabbit polyclonal and monoclonal antibodies. › Next-Generation Sequencing (NGS) Leveraging the expertise of our molecular biologists and geneticists, we are developing cutting-edge NGS technology. Our goal is to produce innovative NGS library preparation kits while integrating advanced bioinformatics platforms. This will accelerate bio medical research and aid in the discovery of bio markers for genetic and epigenetic diseases.
Our Mission
Antibodies & Proteins Next-generation Sequencing Products
Molecular Enzymes & Raw Materials
To become a global leader in biomolecular solutions. Our Values: › Customers Come First – We prioritise our customers’ needs and success. › Collaboration Over Individualism – We believe in teamwork and shared achievements. › Clarity & Transparency – Honesty and openness drive our innovation. › Embracing Challenges – We see obstacles as opportunities for growth.
CRO Services
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
24 | 25
Name › Absea Biotechnology Address/P.O. Box › Building D95, Robert-Roessle-Str. 10 Postal Code/City › 13125 Berlin Country › Germany Contact Person › Philip Loessl Telephone › +49-30-94893560 Email › info@abseabio.com Website › www.absea.bio Social Media › I Number of Employees › 200+ Founded (year) › 2020 Areas of Activity › Comprehensive catalog: 40K+ mAbs, 14K+ human proteins, 13K+ isotopelabeled protein standards, 2K+ antibody pairs and IP-beads. High-throughput services: AI-guided protein construct design+production, mAb development+pairing+selective conjugation Large-scale data: multiplex IHC/IF/IP/ WB/FACS/ELISA, unique mass spec pipelines for pharma and AI
Proteome-scale reagent libraries and profiling technologies to advance biomedicine, pharma, and AI Absea Biotechnology provides a proteome-scale infrastructure for academic and industry partners worldwide. Our strong commitment to innovation, scalability and customization, we address critical gaps in the protein biotechnology market. Our vast biomolecule portfolio comprises >14,000 soluble human proteins, covering 70% of the human proteome. Over 90% of these proteins are readily producible as 15N-labeled standards, enabling biomarker detection with attomole sensitivity as well as multiplexed absolute protein quantification by MS. Our portfolio of >40,000 monoclonal antibodies (mAbs) is validated for applications such as ELISA, western blot, immunohistochemistry, immunofluorescence, immunoprecipitation, and flow cytometry. The mAbs are sequenced and ready to be engineered and recombinantly produced in our CHO cell platform. Our bespoke protein and antibody development benefits from AI- and data-driven technologies. Our proprietary SIEVE® algorithm allows us to achieve a >75% success rate in soluble protein expression, setting a new benchmark for efficiency and scalability in protein production. With InformAb™️ and SpeedyDate™️, we are able to produce and validate mAbs for up to 300 new targets each month. All these mAbs can be selectively functionalized with Absea’s USB® coupling chemistry.
ABSEA BIOTECHNOLOGY
Our MS-based Architectomics™ pipelines provide a holistic view of protein behavior, empowering drug discovery and biomedical research with actionable molecular insights. We offer three complementary programs: › Drug-centric: Proteome-wide profiling of on/off-targets and binding sites to better understand drug mechanisms. › Protein-centric: Mapping targeted interactomes, epitopes, paratopes, and disulfide bonds for in-depth characterization of protein therapeutics and disease markers. › Cell-wide: Discovering health and disease-related protein interaction networks, binding sites, structures, and localizations directly in intact human cells and microbes. Key application areas of our reagent and data solutions are › Early-stage drug discovery (e.g. E3ome panel with >200 mAbs for targeted degrader research) › Generation of ground-truth data for AI (e.g. biomolecular interaction networks with matched affinities) › Immunopeptidomics (e.g., IP-validated MHC antibody panel) › Clinical proteomics (e.g., heavy-isotope labeled protein standards) › Spatial pathology (e.g., >5,000 IHC-validated mAbs) › Neurobiology (e.g., >50 Tau phospho-isoform specific antibodies, APOE4-specific antibodies) › Immunology (e.g. comprehensive cytokine protein panel, Ig-subclass specific mAbs)
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
26 | 27
Name › Austrian Centre of Industrial Biotechnology (acib GmbH) Address/P.O. Box › Krenngasse 37 Postal Code/City › 8010 Graz Country › Austria Contact Person › Katrin Weinhandl Telephone › +43-664-88878904 Email › Katrin.weinhandl@acib.at Website › www.acib.at Social Media › I I Number of Employees › ca. 150 Founded (year) › 2010 Areas of Activity › Biocatalysis, Enzyme Technology, Renewable Resources & Biorefineries, Plant Biotechnology, Biodiversity, Sustainable Microbial Biotechnology, Bioprocess Technology, Biopharmaceuticals, Diagnostics
acib is an international, non‑profit research centre dedicated to advancing industrial biotechnology and strengthening the resilience of industrial value chains in the transition towards a sustainable, bio‑based economy. Headquartered in Graz, Austria, acib develops innovative, environmentally friendly and economically viable biotechnological solutions for the biotech, pharmaceutical and chemical industries. Inspired by nature’s principles, acib translates biological systems into robust industrial concepts that help industries respond to global challenges such as climate change, resource scarcity and increasingly volatile supply chains. A strong focus lies on developing biotechnological solutions that enhance industrial resilience by improving process robustness, reducing dependency on critical raw materials and energy inputs, and enabling more flexible, future‑proof production systems.
Relevant R&D budget › €10m/year (COMET centre) Request for › Interested in joining our network? We Further Collaborations collaborate closely with industrial partners on cutting-edge research and innovation projects. acib actively seeks strong partners from industry to jointly advance key technologies, translate scientific excellence into real-world applications, and accelerate the integration of innovative solutions into industrial processes. We invite you to browse through our project offers: www.acib.at/offers Let’s get in contact: bd@acib.at
Member of
acib’s research portfolio spans key technology fields including biocatalysis and enzyme technology, renewable resources and biorefineries, plant biotechnology, applied biodiversity, sustainable microbial biotechnology, bioprocess technology, biopharmaceuticals and diagnostics. Together, these competencies allow acib to design integrated concepts that combine sustainability with efficiency, competitiveness and security of supply.
ACIB
Acting as a central innovation hub, acib connects science and industry across the entire innovation chain. Around 150 scientists work at acib in close collaboration with a strong international network of academic and industrial partners. By jointly developing application‑oriented solutions, acib supports companies in building resilient production concepts, increasing efficiency and accelerating the transfer of biotechnological innovations into industrial practice. The centre operates as a one‑stop shop for industrial biotechnology – from early research ideas to scalable, market‑ready applications. As a COMET K2 Competence Centre, acib conducts long‑term, excellence‑driven research together with partners from multiple countries, combining scientific depth with industrial relevance. This collaborative framework enables the co‑creation of technologies that strengthen competitiveness while supporting the transformation towards a circular, bio‑based economy. Beyond technology development, acib places strong emphasis on responsible research and innovation, transparency and science communication. Partnering with acib means gaining access to cutting‑edge biotechnology expertise, interdisciplinary research teams and a trusted innovation environment – to jointly develop solutions that turn scientific excellence into lasting industrial and societal impact.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
28 | 29
Name › AiCuris Anti-infective Cures AG Address/P.O. Box › Friedrich-Ebert-Str. 475 Building 302 Postal Code/City › 42117 Wuppertal Country › Germany Contact Person › Anja Vogelsang (PR/IR), Evgenii Bondarenko (BD) Telephone › +49-202-317-63-0 Fax › +49-202-317-63-11-77 Email › info@aicuris.com Website › www.aicuris.com Social Media › I Number of Employees › 70 Founded (year) › 2006 Areas of Activity › R&D antiviral therapeutics for immunocompromised patients External › Merck & Co., Inc., Rahway, NJ, USA Collaborations (MSD in Germany), German Center for Infection Research (DZIF)
Who we are Aicuris is a privately held, late-stage biopharmaceutical company focused on developing novel antiviral therapies for immunocompromised people, including people living with immune deficiencies or receiving immunosuppressive treatments, who are at heightened risk of severe and difficult-to-treat infections. Leveraging its research and clinical development expertise to advance a growing pipeline of highly differentiated candidates, Aicuris aims to drive patient impact by advancing therapies to effectively treat potentially life-threatening infections in immunocompromised people. Aicuris is headquartered in Wuppertal, Germany, and operates a US subsidiary, Aicuris U.S., Inc., in Waltham, Massachusetts. Led by an experienced international management team, Aicuris is building a fully integrated organisation across the entire value chain from research and development to commercialisation.
Proven track record Aicuris developed PREVYMIS ® (letermovir, licensed to MSD), a first-in-class, non-nucleoside inhibitor to prevent life-threatening cytomegalovirus (CMV) reactivation. PREVYMIS ® is approved in more than 60 countries for prophylaxis in adult CMV-seropositive patients following allogeneic hematopoietic stem cell transplantation. More recently, its label was expanded to include prevention in CMV-seropositive donor and CMV-seronegative recipient kidney transplant and pediatric patients, and it is approved in Japan for solid organ transplant patients, deepening its global impact on transplant care worldwide. PREVYMIS® is marketed by Merck & Co (MSD outside the US). Aicuris receives royalties from PREVYMIS® sales and is cash-flow positive.
Member of
AICURIS
Promising pipeline Aicuris’ proprietary lead candidate pritelivir is an orally administered antiviral targeting the helicase-primase complex of herpes simplex virus (HSV1 and HSV2). With its differentiated mechanism of action, pritelivir is being developed for immunocompromised patients with refractory HSV infections, with or without resistance to standard-of-care therapies. Pritelivir recently met the primary endpoint in its pivotal Phase 3 trial in this population. These results will form the basis of an NDA submission with the U.S. FDA. Aicuris is also advancing AIC468, an antisense oligonucleotide designed to address BK virus (BKV) reactivation in kidney transplant recipients. By targeting the Large T antigen, AIC468 inhibits viral replication and is designed to prevent patients from potential severe consequences of BK viraemia, including kidney tissue damage and graft loss. This targeted approach may help preserve graft function and lower the risk of transplant rejection. AIC468 demonstrated favorable safety and pharmacokinetics in a Phase I clinical trial in kidney transplant recipients, and initiation of Phase II is expected in 2026.
Partnering opportunities Aicuris is committed to advancing therapeutic innovation for immunocompromised patients and pursues opportunities beyond a single platform or modality. The company is open to collaborations and licensing opportunities that expand its antiviral portfolio in areas of high unmet medical need, including programmes that complement Aicuris’ expertise in development for immunocompromised populations.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
30 | 31
Name › AIT Austrian Institute of Technology GmbH Address/P.O. Box › Giefinggasse 4 Postal Code/City › 1210 Vienna Country › Austria Contact Person › PD Dr. Andreas Weinhäusel Telephone › +43-50550-4300 Email › andreas.weinhaeusel@ait.ac.at Website › www.ait.ac.at, molecular-diagnostics.ait.ac.at Social Media › I Number of Employees › 1,600 Founded (year) › 2009 Type of Laboratory | Molecular biology laboratories | Chemistry/Physics laboratories | Cell culture and BSL2 level laboratories | Clean room laboratories for thin film technologies Areas of Activity › | Molecular diagnostics | Multi-omics | Bioinformatics | Biological barriers | DNA Nanotechnology | Biosensor development | Point-of-care systems Annual turnover › €218m Biological Patents › | DNA-methylation- & autoantibody biomarker panels for early cancer diagnosis (lung, breast, colon, thyroid) External › National and international clinics and Collaborations academics, e.g. | Imperial College London | Medical University Vienna | Medical University Graz | University Hospital SchleswigHolstein Request for › National and international industry, e.g. Further Collaborations | Boehringer Ingelheim | Universal Dx I MultiOmic Health I HMNC Brain Health l GenomeScan l Infineon Technologies
Comprehensive molecular diagnostics solutions The Competence Unit Molecular Diagnostics is part of AIT Austrian Institute of Technology, Austria’s largest non-university research institute, and develops healthcare solutions for a wide range of applications with a strong focus on non- and minimally invasive diagnostics. AIT’s Molecular Diagnostics Unit drives innovation in diagnostics via its system expertise which ranges from biosample preanalytics and study design to biomarker discovery/validation, bioinformatics, biological barrier models, biosensors and integrated point-of-care systems. The team applies its comprehensive technology portfolio to support clinical and industrial partners to turn diagnostic needs into robust assays and scalable workflows covering various areas such as health monitoring, disease detection, therapy response prediction/ monitoring, and therapeutic target identification.
Multi-omics from tissue and body fluids At the core of AIT’s activities is multi-omics biomarker discovery in a broad range of complex diseases applying Next Generation Sequencing (NGS) and microarrays in both tissue and body fluids (= liquid biopsy). Nucleic acid biomarker profiling covers genomics (genotyping and mutation detection including low-frequency variants), epigenomics (genome-wide or targeted DNA methylation analysis via arrays, Illumina/Nanopore NGS, PCR), metagenomics (metagenome- or 16SrRNA -based). Transcriptomics comprises analysis of mRNAs and non-coding RNAs via NGS or targeted (microfluidic) PCR assays, with special workflows for small/microRNA sequencing from extracellular vesicles (EVs) derived from diverse body fluids (serum/plasma, saliva, CSF). While metabolomics profiling is typically done by trusted partners, AIT’s proteomic biomarker capacities comprise the analysis of diagnostically most relevant antibody profiles via protein/peptide arrays, beadbased multiplex assays or NGS-based. For most sensi-
AIT
tive proteome analysis AIT relies as a certified service provider on all types of assays offered by OLINK. AIT further provides multiplex analysis of surface proteins of choice on extracellular vesicles applying an immuno qPCR approach.
Integrative pathway analysis and biological barrier models To connect multi-omics-derived molecular signals with biological mechanism and pathways, AIT provides advanced bioinformatics (multivariate statistics, disease modelling, data integration). Human in vitro biological barrier models (blood-brain barrier, lung, kidney, oral mucosa, intestine) based on cell lines, hiPSC or primary cells enable studies not only on biomarker origin/causality, but also on drug transport across barriers or toxicity of substances.
Sensor concepts for point-of-care diagnostics Finally, the AIT Molecular Diagnostics Unit develops miniaturised point-of-care systems based on various sensor concepts (photonic, electrochemical, magnetic) which can be applied in remote care and are typically designed for body fluid analysis (blood, saliva, interstitial fluid). Realisation of such integrated diagnostic systems is enabled by micro-/nanofabrication, controlled surface modification, as well as integration of sample processing, microfluidics and electronic readout. In the area of infectious disease, the Molecular Diagnostics team applies DNA-based high-multiplex assays for pathogen and antibiotic resistance detection using among others its own oligo design software and DNA nanostructures.
Member of 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
32 | 33
Name › Axolabs GmbH Address/P.O. Box › Fritz-Hornschuch-Str. 9 Postal Code/City › 95326 Kulmbach Country › Germany Contact Person › Dr. Ingo Röhl Telephone › +49-9221-82762-0 Fax › +49-9221-82762-99 Email › info@axolabs.com Website › www.axolabs.com Social Media › I Number of Employees › >400 Founded (year) › 2000 (as Ribopharma; acquired by LGC in 2017) Type of Laboratory › S1, S2 Areas of Activity › Research solutions for preclinical and clinical development with a focus on nucleic acid therapeutics (NAT), including bioinformatics-guided sequence selection, high quality oligonucleotide manufacturing, analytics (GMP), bioanalytics (GLP, GCP), lead molecule identification, and in vitro and in vivo pharmacology External › Axolabs collaborates with research Collaborations groups around the world in the field of oligonucleotide therapeutics, including > 15 Big Pharma enterprises, > 200 biotech companies, and > 30 academic research institutes
Member of
Your complete nucleic acid therapeutics journey. From discovery to commercialisation. Axolabs is the leading custom research organisation focused on the discovery, development and manufacture of oligonucleotide and nucleic acid therapeutics. Founded firmly on our world-leading know-how and more than 20 years of experience, we provide high-end preclinical and clinical development solutions tailored to our clients’ needs. From discovery hubs to GMP-certified production sites, Axolabs’ facilities are built to support nucleic acid therapeutics development. Our global presence includes state-of-the-art sites in Kulmbach and Berlin, Germany and Petaluma, US, with each site specialising in a specific phase of your drug development journey.
Research and early development services We offer a comprehensive suite of research and early development services, starting from in silico analyses to late-stage preclinical testing including: › Lead Identification › Safety and Toxicity Analyses › Cell-Based Assays for Efficacy, Viability, and Toxicity Efficacy Assays › Viability and Toxicity Monitoring › Cell Differentiation and Characterisation › Protein Quantification and Analysis › Functional and Mechanistic Studies › Sequencing (NGS, Oxford Nanopore) › CRISPR/Cas Technologies: gRNA Design and Validation › GLP/GCP Bioanalytical Services › DMPK Services
A XOL ABS
Manufacturing services From early-stage research to commercial-scale cGMP production, facilitating a smooth handover from research to production. › Preclinical screening synthesis › Chemically modified RNA therapeutics and their conjugates › Synthesis of long (oligonucleotide) entities › Organic synthesis laboratory › Lipid nanoparticle (LNP) formulation and manufacturing › Large-Scale Chemical Manufacturing › Integrated Synthesis Platforms: OligoPilot™, OligoProcess™, and Asahi Kasei Bioprocess (AKB) › Scale-Up and Process Optimisation › cGMP Manufacturing › GMP analytics
Integration across the Development Continuum Our integrated platforms provide quality assurance and seamless transitions between development and commercialisation › Streamlined Data Flow from research to manufacturing › Technology Transfer and Scale-Up Efficiency › Regulatory and Quality Considerations
Start your Axolabs journey. Visit axolabs.com or email info@axolabs.com
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
34 | 35
Name › Biaffin GmbH & Co KG Address/P.O. Box › AVZ 2, Heinrich-Plett-Str. 40 Postal Code/City › 34132 Kassel Country › Germany Contact Person › Dr. Bastian Zimmermann Telephone › +49-561-8044668 Fax › +49-561-8044665 Email › info@biaffin.com Website › www.biaffin.com www.proteinkinase.biz Social Media › F I Q Number of Employees › 8 Founded (year) › 2001 Type of Laboratory › Analytical, ISO 9001:2015 certified Areas of Activity › Service provider for biomolecular interaction analysis using SPR Biacore technology; supplier of recombinant proteins and reagents for kinase research and signal transduction External › Collaborations with academic research Collaborations groups, CDMOs and commercial partners Request for › Biaffin is looking for strategic partners Further Collaborations interested in complementing their analytical portfolio with SPR Biacore technology.
Company overview Biaffin GmbH & Co KG is an ISO 9001:2015 certified bioanalytical service provider specialised in the application of biosensors based on surface plasmon resonance (SPR) for biomolecular interaction analysis (BIA). BIA technology is ideally suited for highly accurate kinetic characterisation of any interacting molecules in real time in a label-free state. Biaffin has extensive knowledge and many years of experience in various application areas and supports biopharmaceutical drug development programme of pharma, biotech, and generic drug companies as well as scientific institutions worldwide as a competent partner. Our services are performed by a highly specialised team (PhD level scientists) in a laboratory well equipped with several state-of-the art SPR instruments (5x Biacore T200, 1x Biacore 8K+, 1x Biacore 1S+). Sufficient capacity of SPR instruments allows B iaffin to start interaction studies on short notice, quickly run multiple projects in parallel, and provide results in a timely manner. A qualified Biacore T200 instrument is available for SPR assay validation and GMP-like SPR analysis. The company’s expertise is documented by many peer-reviewed publications in renowned scientific journals.
Analytical services for biopharmaceutical development For the development of therapeutic antibodies, bio pharmaceuticals, and biosimilars, Biaffin offers reliable SPR services for a highly accurate, quantitative kinetic characterisation, semi-quantitative kinetic ranking, or rapid qualitative screening of drug candidates. SPR assays have already been established for many target proteins and can be developed quickly by application of established protocols for reversible and site-directed coupling of biomolecules using specific capture surfaces. These assays can be applied for comparability and stability studies and batch-to-batch comparison during process optimisation. Available assay formats include dual-potency assays, pair-wise epitope mapping, and determination of active concentration based on binding activity (calibration-free methods). Assays can be validated and conducted under GMP-like conditions on a qualified Biacore instrument.
BIAFFIN
ADCC SPR assays ADCC SPR assays are established for interaction analysis of antibodies with Fc gamma receptors (CD16, CD32, CD64) including receptor variants and different species, neonatal Fc receptor (FcRn), and complement C1q binding.
Small molecule drug development Biaffin’s services in small molecule drug development comprise customised SPR assay development for defined target proteins, fragment screening, hit validation, secondary screening, kinetic profiling, competition analysis, and lead optimisation of compounds to improve specificity, selectivity, and potency. Early ADME studies (serum protein binding) and studies on mode of action, cofactor requirements, and thermodynamic binding analysis further support the drug development process.
Catalogue products Apart from analytical services, Biaffin offers a range of products serving customers’ needs in kinase research and exploring cellular signal transduction pathways. Biaffin’s product portfolio, available from the online shop www.Proteinkinase.biz, comprises recombinant proteins (kinases, cytokines, receptors, CD antigens), peptide substrates, specific inhibitors, and a biochemical ATP determination assay for customers’ in-house research.
Quality statement Biaffin has successfully implemented and maintains a Quality Management System certified according to the ISO 9001:2015 international standard, enhancing our ability to supply high-quality products and provide reliable, innovative services according to the highest quality standards, which consistently meet the needs and expectations of our clients.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
36 | 37
Name › Bioengineering AG Address/P.O. Box › Sagenrainstrasse 7 Postal Code/City › 8636 Wald Country › Switzerland Telephone › +41-55-256-81-11 Email › sales@bioengineering.ch Website › www.bioengineering.ch Number of Employees › 85 Founded (year) › 1972 Areas of Activity › l Engineering & design l Service l Plants l Bioprocess control l Lab & pilot l Components
Company profile Bioengineering AG, founded in Switzerland with subsidiaries in Korea, China, and the USA, has been a trusted partner to the biotech industry for over 50 years. Our global reach and depth of experience make us a valued choice for leading companies. Guided by continuous improvement and a culture of responsibility and solution-focused collaboration, we build trusted relationships that support progress and quality in every project.
What we do We design and build equipment and systems that improve the efficiency and reliability of bioproduction. Our engineering teams unify technological expertise with a deep understanding of customer needs to create customised bioreactors and fermenters for applications ranging from laboratory scale to production facilities. Committed to quality and partnership, we provide solutions that meet the evolving needs of the biotech and pharmaceutical industries.
Product portfolio From research to production, Bioengineering offers customised solutions that grow with your requirements. Our product portfolio ranges from 1-liter laboratory reactors to 30,000-liter production plants and includes: KLF: The only in-situ sterilisable glass benchtop fermenter on the market. Ideal for research and down scaling studies. RALF: Autoclavable benchtop fermenter for cell culture or microbial fermentation. NLF & LP/P: Laboratory/pilot fermenter for research or GMP production. Plants: Customised plants for GMP biopharma, novel food & biotech. Peripheral solutions: Media vessels, CIP systems, Inversina mixers, dosing systems.
BIOENGINEERING
What we provide From project management and process engineering to automation and installation, we bring your vision to life with precision. Our full set of qualification services makes sure that your systems meet the highest standards and regulations. We also provide ongoing support, including maintenance and replacement parts for any issues. This ensures that your systems perform at their best, from lab reactors to full-scale production plants. › Project management › Process engineering › Automation › Manufacturing › Qualification › On-site installation › Service • Spare parts • Field service • Preventive maintenance • Technical support • Revamping • Training
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
38 | 39
Name › Biomay AG Address/P.O. Box › Ada-Lovelace-Strasse 2 Postal Code/City › 1220 Vienna Country › Austria Contact Person › Dr. Konstantin Tomanov Telephone › +43-1-7966296-100 Email › info@biomay.com Website › www.biomay.com Social Media › I Number of Employees › 110+ Founded (year) › 1984 Type of Laboratory › CDMO Areas of Activity › GMP manufacturing & aseptic filling of plasmid DNA, mRNA, recombinant proteins; supply for clinical phases I-III, market material; OTS products for gene therapies
End-to-End Manufacturing Solutions Biomay specialises in the manufacturing and aseptic filling of plasmid DNA, LNP-formulated mRNA and recombinant proteins, derived from microbial fermentation. With a proven track record of over 250 successfully released GMP products in the past 15 years, the company supports clients in the development and production of biopharmaceuticals. Biomay operates two state-of-the-art, fully integrated biomanufacturing facilities, both of which have been inspected by the U.S. Food and Drug Administration (FDA).
Extensive Range of Services for Client Projects Biomay offers fully scalable GMP manufacturing across five parallel production lines, with bioreactor capacities of 30L, 50L, 150L and 750L. Routinely, yields of up to several hundred grams per batch of starting material, drug substance, or drug product are achieved. Notably, Biomay’s manufacturing process is free of solvents, antibiotics and animal components. Biomay operates five GMP-commissioned clean rooms for mRNA production, LNP formulation and aseptic filling. State-of-the-art enzymatic run-off transcription is used for mRNA synthesis, with in-house linear DNA template production, various capping and modification options, and a comprehensive GMP-qualified process using single-use equipment. The company has been producing recombinant proteins since its foundation. The strong track record spans four decades of expertise and includes various protein vaccines, recombinant allergens, as well as the Cas9 nuclease used in CASGEVY, the first approved CRISPR/ Cas9-based gene-editing therapy. For precision medicine applications, Biomay operates a dedicated facility for personalised tumour vaccine production, using 3L bioreactors in multiple parallel clean rooms. This setup is optimised for rapid turnaround while maintaining strict quality standards.
BIOMAY
All products are comprehensively analysed in-house for regulatory compliance, allowing a true end-to-end solution.
Ready-to-Use Cas9 Nuclease, Cas9 mRNA and Viral Vector Plasmids Supporting the growing demand for gene-editing and gene therapy products, Biomay has a set of off-the-shelf (OTS) products such as CRISPR-Cas9 nuclease for gene-editing applications, as well as starting vectors for adeno-associated virus (AAV) and Lentivirus (LV) media ted gene therapies. Clients can choose from a wide range of AAV rep/cap serotypes, allowing for maximum flexibility in tissue specificity. A fluorescent reporter (eGFP), a size-optimised AV-Helper and transgene vectors complete the portfolio. Primarily used for CAR-T applications and ideal for large payloads, 2nd and 3rd generation LV plasmids are offered. AAV and LV plasmids are available for research use and in GMP quality. The latest addition to the growing catalogue is Cas9 mRNA, available in both GMP and research grades. All OTS products are immediately accessible and distributed via the company’s online platform. Driven by scientific excellence and rigorous testing, Biomay consistently delivers highly pure material, allowing scientists to focus on meaningful research.
A Reliable Partner for Long-Term Collaboration Biomay supports clients throughout the entire product life cycle – from clinical phases I–III to market readiness and commercial supply – a commitment reinforced by manufacturing the Cas9 nuclease for CASGEVY. During the COVID-19 pandemic, Biomay contributed a significant quantity of plasmid templates for Pfizer-BioNTech’s mRNA vaccine, Tozinameran/Comirnaty. With continued growth and expansion capacity at its facilities, Biomay remains well-positioned to meet both current and future custom manufacturing demands, providing tailored solutions for its clients.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
40 | 41
Name › BioNTech SE Address/P.O. Box › An der Goldgrube 12 Postal Code/City › 55131 Mainz Country › Germany Contact Person › Peter Mitterhofer, General Manager Germany Telephone › +49-6131-9084-0 Email › service@biontech.de Website › www.biontech.com/de Social Media › I Number of Employees › 7,807 (As of December 31, 2025) Founded (year) › 2008 Areas of Activity › Cancer therapy, vaccines against infectious diseases
BioNTech’s vision: Translating science into survival BioNTech is a global next-generation immunotherapy company aiming to pioneer novel medicines against cancer, infectious diseases, and other serious diseases. Since its founding in 2008, BioNTech has focused on harnessing the power of the immune system to address human diseases with unmet medical needs and major global health burdens. The company operates a fully integrated model combining decades of immunology research with a multi-technology innovation engine, GMP manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science, artificial intelligence (AI), and machine learning (ML) to discover, develop, and commercialise its marketed product and product candidates.
Multi-technology innovation engine BioNTech has built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes investigational mRNA cancer immunotherapies and protein-based therapeutics, such as targeted antibodies (monoclonal, bispecific, and antibody-drug conjugates, or ADCs) in oncology and mRNA-based vaccines against infectious diseases.
Advancing combination therapies in oncology BioNTech’s primary focus is oncology, where the company endeavours to address the full continuum of cancer from early to late disease stages. Cancer heterogeneity and interindividual variability, driven by random sequential mutations, are two of the root causes of treatment failure. BioNTech’s strategy centres on addressing these challenges by combining treatment approaches with non-overlapping, potentially synergistic mechanisms of action to augment anti-tumour activity and counteract resistance mechanisms. Member of
BIONTECH
Combating global health threats in infectious diseases In infectious diseases, BioNTech aims to develop vaccines and therapeutics targeting respiratory viruses, latent viruses, bacteria, and parasites. The company’s scientific approach and mRNA technology have the potential to significantly contribute to combating global health threats caused by infectious diseases. BioNTech has pursued strategic partnerships and corporate collaborations to partially fund its infectious disease global health programmes and continues to prioritise equitable access to innovative vaccines for high medical need indications.
Driving innovation to help shape the medicine of the future
M-GL-NPR-0001
BioNTech’s approach has resulted in a robust and diversified product candidate pipeline across oncology and infectious diseases. This pipeline has led to the approval of its first marketed pharmaceutical product, an mRNAbased vaccine against COVID-19. Innovation remains central to BioNTech’s mission, and the company sees potential for its technologies to expand beyond oncology and infectious diseases, addressing additional areas of high and/or unmet medical need.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
42 | 43
Name › Boehringer Ingelheim Biopharmaceuticals GmbH Address/P.O. Box › Binger Strasse 173 Postal Code/City › 55216 Ingelheim Country › Germany Contact Person › Rebekka Wuester Telephone › +49-6132-77-0 Fax › +49-6132-72-0 Email › bioxcellence@boehringer-ingelheim.com Website › www.bioxcellence.com Number of Employees › 54,500 in 2024 Founded (year) › 1885 in Ingelheim, Germany Type of Laboratory › S1 Areas of Activity › Focus on human pharmaceuticals, animal health and biopharmaceutical contract manufacturing Net Sales › 26.8 billion EUR in 2024 Relevant R&D Budget › 6.2 billion EUR in 2024 Request for › Boehringer Ingelheim BioXcellence™ Further Collaborations is a dedicated partner for biopharma companies, providing comprehensive development and GMP manufacturing services. Renowned for its reliability, the company supports clients throughout the lifecycle of their products, thus transforming biologic innovations into commercial realities.
Company profile Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. BioXcellence Manufacturing – Tailored Capacities. Reliable Supply. Your Success, Our Commitment. Boehringer Ingelheim BioXcellence™ is a leading bio pharmaceutical contract manufacturer – a reliable partner that accompanies customers throughout the life cycle of their products. We provide E2E biopharmaceutical manufacturing based on mammalian cell culture and microbial fermentation. We have extensive experience with a variety of different host cells, producing a broad range of molecules in accordance with cGMP manufacturing guidelines and covering all stages of development, including aseptic filling. Our focus is on creating value for our customers through robust processes, effective preparation for launch, and global clinical and commercial supplies of high-quality biopharmaceuticals. We are committed to maintaining high-quality standards in all operations, with robust systems designed to meet stringent regulatory requirements, and strong quality control capabilities that ensure product quality at every manufacturing stage. Our team’s extensive regulatory experience and impressive inspection track record demonstrate our ability to navigate complex regulations and integrate in-depth technological knowledge into our operations.
World-Class Expertise
Member of
With over 40 years of biotechnology experience and a team of dedicated and highly trained employees, we have helped our customers bring more than 45 biopharma ceutical medicines to the market, serving patients all
BOEHRINGER INGELHEIM
over the world. Our expertise spans across various host cells, enabling us to produce a wide array of molecules. Our commercial portfolio comprises monoclonal antibodies, recombinant proteins, antibody fragments, and recombinant vaccines, and is complemented by intensive experience in bi- and multispecific antibodies, Fc fusion proteins, scaffolds, peptide hormones, and pDNA.
World-class Facilities Our network of manufacturing facilities spans the globe, from Fremont, California in the United States to Biberach in Germany, Vienna in Austria, and Shanghai in China. With around 460 kL for mammalian cell culture and 12 kL for microbial fermentation in fully licensed multiproduct facilities we are your right partner for high-quality global supplies of biopharmaceuticals to patients. This is evidenced by our regulatory excellence. Our operations are based on fully licensed multi-product facilities for all major markets. One-quality, one-compliance, and oneregulatory form the foundation of our global network.
Your World-class Production Partner For many of our customers, we are the preferred partner for reliable supplies. Seven of the top 10 pharmaceutical companies already trust us due to our extensive commercialisation experience. At Boehringer Ingelheim, we are deeply invested in the success of your product. Our shared passion is reflected in our commitment to providing the highest quality services and solutions to ensure your product reaches its full potential. Aside from our extensive experience and technical expertise, which complements yours, there are several other compelling reasons to choose us as your trusted contract manufacturing partner. At Boehringer Ingelheim, we have learned over the generations that the challenging path towards health innovation requires long-term commitment, resilience, and transformative action. Let’s build a future together based on our history. We have capabilities to complement your expertise and are committed to turning your biologic innovation into commercial reality. 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
44 | 45
Name › CeGaT GmbH Address/P.O. Box › Paul-Ehrlich-Strasse 23 Postal Code/City › 72076 Tübingen Country › Germany Telephone › +49-7071-565-44-55 Fax › +49-7071-565-44-56 Email › info@cegat.com Website › www.cegat.com Social Media › I F Number of Employees › ~ 200 Founded (year) › 2009 Areas of Activity › Genetic analysis, next-generation sequencing (NGS)
About CeGaT CeGaT is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications. Founded in 2009 in Tübingen, Germany, the company combines state-of-the-art sequencing technology with medical expertise – with the aim of identifying the genetic causes of diseases and supporting patient care. For researchers and pharmaceutical companies, CeGaT offers a broad portfolio of sequencing services and tumour analyses. CeGaT generates the data basis for clinical studies and medical innovations and drives science forward with its own insights. The owner-managed company stands for independence, comprehensive personal customer service, and outstanding quality. CeGaT’s laboratory is accredited according to CAP/CLIA, DIN EN ISO 15189, and DIN EN ISO/IEC 17025 and thus meets the highest international standards.
Your true partner for next-generation sequencing (NGS) Our vision is to make next-generation sequencing available to all life scientists and bring diagnostic knowledge into sequencing service. We are your true partner for next-generation sequencing. Being pioneers in NGS-based genetic diagnostics, we have a profound understanding of the underlying technology. Based on this, we offer practical applications for research and medicine. Consistently high quality is our maxim: We perform all projects in-house and automate processes whenever possible.
Member of
We strongly believe that teamwork is key. Our interdisciplinary team consists of specialists from various disciplines who contribute their specific know-how. A dedicated project manager supports you from beginning to completion and will be your individual contact. Together, we realise smart sequencing solutions to address your research questions.
CEGAT
A comprehensive product portfolio to match your project’s requirements To support scientists in accomplishing projects of any scope, we offer a broad product portfolio. You can choose from a wide range of sequencing services, such as: › Whole Genome Sequencing › Whole Exome Sequencing › Transcriptome Sequencing › Ready to Load Sequencing The portfolio is complemented by analyses suited for microbiome, immunology, translational oncology, epigenomics, and proteomics studies. We are also your partner of choice for NGS services within clinical studies. All our services can be tailored to your requirements, be it the isolation of nucleic acids, data output format, or further bioinformatic analyses.
High throughput technology meets outstanding scientific expertise The rapid advancement of technology is constantly increasing the potential of genetic analyses. Therefore, CeGaT continuously invests in the latest equipment. We constantly improve sequencing quality and data analysis by using the most advanced technologies and pipelines available. In-house, we run five Illumina NovaSeq™ 6000, four NovaSeq™ X Plus, and two MiSeq™ systems for high-throughput short-read sequencing. In addition, our PacBio Sequel IIe and Revio platforms enable high-quality long-read sequencing. Together, this setup provides a very large sequencing capacity, allowing the rapid processing of genetic material. For consistently high quality as well as time and cost savings, we rely on the automation of processes. At the same time, human expertise is indispensable to us and an essential pillar of our company. The entire process is supervised by a dedicated project manager who provides advice and support from project design to the final report. We also adopt the strict requirements of genetic diagnostics for research projects. 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
46 | 47
Name › Collaborative Drug Discovery, Inc. Address/P.O. Box › Nine Hills Road Postal Code/City › CB2 1GE Cambridge Country › United Kingdom Contact Person › Dr. Mariana Vaschetto Telephone › +44-1223-803830 Email › mariana@collaborativedrug.com Website › www.cddvault.com Social Media › F I Number of Employees › >100 Founded (year) › 2004 Areas of Activity › | Drug discovery collaboration | Collaborative data management | Cloud-based research tools | Data analysis and management | Workflow automation | AI/ML integration in drug discovery | Cross-team collaboration
Introduction to Collaborative Drug Discovery (CDD) Collaborative Drug Discovery (CDD) is a software company advancing pharmaceutical research through powerful tools for managing chemical and biological data. Founded in 2004, its flagship platform, CDD Vault, was built to meet FAIR data standards and designed to scale - helping teams accelerate research, reduce administrative burden, and create a secure foundation for AI-driven discovery and investor-ready reporting. CDD Vault supports both small molecule and biologic research, enabling integration and analysis of diverse datasets within one platform. Researchers can manage chemical structures, reaction pathways, and biological assay data while also working with complex modalities such as peptides, antibodies, nucleic acids, and bioconjugates including antibody-drug conjugates (ADCs). The platform includes enhanced sequence-based registration with chemically aware structures and a built-in macromolecule editor for accurate biologics representation and structure-activity analysis. By unifying chemical and biological data management, CDD bridges a key gap in modern drug discovery workflows.
The Flagship Product: CDD Vault CDD Vault is a secure, cloud-based system for managing, visualising, and sharing drug discovery data. Designed for scientists, it provides a collaborative environment to store, analyse, and interpret research data. Key capabilities include: › Structure-Activity Relationship (SAR) Tools: Correlate chemical and biologic structures with activity data. › Data Visualisation: Intuitive graphs and plots for interpreting complex datasets. › Collaboration Controls: Role- and project-based permissions for secure internal and external sharing. › Integrated Assay & Activity Management: Centralised assay definitions and biological data analysis. › Electronic Lab Notebook (ELN): Flexible experimental data capture linked to compounds and assays. › Inventory & Sample Management: Tracking of compounds, biologics, and samples.
COLLABORATIVE DRUG DISCOVERY
Driving Collaboration CDD supports seamless collaboration among medicinal chemists, biologists, and computational scientists by enabling shared insights and transparent communication. Integration with external tools and a RESTful API allow efficient data exchange and comprehensive analysis.
Industry Applications CDD Vault is widely used by pharmaceutical companies, academic institutions, and research organisations to support: › Target identification and validation › Lead optimisation › Preclinical research › Small molecule and macromolecule development
Security and Compliance CDD maintains rigorous security standards and regulatory compliance, including 21 CFR Part 11, ensuring data confidentiality and integrity in regulated environments.
Future-Focused Innovation Built for scalability and FAIR principles, CDD Vault continues to evolve with AI-assisted generation and analysis tools that enhance SAR interpretation across chemical and biologics datasets. Structured data tagging makes datasets machine-readable and AI-ready. These capabilities help researchers extract actionable insights, reducing the time and cost of bringing new therapeutics to market.
Conclusion Collaborative Drug Discovery is transforming how teams manage and collaborate on chemical and biological data. Through its unified, intuitive platform, CDD accelerates drug discovery and supports the development of better therapies worldwide.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
48 | 49
Name › comprei Reinraum-Handel und Schulungs GesmbH Address/P.O. Box › Europastraße 10 Postal Code/City › 9524 Villach Country › Austria Contact Person › Simon Fiala Head of training and learning solutions Telephone › +43-4242-44075 Email › office@comprei.eu Website › www.comprei.eu Social Media › I Number of Employees › 120 Founded (year) › 1999
comprei – contamination in control In contamination‑critical high‑tech industries, every movement matters. Employees must act with absolute precision and awareness in the cleanroom every single day. A strong Contamination Control Strategy (CCS) only succeeds when people are not just trained—but continuously engaged, sensitized, and empowered. This is exactly where comprei learning solutions come in. As a tailor-made service, they are characterised by › a distinct process orientation in coordination with manufacturing and quality management › the focus on clear individual learning objectives with maximum real-world relevance › a high proportion of impressive visualisations and simulations comprei training courses motivate learners to do more than just adhere to procedures and implement rules. We allow learners to clearly comprehend the background and understand the reasons in depth - for always acting confidently and appropriately in highly clean environments.
What can your individual learning solution look like? Continuous learning support › Ongoing learning impulses in a playful and lowthreshold digital way › Practical training, simulation, and reflection in person › Tracking of learning progress and intervention by training officers › Flexible adaptation of learning content and addressing trends
Classroom training on site or at the comprei training center › Individualisation of the learning content › Impressive visualisation and practical training
Live online training / webinar › Efficient use of time and minimal organisational effort › Option as a refresher and for small learning units without hands-on training
COMPREI
Examples for content packages Safe and confident in the GMP cleanroom for operators in biotech and pharma Sustainable motivation and awareness of correct behaviour in the GMP environment. Experiment in our simulation cleanroom, experience the effects of your behaviour and become aware of critical factors influencing your processes and products.
Special package: Aseptic handling in manufacturing and sterile fill-and-finish for operators in the aseptic manufacturing and filling of pharmaceuticals Raising awareness of aseptic movement and handling. Simulation of movement in the cleanroom, interventions on the filling line/RABS and handling on the isolator. Visualisation of risks and best practice based on SOPs and protocols. Assessment and training of aseptic practices such as gowning, movement, handling/interventions.
Certification programme cleanroom expert for hygiene managers, production managers, QA officers, cleanroom managers, training officers, etc. 9 days of instruction in 3 modules, including project work and final exam for the certificate
Certifications › ISO 21001:2018 Management systems for educational organisations › ISO 29993:2017 Learning services outside formal education › ISO 9001:2015 Quality management systems
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
50 | 51
Name › CZ VACCINES Address/P.O. Box › A Relva s/n Torneiros Postal Code/City › 36410 O Porriño Country › Spain Contact Person › Mercedes Rodriguez Telephone › +34-986-330400 Email › mercedes.rodriguez@czvaccines.com czvaccines@czvaccines.com Website › https://czvaccines.com Social Media › I Number of Employees › 600+ (Zendal Group) Founded (year) › 1993 Areas of Activity › | Biotechnology | CDMO | Development | Manufacturing | Vaccines | Viral & microbial vaccines and cell therapy | Aerobes and anaerobes, yeast | Covid-19 vaccines | Tuberculosis vaccines | One-Stop Shop | Biomedicine | Aseptic filling | Lyophilisation | GMP upstream & downstream processes | Biotech production sites in Spain and Portugal Relevant R&D Budget › 11% revenue
Full-service biologics CDMO EU GMP certification CZ VACCINES is a full service provider. We cover the entire value chain from contract development through clinical phases I to III to commercial production of vaccines and biological products.
30 years in vaccines CZ VACCINES has extensive scientific experience in developing new and ambitious projects that include different categories and vaccine platforms: › Human vaccines and animal vaccines › Against viral, bacterial, and parasite diseases › Conventional vaccines › Genetic engineering of live attenuated vaccines › Subunit vaccines (recombinant protein) › Latest generation DNA vaccines
End-to-End CDMO › Live and inactivated bacterial and viral vaccines up to BSL-2 › Roller bottles, cell factory and wave bioreactor › Single-use and stainless steel bioreactors › Aseptic processing systems › Centrifugation, and ultrafiltration and diafiltration › Chromatography (ÄKTA ready) › Aseptic filling into vials › Lyophilisation (clinical trial material and large scale) › Process development / optimisation › Quality control testing: microbiological, sterile / nonsterile, chemical-physical, and biological › Storage: (2º-8ºC), (-20ºC), (-30ºC), (-80ºC)
CZ VACCINES
Large-scale biotech manufacturing CZ VACCINES has large manufacturing capacity located in several GMP certified biotech production plants in Spain and Portugal
cGMP-production capabilities Upstream: › Single-use bioreactors: 2x50L + 3x250L + 3x2,000L › Stainless steel bioreactors: 100L + 300L+ 2x2,500L
Downstream: › Single-use mixers: 500L, 650L and 1500L
Media: › Single-use and stainless-steel bioreactors: From 200L up to 3,000L
Purification: › State-of-the-art purification processes: chromatography (ÄKTA ready), centrifugation, ultrafiltration, diafiltration, tangential flow filtration
cGMP fill and finish capabilities › Liquid and lyophilised products up to BSL-2 › 4 filling machines: 6,000 vials/hour - 2x12,000 vials/ hour – 24,000 vials/hour › 2 freeze dryers: up to 24,000 vials per run, and up to 180,000 vials per run with automatic loading and unloading system › Component size: 2R-10R-20R › Manual and automatic visual inspection › Labeling and packaging
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
52 | 53
Name › DC Advisory Address/P.O. Box › Neue Mainzer Strasse 1 Postal Code/City › 60311 Frankfurt am Main Country › Germany Telephone › +49-69-9720-040 Email › enquiries@dcadvisory.com Website › www.dcadvisory.com Social Media › I I Number of Employees › 750+ Founded (year) › 1902 Areas of Activity › DC Advisory’s global Healthcare team has extensive experience across a broad range of healthcare sub-sectors, with a track record in delivering results for clients, anywhere in the world. Sub-sectors include: | Care & Services | Healthcare IT & Supply Chain | Medtech & Life Sciences | Pharma
DC Advisory is an international investment bank committed to making a difference. Part of Daiwa Securities Group Inc., we offer access to over 750 professionals in 24 locations throughout Asia, Europe, and the US. Across 11 industry-focused teams, we offer tailored, independent advice on M&A, debt raisings and restructurings, private capital markets, secondary advisory, and access to unrivaled Asia investment knowledge. Globally, DC Advisory has completed 80 Healthcare transactions since 2020. Selected notable transactions include: › Isto Biologics, a portfolio company of Thompson Street Capital Partnes, on its majority stake sale to Keensight Capital › Savanne Life Sciences on its majority investment in Franklin Biolabs › A rlington Capital Partners and Riverpoint on the acquisition of CP Medical › Blackstone on its acquisition of I`rom Group Co. Ltd › Näder Holding on its €1.1bn debt financing to support buyback of shares from EQT › Eurazeo on the sale of Peters Surgical to Advanced Medical Solutions Group plc › A ltor Equity Partners on the acquisition of VTU Group › c-Lecta on the sale of a majority stake to Kerry Group
Key contacts Martin Moser Managing Director Frankfurt am Main | Germany Martin.Moser@dcadvisory.com Dr. Wolfgang Kazmierowski Managing Director Frankfurt am Main | Germany Wolfgang.Kazmierowski@dcadvisory.com Andrew Murray-Lyon Managing Director London | United Kingdom Andrew.Murray-Lyon@dcadvisory.com
DC ADVISORY
David Lyons Managing Director Dublin | Ireland David.Lyons@dcadvisory.com Joaquín Gonzalo Managing Director Madrid | Spain Joaquin.Gonzalo@dcadvisory.com Marzia Cormun Director Milan | Italy Marzia.Cormun@dcadvisory.com Manish Gupta Managing Director Chicago | United States Manish.Gupta@dcadvisory.com Hector Torres Managing Director Chicago | United States Hector.Torres@dcadvisory.com Rich Blann Managing Director New York | United States Richard.Blann@dcadvisory.com Justin Balciunas Managing Director Washington, D.C. | United States Justin.Balciunas@dcadvisory.com Koki Kaita Senior Managing Director Tokyo | Japan Koki.Kaita@dawia.co.jp Shinta Niwa Managing Director Tokyo | Japan Shinta.Niwa@daiwa.co.jp 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
54 | 55
Name › Enzymicals AG Address/P.O. Box › Walther-Rathenau-Str. 49b Postal Code/City › 17489 Greifswald Country › Germany Contact Person › Dr. David Liese Telephone › +49-3834-515470 Email › info@enzymicals.com Website › www.enzymicals.com Social Media › I Number of Employees › 12 Founded (year) › 2009 Type of Laboratory › | S1 Biotech | Chemistry & Analytics | Process Engineering | K ilo Lab & Small-Scale Manufacturing Areas of Activity › | Biocatalysis Research | Development and scale-up of chemoenzymatic processes incl. DSP | Customer-specific solutions in enzyme technology and biotransformation | Development and production of enzymes | Applications in pharma, fine chemicals, F&F Patents › IP protected by international patent applications and granted patents External › | Broad international academic R&D Collaborations collaborations, most notably Greifswald University, Prof. Bornscheuer
Enzymicals AG: Industrial Biocatalysis from gram to ton With over 15 years of industry experience, Enzymicals AG is a trusted partner for industrial biocatalysis, delivering end-to-end solutions from catalyst lead finding to process optimisation, scale-up, and manufacturing support – reliably spanning gram to ton scale.
Driving the Industrial Shift towards Biology-Inspired Production At Enzymicals, we are committed to the implementation of biocatalysis technologies in industry, and are playing an active role in the global transition towards biology-inspired production concepts. As part of a strong EU-based partner network, we ensure the highest standards in IP protection and supply chain security. Operating as a CRO with a client-centric business model, we grant our partners full ownership of all newly generated intellectual property. This allows clients to develop strategic IP portfolios while maintaining complete freedom to operate – a decisive advantage in competitive markets.
Interdisciplinary Expertise for Complex Challenges Our team of highly skilled chemists and biologists specialises in complex chemical synthesis and integrated biocatalytic solutions. Process optimisation is a core strength of Enzymicals, and we combine enzymology, reaction engineering and chemical expertise to maximise yield, selectivity, robustness and cost-efficiency. Our service portfolio includes: › Advanced biocatalysis and enzyme screening › Tailor-made enzyme panel and recombinant expression service › Fermentation development for protein manufacturing (E. coli, Pichia, and Bacillus, but also with more specialised expression systems when required) › Systematic process optimisation (DOE-based approaches, parameter screening and intensification) › Chemo-enzymatic process design and optimisation
ENZYMICALS
Comprehensive Enzyme Services – From Library to Custom Design Enzymicals is a leading provider of enzymes for diagnostics, research and commercial production. With access to one of the world’s largest off-the-shelf collections of biocatalysts combined with a broad in-house library – covering enzymes from 50 classes – we offer rapid and targeted catalyst screening services. If the desired enzyme is not available in our collection, we will design and express tailor-made enzyme panels in suitable microbial hosts. This flexibility allows us to supply any biocatalyst of interest at both analytical and commercial scale.
Seamless Transition from Screening to Kilogram-Scale Synthesis Our chemical expertise ensures that screening hits are efficiently translated into optimised, scalable processes. These range from traditional batch reactions to advanced technologies such as enzymatic flow systems and rotating bed reactors. Comprehensive capabilities in bioprocess development allow efficient scale-up across a broad range of cultivation and biocatalysis systems from microtiter plate scale to 2 L parallel fermentations and 30 L in-house fermentations, and from milliliterscale biocatalysis to 0.5 L parallel reactors and 20 L glass reactors.
Network Capabilities – From Pilot to Production Through our network, we enable pilot to ton-scale manufacturing under non-GMP and GMP conditions. Combining superior catalysts, optimised chemistry, and integrated processing, we accelerate development timelines and deliver market-ready solutions.
Let’s Create Value Together Enzymicals AG – your dedicated partner for industrial biocatalysis and process optimisation from gram to ton.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
56 | 57
Name › EVONIK Operations GmbH Address/P.O. Box › Kirschenallee Postal Code/City › 64293 Darmstadt Country › Germany Contact Person › Dr. Tim Pohlmann Telephone › +49-151-120-260-80 Email › tim.pohlmann@evonik.com Website › www.evonik.com Social Media › F I I Number of Employees › >1,000 Founded (year) › 1982 Type of Laboratory › L1/L2/S1/S2, Areas of Activity › | CDMO, Microbial Fermentation | Manufacturing: cGMP, FSSC 22000, EFfCI, ISO 9001, FAMI-QS | Strain and process development | Piloting and Scale-up External › CDMO, Joint Development, Supply Collaborations Agreements, Joint Venture, Venture Capital Request for › Long-term business orientation Further Collaborations
A global precision fermentation leader from strain development to large-scale production The Business Line Health Care at Evonik operates a global network of biotechnological production sites at different scales with up to 250 m³ fermentors. This network includes a versatile multi-product site in Slovakia, designed for process scale-up and market launch of new and innovative products, which is available to our industrial partners. Evonik has leveraged its expertise in fermentation and biocatalysis technologies, including strain development, process optimisation, piloting, and large-scale manufacturing to bring a wide range of products to market. These products span various application fields, such as APIs, pharma intermediates, biomaterials, food ingredients, excipients, and cosmetics. With a total CDMO fermentation capacity exceeding 4,000 m³, Evonik’s network of sites in the U.S. and Europe is well positioned to support customer projects and products, regardless of scale or process complexity.
Evonik CDMO services – a one-stop shop In addition to development and production services, Evonik can support customers in techno-economical assessments (TEA) and life cycle assessments (LCA). Leveraging Evonik’s extensive engineering experience, Evonik can also facilitate the realisation of brownfield or greenfield concepts in case the volume demand should exceed current capacities. As such, Evonik positions itself as a comprehensive, one-stop shop and full-service provider.
EVONIK
Sustainability as a growth driver for biotechnology services Industrial biotechnology is a crucial driver for growth and innovation, enabling the development of novel, natureinspired products that are inaccessible through chemical synthesis, thereby complementing Evonik’s existing technologies and services. Advances in synthetic biology and a shift towards sustainable manufacturing methods are increasing the demand for Contract Development and Manufacturing Organizations (CDMOs) with bestin-class microbial fermentation capabilities. For over four decades, Evonik has been a dependable partner to pharmaceutical companies and other innovators aiming to industrialise disruptive biofabrication technologies.
The Evonik biotechnology platform The Evonik Biotech Hub serves as a central hub for various scientific disciplines within the global biotechnological network. With more than 100 scientists at three international sites, the Biotech Hub is the competence centre for industrial biotechnology at Evonik, providing everything from groundbreaking ideas to industrial bioprocesses, facilitating the transformation of business opportunities into commercially feasible processes. The profound understanding of biological systems, like the interactions in different target systems or the elucidation of the mode of action, as well as the differentiating capability in designing and operating efficient and sustainable manufacturing processes for biomolecules and microbial solutions, enables the Biotech Hub to develop tailored and competitive solutions allowing its customers to assume a leading position in their respective markets.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
58 | 59
Name › Evotec SE Address/P.O. Box › Manfred Eigen Campus Essener Bogen 7 Postal Code/City › 22419 Hamburg Country › Germany Contact Person › Sarah Fakih (EVP Head of Global Communications & Investor Relations) Telephone › +49-40-560810 Email › info@evotec.com Website › www.evotec.com Social Media › I Number of Employees › >4,800 Founded (year) › 1993 Areas of Activity › Drug discovery & preclinical development; integrated R&D services; small molecules & biologics; cell therapies; AI-driven discovery; PanOmics & iPSC-based disease modeling; ADME-Tox(Cyprotex); biologics development & manufacturing (Just – Evotec Biologics); oncology; neuroscience/CNS; metabolic & cardiovascular diseases; immunology; infectious diseases. Annual turnover › € 797.0 m (2024) Relevant R&D budget › € 50.8 m (2024) Biological Patents › A broad portfolio of patent families relating to compounds, targets, and assays. External › Evotec is working with more than 800 Collaborations pharma and biotech companies, academic institutions, and healthcare stakeholders globally. Request for › Our sales teams are happy to discuss Further Collaborations our end-to-end R&D solutions, in- and out-licensing opportunities, and how we can assist you in meeting your drug discovery and preclinical development needs.
Member of
Evotec is a globally operating life science company advancing drug discovery, preclinical development, and manufacturing through highly integrated, technologyenabled partnerships. Headquartered in Hamburg, Germany, Evotec delivers comprehensive solutions that translate deep molecular disease understanding into innovative, high-quality therapeutics across multiple modalities. Evotec’s activities cover the full continuum from target identification to clinical and commercial manufacturing, enabling flexible collaboration models for pharmaceutical, biotechnology, academic, and non-profit partners worldwide. By combining advanced science, leading technologies, and data-driven innovation, Evotec accelerates the discovery and preclinical development of differentiated medicines across a broad range of therapeutic areas. The company’s partnership approach goes beyond traditional service delivery by offering access to proprietary platforms, extensive multimodal data resources, and shared scientific risk and reward.
Discovery & Preclinical Development A core strategic pillar of Evotec’s business is its Discovery & Preclinical Development (D&PD) segment, which integrates biological expertise with proprietary technology platforms to make early-stage R&D more predictive and effective. At the intersection of science, technology, and data, Evotec applies industrialised, multimodal approaches to understand disease biology and translate insights into high-quality development candidates. Key capabilities include the PanOmics multi-omics platform, extensive molecular patient databases, and iPSC-based disease modelling, enabling highly translational, patient-relevant research across diverse indications.
EVOTEC
A defining feature of D&PD is the integration of AI and machine learning throughout discovery workflows. Scalable data infrastructures, advanced analytics, and AI-enabled models support faster hypothesis generation and validation, deeper target characterisation, and smarter compound and modality design. By systematically linking biological data with predictive algorithms, Evotec enhances decision-making, reduces attrition risk, and improves the probability of clinical success.
Just – Evotec Biologics Evotec’s second strategic pillar, Just – Evotec Biologics, extends the company’s capabilities into the design, preclinical development, and manufacturing of biologics. Built on the proprietary J.DESIGN platform, it combines molecular optimisation, process development, and continuous bioprocessing to deliver efficient, scalable, and flexible production of modern biotherapeutics. This advanced manufacturing approach is designed to reduce scale-up risk, shorten timelines, and improve cost efficiency while maintaining the highest quality standards, supporting both innovative biologics and next-generation modalities. Through the combination of integrated discovery platforms, strong AI-enabled analytics, and next-generation biologics manufacturing, Evotec positions itself as a long-term innovation partner committed to improving efficiency, predictability, and success rates of drug development to bring new therapies to patients faster.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
60 | 61
Name › FGK Clinical Research GmbH Address/P.O. Box › Heimeranstr. 35 Postal Code/City › 80339 Munich Country › Germany Contact Person › Martin Krauss Telephone › +49-89-893-119-0 Email › martin.krauss@fgk-cro.com rfp@fgk-cro.com Website › www.fgk-cro.com Social Media › I Number of Employees › 240 Founded (year) › 2002 Areas of Activity › Full service CRO for conduct of clinical studies, offering support in | Regulatory Affairs | Project Management/Monitoring | Medical Safety | Data Management/Biostatistics | Medical Writing | eSolutions | Quality Assurance all over Europe and US. Our daughter companies create special added value for our clients: | “FGK Representative Service”: EU Representation Services which are legally required for non-European sponsors conducting clinical studies in the EU (EEA). | “FGK Pharmacovigilance”: Post-Market PV services including QPPV and PMSF. External › BVMA - Federal Association of Collaborations Contract Research Organisations Request for › Small to mid-sized biotech, device or pharmaceutic seeking flexible support in their clinical development
Further Collaborations
Member of
Company overview FGK Clinical Research GmbH is a well-established and 100% privately owned full-service CRO with offices in Munich (HQ) and Berlin (branch office), Poland, Czech Republic, Hungary, The Netherlands, United Kingdom and US (Boston). We provide full service for all phases of clinical studies. Our client base from all over the world includes biotechnology, medical device and pharmaceutical companies. FGK has experience in conducting international, multicenter studies with hundreds of patients as well as single country studies with few patients. We have already conducted clinical trials in all major indication areas and have experience in rare diseases and orphan drugs, advanced new therapies, cell and gene therapies, pediatric diseases as well as first in human studies. With our highly qualified medical, scientific and regulatory experts, we guide our customers through the clinical trial process, from planning and approval to the final report. We also provide legal representation services to our non-European customers. As an ownerdriven company, our flat hierarchies, extremely stable teams, and yearlong study expertise are the basis for a sponsor-oriented, flexible approach to conduct every project in the highest quality for an optimal outcome throughout the complete clinical development.
Our approach to a project The main philosophy for FGK is to prepare and conduct studies in close cooperation with the sponsor. Our operational team works hand-in-hand with all other departments involved. This also applies for the project manager, who is the central contact person delivering all required information to the sponsor. Timely approvals and efficient troubleshooting are achieved through a combination of centralized project management and local monitoring, as well as local expertise and regulatory submissions within the country of study conduct.
FGK CLINICAL RESEARCH
Services Clinical Operations › Project management, primary liaison for sponsor communication, status reports, etc. › Feasibility, site management, monitoring, etc. Regulatory Affairs › Consulting on regulatory topics › Review of study documents (e.g. protocol, informed consent form, labels) › Clinical Trial Application with submission to EU and non-EU regulatory bodies › Legal representative – also visit www.fgk-rs.com Medical Safety/Pharmacovigilance › Adverse Event Management and assessment/reporting › Drug safety, medical monitoring and coding of medical terms › Pharmacovigilance – also visit www.fgk-pv.com Medical Writing › Investigator’s brochures, study protocols, ICF and subject information › Clinical expert reports, clinical publications, IMP and submission dossiers Data Management › CRF design and review, clinical trial databases › Data validation, processing and cleaning, external data handling, CDISC SDTM Biostatistics and Programming › Study design, sample size calculations › Statistical consultancy, analysis plan, programming and reporting › CDISC ADaM Quality Assurance › Audits of investigator site, database and system audits, internal audits eSolutions › eCRF/ePRO, RTSM, eTMF, CTMS, DCT elements 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
62 | 63
Name › Formycon AG Address/P.O. Box › Fraunhoferstr. 15 Postal Code/City › 82152 Planegg Country › Germany Contact Person › Sabrina Müller Telephone › +49-89-864-667-149 Fax › +49-89-864-667-110 Email › ir@formycon.com Website › www.formycon.com Social Media › IQ Number of Employees › 200 Founded (year) › 2012 Areas of Activity › Biosimilar development
Who We Are Formycon is a globally operating, independent biosimilar specialist with a broad product pipeline and an established, scalable development platform for biosimilars spanning various therapeutic indications. With its biosimilars – follow-on products for approved biopharmaceutical drugs – Formycon is making a significant contribution to improving patient access to highly effective and affordable medicines.
Biosimilars – Medicines for the Future A biosimilar medicine is a biological medicine highly similar to another already approved biological medicine. Biosimilars are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems.
Our Expertise Formycon is a “pure-play” biosimilar company, covering the entire value creation chain, from the selection of promising biosimilar candidates through to regulatory approval and the delivery of market-ready products. This includes, in particular: cell line development, comparative analytics, formulation and process development, as well as preclinical and clinical development activities, the preparation of regulatory submission packages for the relevant regulatory authorities, and the coordination of the respective approval processes. In addition, Formycon has comprehensive expertise in the planning, management and oversight of its supply chains and international product logistics.
Member of
FORMYCON
Products and Pipeline: With FYB201 (reference product Lucentis®) and FYB202 (reference product Stelara®), Formycon already has two biosimilars on the market. Another biosimilar, FYB203 (reference product Eylea ®) will be launched in 2026. Four pipeline candidates – including FYB206 (reference product Keytruda ®) and FYB208 (reference product Dupixent®) are currently in development, with FYB206 already demonstrating positive clinical data. Two further biosimilar candidates, FYB209 and FYB210, are currently in the preclinical development phase. For the global marketing of its biosimilar products, Formycon relies on commercialisation partnerships within defined geographic regions with internationally renowned pharmaceutical companies such as Fresenius Kabi, Sandoz, Teva, MS Pharma, Lotus, Zydus and many others. In addition, contract development and manufacturing organisations (CDMO) are important partners within the value chain for the development of biosimilars.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
64 | 65
Name › Galimedix Therapeutics, Inc. Address/P.O. Box › 3704 Calvend Lane Postal Code/City › Kensington, MD 20895 Country › USA Address/P.O. Box › Am Klopferspitz 19 Postal Code/City › 82152 Planegg/Martinsried Country › Germany Contact Person › Alexander Gebauer, MD, PhD, Co-founder and Executive Chairman Email › info@galimedix.com Website › galimedix.com Social Media › I Number of Employees › <10 Founded (year) › 2018 Areas of Activity › Small molecules, amyloid beta neuropathologies, Alzheimer’s disease, dry age-related macular degeneration, glaucoma External › Théa Open Innovation Collaborations Request for › We are looking for licensing/coFurther Collaborations development partners for GAL-101 (topical/oral) for the treatment of ophthalmic indications in Asia Pacific. In addition, we seek external funding for our technology in AD and are open for regional or global partnering in AD to develop our potentially diseasealtering medications.
Fighting dementia and blindness Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s novel small molecules offer the hope of changing the course of diseases where amyloid beta (Aβ) plays a role, such as in Alzheimer’s disease (AD), dry age-related macular degeneration (dAMD) and glaucoma – Galimedix’s initial areas of focus. Galimedix has a licensing agreement with Théa Open Innovation (TOI), a major ophthalmo logy player, for the development and commercialization of GAL-101 in ophthalmology for all regions except Asia Pacific and CIS. Global rights for all non-ophthalmology indications including AD are with Galimedix.
Targeting neurodegeneration at its source Normal Aβ monomers are impor tant to neuronal function, but misfolding of these monomers can lead to the development of toxic aggregated forms of Aβ – oligomers and protofibrils – that can be highly damaging to brain and retinal cells. Recent approvals of anti-Aβ drugs have validated them as a key target in AD. Many studies have indicated that these oligomers and protofibrils are an underlying cause of neurodegenerative diseases of the eye, such as dAMD and glaucoma. All three diseases are chronic, age-related disorders with no known cure and normally lead to irreversible loss of function. Galimedix´s compounds have shown in-vivo that at least partial recovery of function is possible. Galimedix aims to stop neurodegeneration at its source by blocking a key step in the neurodegenerative process, namely, preventing the formation of toxic Aβ oligomers and protofibrils. This is in contrast to most products in development and on the market, which aim to remove already formed toxic species.
GALIMEDIX
Small molecules designed to prevent toxic Aβ oligomer formation Galimedix is developing cutting-edge Aβ aggregation modulators that target the beginning of the Aβ peptide aggregation cascade. Lead product candidate, GAL-101, and the company’s next generation compound, GAL301, both act upstream to most other Aβ-targeting approaches on the market and in advanced development. This unique mode of action, which not only removes already formed toxic species, but prevents their formation, too, could enable these small molecules to effectively impact disease progression without disturbing normal neuronal function.
GAL-101: Current stage of development
© The Yuri Arcurs Collection - Freepik.com
Galimedix’s current pipeline
Compelling pre-clinical data support the potential of Galimedix’s product candidates to slow or stop neurodegeneration and also restore lost neuronal function. A Phase 2 proof-of-concept study in dAMD is ongoing. A clinical study with eye drops in glaucoma is also planned, an open IND in US was received. Phase 1 clinical results with the oral formulation have shown that GAL-101 is well tolerated and clinically safe. G AL-101 effectively crosses the blood-brain barrier, target engagement could be shown in plasma and CSF, and its pharmacokinetic (PK) profile strongly supports advancing the small molecule into Phase 2 development in Alzheimer’s disease. Galimedix’s approach could offer potentially gamechanging oral and topical neuroprotective therapies for the treatment of serious brain and eye diseases that impact millions of people. The current market for each of the lead indications – AD, dAMD and glaucoma – in the US and Europe alone is in the several billion dollar range and growing steadily.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
66 | 67
Name › HealthCapital – Cluster Healthcare Industries Berlin-Brandenburg Address/P.O. Box › Fasanenstr. 85 Postal Code/City › 10623 Berlin Country › Germany Contact Person › Carolin Clement Telephone › +49-30-46302-463 Email › info@healthcapital.de Website › www.healthcapital.de Social Media › I #HealthCapitalBB Areas of Activity › l Technology transfer between science and industry l Initiation and support of networks l Support for technology-oriented start-ups l Funding support for innovative project concepts l Providing and presenting regional life sciences information l Building and coordinating of scientific and interdisciplinary networks l Establishing contacts between experts from all disciplines l Organisation of events and seminars, Public Relations work for the life sciences region External › l Member of the Council of European Collaborations Bioregions (CEBR) l Member and contact point in Berlin for Enterprise Europe Network (EEN) l Collaborations with European Life Science clusters and SMEs in several European projects and other activities l Bio Deutschland l Global Health Hub
Member of
The Berlin-Brandenburg BioRegion – a Leading Hub for Life Sciences The Berlin-Brandenburg region is one of the leading, international locations for life sciences. The area concentrates on clinical research via a dense and compact healthcare network, and boasts a state-of-the-art IT infrastructure. It is no coincidence that the region is Germany’s ‘health capital’ as it is home to both the German government, as well as the centre for healthcare industries. The region’s distinction is anchored in its unique research and clinical landscape, as well as its ability to closely link the key players in the life sciences and healthcare. Biotechnology, in particular, is a strong driving force within the Berlin-Brandenburg healthcare industries cluster – HealthCapital – generating innovation and growth there and beyond. Through networking the pharmaceutical, diagnostics and medical technology sectors completely new fields of business are created. More than 300 biotechnology and 35 pharmaceutical companies are located in the German capital region. They include market leaders like Bayer, BERLIN-CHEMIE (Menarini), Daiichi Sankyo, Pfizer, Bausch + Lomb, Sanofi, and Takeda. Along with the sectors many small and mid-sized companies, they benefit from close cooperation, both with science and with more than 150 hospitals – above all, one of Europe´s largest university hospitals: Charité – Universitätsmedizin Berlin. Customers from research and industry have access to patient cohorts of urban and rural populations of about 180 ethnicities, covering all medical indications. The many technology parks and networks in the various branches of modern biotechnology create the excellent infrastructure and technological support that characterize the BerlinBrandenburg life sciences area. Focus of biotech activity within the region are biomedicine and diagnostics, therapeutics and regenerative medicine as well as industrial biotechnology.
HEALTHCAPITAL
Connected to the European Hotspots Active cooperation in the networks of Europe’s BioRegions has played a central role in the internationalisation efforts in the region. The region is a member of the Council of European Bioregions (CEBR).
Offering Service and Support for Life Sciences in the Capital Region The central contact and coordination office for all issues concerning life sciences in the German Capital Region is HealthCapital. At the interface of business, science and clinics, the HealthCapital cluster management drives networking and the technology transfer and supports companies interested in relocating to the region. Berlin Partner for Business and Technology and the Economic Development Agency Brandenburg (WFBB) are responsible for managing the cluster.
Meet us 2026 at › BIO-Europe Spring | March 23-25 | Lisbon, Portugal › DMEA | April 21-23 | Berlin, Germany › bio:cap | June 9-11 | Berlin, Germany › BIO International Convention | June 22-25 | San Diego, CA, USA › BioJapan | October 7-9 | Yokohama, Japan › BIO-Europe | November 9-11 | Cologne, Germany › MEDICA | November 16-19 | Düsseldorf, Germany
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
68 | 69
Name › HistologiX Ltd Address/P.O. Box › BioCity Nottingham, Pennyfoot Street, Postal Code/City › Nottingham NG1 1GF Country › UK Contact Person › Michaela Downie, PhD Telephone › +44-115-912 4460 Email › info@histologix.com Website › www.histologix.com Social Media › I Number of Employees › 25+ Founded (year) › 2005 Type of Laboratory GLP & GCP Compliant CRO Expert in Tissue-based Biomarker Analysis Areas of Activity › Histology, Immunohistochemistry (IHC), Multiplex Immunofluorescence (mIF), in situ hybridisation (ISH) RNAScope™, DNAScope™ & Digital Image and Data Analysis (IA)
HistologiX is a trusted GLP & GCP-compliant CRO providing tissue-based biomarker analysis. We help you visualise and understand what your drug or device is doing at the cellular and tissue level. Working collaboratively, our scientific team supports biomarker evaluation of cutting-edge therapeutics including cell and gene therapies, oncolytic viruses, therapeutic antibodies, small molecules, and RNA modifying enzymes.
Histology We provide histopathology in a range of species from early discovery, preclinical toxicology, through to clinical trials. Our team is experienced in taking samples from wet or frozen tissue through to slide, ensuring optimum presentation of regions of interest for H&E staining. We also offer an extensive range of special stains to identify specific tissue structures.
IHC & IF Tissue-Based Assays We are specialists in immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) assay development. We also have an extensive panel of optimised IHC and mIF assays. We evaluate tissue samples from target/biomarker validation, efficacy, distribution, proof of concept and mechanism of action studies. We also characterise cell proliferation, apoptosis, tumour and stromal inflammatory cell markers and detect RNA or RNA–protein co-localisation within tissues using RNAscope™. We advise on and source appropriate antibodies and control tissues. We pride ourselves on developing assays with outstanding reproducibility.
Supporting Immuno-oncology We offer optimised IHC/mIF assays to assess the complex tumour microenvironment (TME) in tissues from preclinical models through to clinical patient samples. Our mIF workflows, coupled with digital image and data analysis, enable spatial phenotyping of the TME and immune cell populations with high specificity and clarity.
HISTOLOGIX
TCR Studies With 100+ years of combined experience, we run GLP Tissue Cross Reactivity (TCR) studies for your biotherapeutic on a range of human tissues suitable for Investigational New Drug (IND) and Clinical Trials Application (CTA) submissions. With our non-regulatory TCR studies we support pre-clinical target validation and help you screen clones for unexpected on/off target binding thus providing toxicity/efficacy indicators.
Digital Image & Data Analysis We combine image and data analysis with pathology expertise to combine high-resolution whole-slide imaging, quantitative analysis and expert interpretation. This approach enables accurate evaluation of tumour heterogeneity, biomarker expression and phenotype interactions, all within the context of the surrounding tissue. We deliver reliable data that translate complex tissue biology into clear, reproducible outputs to support decision-making. We also provide brightfield and fluorescent digital scanning services, generating highquality images for archiving or digital image analysis.
Clinical Trials As a long-established, GCP-compliant organisation we have a proven track record in Phase 1/2 clinical trials. We support patient recruitment criteria and stratification, provide pre/post therapy biopsy IHC comparisons and have capacity to support large multisite clinical trials. We advise on tissue handling protocols, standard ischemia, fixation & processing. We offer routine semi-quantitative pathology scoring or harness digital image analysis for in-depth quantitative assessment as an exploratory endpoint, maximising the data from your precious clinical samples.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
70 | 71
Name › Hochschule Campus Wien, Department Applied Life Sciences
Practical, Innovative, and Researchoriented: Department of Applied Life Sciences at Hochschule Campus Wien
Address/P.O. Box › Favoritenstraße 222 Postal Code/City › 1100 Wien Country › Austria Contact Person › FH-Prof.in Diin Dr.in Silvia Apprich Telephone › +43-1-606-68-77-3500 Email › als@hcw.ac.at Website › www.hcw.ac.at/als-en Social Media › F I I Number of Employees › 55 Founded (year) › 2002 Type of Laboratory State-of-the-art laboratories and instruments for microbiology and cell biology, as well as for materials,
The Department of Applied Life Sciences of Hochschule Campus Wien (HCW) offers a wide range of degree programmes with a focus on life science and engineering, including bachelor’s and master’s degrees in molecular biotechnology, biopharmaceutical engineering, bioprocess engineering, and in packaging and resource management.
packaging and recyclability testing and bioengineering (including in-house experimental brewery “Scientific Brewhouse”). Areas of Activity › | Molecular Biotechnology | Industrial Bioengineering | Bioinformatics | Packaging Technology & Resource Management External › Universities, research institutions, Collaborations companies and Start-ups (Biotech, Pharma, Packaging) Request for › FH-Prof.in Mag.a Dr.in Alexandra Graf Further Collaborations
Member of
Research, development and partnerships Research and development constitute a significant and growing part of the Department of Applied Life Sciences’ activities. Partnerships with renowned national & international universities, research institutes, hospitals and industry as well as project-related funding from FWF, FFG and MA23 (funded by the city of Vienna) prove the recognised research expertise of the Department of Applied Life Sciences at Hochschule Campus Wien. Master’s students are constantly involved in R&D activities.
R&D projects: Focus on societally relevant challenges Research in the Department of Applied Life Sciences focuses on solving societally relevant challenges. HCW has built a strong reputation with practical educational content and application-oriented R&D projects in medical, molecular and industrial biotechnology and in packaging and resource management. Applied research and development is bundled in two subject-specific research centers: Research Center Molecular Biotechnology with two research groups currently focusing on allergen-host interaction and cell signalling pathways, and the Research Center Sustainability Assessment and Packaging Solutions which offers businesses and research institutions reliable analyses for materials, packaging and products throughout their entire life cycle. The portfolio is complemented by working groups in the fields of bioprocess engineering, industrial biotechnology and bioinformatics, providing integrated solutions tailored to industry needs.
HOCHSCHULE CAMPUS WIEN APPLIED LIFE SCIENCES
Specialised labs and a scientific brewhouse Students and researchers at the Department of Applied Life Sciences have access to an excellent technical infrastructure with state-of-the-art laboratories for microbiology and cell biology, as well as for materials and packaging testing and bioengineering. The facilities are complemented by the “scientific brewhouse”, a cuttingedge experimental brewery that offers unique insights into biotechnological processes.
Strong network: Biotech and packaging industry The biotech industry is a highly international, dynamic, and well‑connected sector. Therefore, all degree programmes in the Department Applied Life Sciences work closely with partners in science, research, and industry, both nationally and internationally. Across all sections, the department maintains strong collaborations with universities in Austria and abroad, leading research institutes, and relevant industrial partners.
Interdisciplinary combination Through the interdisciplinary combination of life sciences, technology, economics, and sustainability, students acquire profound theoretical knowledge and practical skills that open up excellent career prospects in research, industry, business, and government.
Our Study Programs and Research Centers: › Bachelor’s degree programs: Bioengineering, Molecular Biotechnology, Sustainable Management of Resources, Sustainable Packaging Technology. › Master‘s degree programs: Bioinformatics, Bioprocess Engineering, Biotechnological Quality Management, Molecular Biotechnology, Sustainability Assessment and Resource Management, Sustainable Packaging Design and Technology. › R & D: Research Center Molecular Biotechnology and Research Center Sustainability Assessment and Packaging Solutions. Pictures: © HCW/Schedl
Further information: www.hcw.ac.at/als-en 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
72 | 73
About IDT Biologika
Name › IDT Biologika Address/P.O. Box › Am Pharmapark Postal Code/City › 06861 Dessau-Rosslau Country › Germany Contact Person › Antje Seidler Telephone › +49-34901-8850 Email › info@idt-biologika.com Website › www.idt-biologika.com Social Media › F I Number of Employees › 1,600 Founded (year) › 1921 Areas of Activity › End-to-End Services in Contract Development and Manufacturing of Cell Culture & Microbial Proteins, Monoclonal Antibodies, Vaccines, Gene & Immune Therapeutics, Biosimilars and other Sterile Injectables
Contact us:
IDT Biologika, as part of SK bioscience, is a globally operating biopharmaceutical contract development and manufacturing organization (CDMO) specializing in cell culture and microbial-based proteins, monoclonal antibodies, vaccines, gene and immune therapeutics, biosimilars and other sterile injectables. With more than a century of expertise in biopharmaceutical manufacturing, we provide solutions that combine maximum flexibility, uncompromising quality, and complete regulatory compliance. Beyond delivering technical reliability and scalability, we understand the unique requirements of our customers—from early clinical phases through to commercial supply. Our dedicated teams ensure seamless process development and efficient product transfer, always upholding the highest regulatory standards.
Our services We offer our customers seamless end-to-end solutions and the ability to nimbly scale projects from development through to commercialisation. This includes process and analytical development, drug substance manufacturing up to BSL-2, fill-finish, labelling & packaging, quality control & analytics for clinical and commercial batches. At our customers request we supply their products in vials, pre-filled syringes (with and without safety devices), autoinjectors, or as combination products.
Our site At our site in Dessau-Rosslau, Germany, IDT Biologika operates one of Europe’s premier integrated facilities. With state-of-the-art infrastructure, reliable supply chain, strict quality systems, and experienced teams, we ensure flexibility, reliability, and full compliance with international regulatory standards - helping our customers bring their products to market efficiently and with confidence.
Member of
IDT-BIOLOGIK A
Proven expertise and strong track record Our fully integrated services are underscored by our commitment to quality and the operational excellence that flows through our best-in-class process and cGMP (up to BSL-2) manufacturing capabilities, meeting FDA, EMA, and ANVISA standards. IDT Biologika has made a significant contribution to global health by manufacturing products for international biopharma companies that are used to fight infectious diseases worldwide. In the rapidly emerging area of oncolytic virus-based therapies, we have established ourselves as a trusted partner by manufacturing one of the first commercial oncolytic virus products approved by EMA and FDA. With more than 35 years of proven expertise, we have earned the trust of our customers not only in mammalian and microbial manufacturing, but also in the fill-finish of sterile injectables in general. These achievements reflect the dedication, quality, and long-standing commitment of our company and its people.
Our Technology Excellence Our industry-leading knowledge of bacterial and viral manufacturing and our next-generation platforms build on years of successful partnerships with our customers and continue to drive innovation in biopharmaceutical manufacturing. Our broad technology portfolio includes proprietary cell lines as well as deep expertise with a variety of other cell lines. In addition, we have extensive know-how in handling and manufacturing bacterial strains and viral vectors across diverse production platforms. This covers the entire value chain—from drug substance upstream and downstream processing to final drug product manufacturing. Complementing these capabilities, we also provide our own well-characterized seed and cell banks, ensuring reliability, consistency, and flexibility for our customers’ projects. To further support our partners, we offer a full range of in-house analytical services, enabling seamless integration, highest quality standards, and efficient project execution. Please contact us for further information. 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
74 | 75
Name › Immunic Therapeutics Address/P.O. Box › Lochhamer Schlag 21 Postal Code/City › 82166 Gräfelfing Country › Germany Headquarter: New York City, USA Contact Person › Jessica Breu (Vice President Investor Relations and Communications) Telephone › +49-89-2080477-09 Email › info@imux.com Website › www.imux.com Social Media › F I Q Number of Employees › 90 Founded (year) › 2016 Areas of Activity › | Immunology | Chronic inflammatory and autoimmune diseases External › | University Hospital Frankfurt, Germany: Institute for Infectiology Collaborations | Ludwig-Maximilians-University (LMU) Munich, Germany: Department of Pharmacy | City of Hope, California, USA: Beckman Research Institute, Dept. of Immunology & Theranostics | Charité – Berlin University of Medicine, Germany: Dept. of Gastroenterology, Infectious Diseases & Rheumatology | University of Turin, Italy: Neuroscience Institute Cavalieri Ottolenghi | Kyoto University, Japan: Institute for Life and Medical Sciences
Member of
Immunic (Nasdaq: IMUX) is developing a clinical pipeline of oral, small molecule therapies for chronic inflammatory and autoimmune diseases. The company’s lead asset, vidofludimus calcium (IMU-838), is being developed as a next-generation oral treatment option for patients with relapsing and progressive forms of multiple sclerosis (MS). Immunic’s second clinical-stage asset, IMU-856, has demonstrated clinical proof-ofconcept in celiac disease patients and may represent a completely new treatment approach for a variety of gastrointestinal disorders. IMU-381, currently in preclinical testing, comprises next-generation molecules in preclinical testing for neurologic, gastrointestinal and other autoimmune diseases.
Vidofludimus Calcium: Addressing Multiple Drivers of Neurodegeneration in Multiple Sclerosis Vidofludimus calcium is an orally available, nextgeneration selective immune modulator that acts as a potent, first-in-class nuclear receptor related 1 (Nurr1) activator and as a selective dihydroorotate dehydrogenase (DHODH) inhibitor. Nurr1 is a neuroprotective transcription factor and an emerging target in neurodegenerative diseases. Vidofludimus calcium is currently being investigated in the twin phase 3 clinical ENSURE trials in relapsing MS (RMS). Immunic announced a positive outcome of an interim analysis, confirming the trials can continue as planned. Top-line data for both ENSURE trials is expected by the end of 2026. For progressive MS (PMS), Immunic announced positive results from its phase 2 CALLIPER trial of vidofludimus calcium. The drug showed consistent reductions in disability progression in the overall PMS and all subpopulations, including primary and non-active secondary PMS – both areas with high unmet medical needs. Safety and tolerability remained favourable, with no new safety signals identified. Building on these results, Immunic plans to initiate a phase 3 clinical program in primary PMS, expected later this year.
IMMUNIC THERAPEUTICS
Neuroprotective, Anti-Inflammatory, and Anti-Viral Effects Immunic believes that vidofludimus calcium has the potential to demonstrate important advantages over approved MS treatments through its combined neuroprotective, anti-inflammatory, and anti-viral effects, potentially making it a unique treatment option for all forms of MS. The collective findings support the concept that Nurr1 activation may represent a novel mechanism to prevent neurodegeneration in MS. To date, vidofludimus calcium has shown consistent clinical effects and favourable safety/tolerability in more than 3,400 patients across trials and formulations. The molecule selectively targets hyperactive immune cells without suppressing normal immune function. In phase 2 clinical testing, it demonstrated strong suppression of MRI lesions, showed encouraging signs of reducing confirmed disability worsening, and lowered serum neurofilament light chain (NfL) levels. In addition, vidofludimus calcium’s broad-spectrum anti-viral activity may support lowering the rate of viral infections and reactivations, including Epstein-Barr virus (EBV), potentially resulting in slowing EBV-related neurodegenerative processes.
IMU-856: Targeted to Restore a Healthy Gut by Renewal of the Gut Wall IMU-856 is an orally available and systemically acting small molecule modulator that targets Sirtuin 6 (SIRT6), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. Immunic announced positive phase 1b trial results in celiac disease, with IMU-856 showing benefits across histology, symptoms, biomarkers, and nutrient absorption, while being safe and well tolerated. Further clinical testing is in preperation. Additionally, in a post hoc analysis of this trial, IMU-856 demonstrated a dose-dependent increase of endogenous glucagon-like peptide-1 (GLP-1) levels and, in preclinical testing, showed a dose-dependent reduction of body weight gain and food consumption. 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
76 | 77
Name › Intravacc Address/P.O. Box › Antonie van Leeuwenhoeklaan 9 Postal Code/City › 3721 MA, Bilthoven Country › The Netherlands Contact Person › Wouter van den Braak, MSc Telephone › +31-30-792-0416 Email › bd@intravacc.nl Website › www.intravacc.nl Social Media › I Number of Employees › 35 Founded (year) › 2013 Type of Laboratory ML-II, BSL-2 Areas of Activity › Bacterial and viral vaccine development; Process, formulation and assay development; (Pilot) Production, QC & QA; Analytical services
Your Partner in Vaccine Development Bringing a vaccine from concept to clinic requires speed, expertise and a robust development strategy. Intravacc is an independent CDMO specialised in vaccines and complex biologics. We support biotech and pharmaceutical companies in translating innovative ideas into scalable, GMP-ready processes and highquality clinical material. From early feasibility to Phase I/ II supply, we combine scientific excellence with practical development expertise to reduce technical risk, avoid costly late-stage process redesign and accelerate your path to the clinic.
From Discovery to Clinical Readiness Intravacc offers integrated process and analytical development services tailored to your product. Our multidisciplinary teams design, optimise and scale upstream and downstream processes, develop formulations, establish analytical methods and deliver GMP drug substance for preclinical and Phase I/II studies. We focus on establishing manufacturing-ready processes early in development, reducing technical risk and facilitating a smooth transition to late-stage manufacturing. Our platform-based approaches enable efficient development of viral, bacterial and conjugate vaccines, as well as recombinant proteins.
Proven Experience, Global Impact We build on decades of vaccine expertise and international technology transfer. Our know-how has contributed to widely used vaccines including polio, measles, DPT and Hib, as well as to the global transfer of influenza and Sabin-IPV technologies. Today, we leverage this experience to support partners in developing nextgeneration vaccines and biologics, combining innovation with practical manufacturability. Our facilities at the Utrecht Science Park Bilthoven include over 2,000 m² of ML-II laboratories and GMP cleanrooms for pilot-scale production. Operating under strict quality standards, we support CMC development, documentation and technology transfer worldwide.
INTRAVACC
Advanced Analytical Services Robust analytics are essential for successful development and regulatory approval. At Intravacc, we therefore also provide comprehensive analytical services for the in-depth characterisation of vaccines and biopharmaceuticals. Our LC-MS-based methods enable precise protein identification, absolute quantification and detailed impurity profiling, including advanced host cell protein analysis. Compared to traditional methods, LC-MS delivers deeper, unbiased impurity insight and supports risk-based process optimisation. Our structural characterisation services meanwhile cover a wide array, from primary sequence confirmation and higher-order structure analysis to post-translational modification mapping and molecular heterogeneity assessment. By combining state-of-the-art instrumentation, including high-resolution Orbitrap MS and advanced biophysical techniques, with our expertdriven solutions we ensure sensitive and reliable data generation.
Accelerating Your Success At Intravacc, quality, speed and transparency drive everything we do. Our integrated CDMO and analytical capabilities allow you to work with one experienced partner from early development through clinical supply. Whether you are advancing a novel vaccine platform or strengthening the manufacturability of a complex biologic, Intravacc helps you reduce CMC risk, control timelines and move confidently toward market entry.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
78 | 79
Name › iOmx Therapeutics AG Address/P.O. Box › Fraunhoferstr. 22 Postal Code/City › 82152 Martinsried Country › Germany Contact Person › Dr. Apollon Papadimitriou Telephone › +49-89-8999-7090-0 Email › info@iomx.com Website › www.iomx.com Social Media › I Number of Employees › 47 Founded (year) › 2016 Areas of Activity › | Next-generation cancer therapies | Drug development | Immuno-oncology
Overcoming Resistance in Solid Tumours with Next-Generation Immuno-Oncology Therapeutics iOmx Therapeutics is a clinical-stage biotechnology company developing breakthrough immuno-oncology therapeutics designed to overcome resistance in major solid tumour indications. Building on deep insights into tumour immune-evasion biology, the company translates previously unexplored escape mechanisms into novel, biomarker-driven drug programmes with the potential to redefine future standards of cancer care. Founded in 2016 and headquartered in Martinsried/ Munich, iOmx combines cutting-edge tumour immunology capabilities with strong biologics development expertise. Its mission is to translate its tumour immunology insights into powerful and differentiated cancer drugs with multimodal mechanisms of action, showing single-agent activity.
A New Generation of Immuno-Oncology While checkpoint inhibitors have transformed cancer treatment, most patients with solid tumours still do not benefit due to complex immune escape mechanisms. iOmx addresses this unmet medical need by targeting novel pathways beyond PD-1/PD-L1 with multifunctional biologics designed for precision, potency, and durable anti-tumour activity. The company’s discovery platform translates immuneevasion insights into innovative antibody-based therapeutics, including bispecifics and T-cell engagers.
Advancing a High-Value Biologics Pipeline iOmx is advancing a diversified pipeline of novel immuno-oncology programmes designed to expand the reach of immunotherapy into resistant solid tumours.
Member of
IOMX
iOmx’s latest programme, IOMX-0675, marks the beginning of a new generation of therapeutics. IOMX-0675 is a unique dual-targeting antibody blocking the immunosuppressive receptors LILRB1 and LILRB2 on immune cells. By reactivating both innate and adaptive immunity, the programme is designed for cancers resistant to checkpoint inhibition. Beyond this asset, iOmx is developing next-generation multifunctional bispecific antibodies and T-cell engagers designed to recruit immune cells directly into the tumour microenvironment and deliver synergistic antitumour activity.
Scientific Excellence Driving Clinical Impact iOmx brings together a highly experienced team with deep expertise in antibody discovery and engineering, translational tumour immunology, and clinical development. Backed by top-tier international life-science investors, iOmx is rapidly driving its development programmes toward value-defining clinical milestones.
Shaping the Future of Cancer Therapy With its focus on overcoming resistance in solid tumours, iOmx is pioneering a new generation of immunooncology therapeutics. By translating deep tumour immunology insights into powerful multimodal biologics, the company is positioned to expand the benefits of immunotherapy to a broader patient population, defining the next backbone of cancer treatment.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
80 | 81
Name › Fördergesellschaft IZB – Innovations- und Gründerzentrum Biotechnologie mbH Address/P.O. Box › Am Klopferspitz 19 Postal Code/City › 82152 Planegg/Martinsried Country › Germany Contact Person › Christian Gnam Telephone › +49-89-5527948-0 Fax › +49-89-5527948-29 Email › info@izb-online.de Website › www.izb-online.de Number of Employees › 36 Founded (year) › 1995 Type of Laboratory › S1 Areas of Activity › l Biotechnology l Life Sciences Number of Firms › over 40 start-ups External › l Collaborations with the scientific Collaborations faculties on the Campus Martinsried l Munich Life Science Pitch Day with the High-Tech Gründerfonds Management GmbH l IZBrunch - Science meets Sciencs l Law Lab - law for biotech businesses
Hotspot for Life Sciences The Innovation and Start-up Center for Biotechnology (IZB) with sites in Planegg-Martinsried and FreisingWeihenstephan near Munich is one of the leading biotechnology centres in Europe. The company Fördergesellschaft IZB mbH, founded in 1995, operates the IZB. The IZB hosts over 40 biotech companies with more than 700 employees across a 26,000 m² area. At the main site in Planegg-Martinsried, spanning 23,000 m², resident start-ups primarily focus on medical biotechnology. The IZB in Freising provides ideal conditions for founders in the life sciences sector.
Outstanding infrastructure The IZB offers young companies a superior environment and infrastructure for realising their product and service ideas. Crucial for successful growth are S1 laboratories and office spaces that flexibly adapt to the companies‘ needs. Additionally, the IZB provides excellent infrastructure. At the Martinsried location, start-ups have access to modern conference rooms, a design hotel, the restaurants „The Bowl“ and „Seven and More“, as well as the Bio Kids kindergarten.
A strong network Another vital success factor for IZB start-ups is the close proximity of both locations to cutting-edge research. On the Weihenstephan Campus, you’ll find the TUM school of Life Sciences of the Technical University of Munich, as well as the University of Applied Sciences Weihenstephan-Triesdorf. Adjacent to the IZB on the Martinsried/ Großhadern campus, you’ll find, among others, two Max Planck Institutes, faculties, and facilities of LMU, as well as the University Hospital of Munich-Großhadern. The close proximity of the scientific institutes around the Martinsried campus provides an enormous competitive advantage. Young scientists can benefit from incorporating scientific and research expertise into their own companies; short distances promote interaction and cooperation between biotech companies - in the face of globalisation, both factors are essential for successfully entering world markets.
IZB
The IZB fosters and supports this strong network through various measures: The Faculty Club offers an exceptional venue for founders and scientists to exchange ideas and know-how. With an array of event formats like the IZBrunch and the Munich Life Science Pitch Day, the IZB has established itself as a key meeting point in the industry, extending far beyond Munich.
IZB – in brief › 26,000 m2 laboratory and office space for start-ups and growing companies › Home to more than 40 start-ups › Business development support › In-house estate management › Center of an impressive research campus › Access to an international network › Flexible lab and office structures › Close contacts with investment partners › Joint location marketing › A ttractive, modern conference rooms, also for external booking › IZB Residence CAMPUS AT HOME (42 Rooms) › Faculty Club G2B › Restaurants: SEVEN AND MORE and THE BOWL Food Lounge › 2 day care centres (Bio Kids & Bio Kids2) Visit us:
Get our Newsletter:
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
82 | 83
Name › KUPANDO GmbH Address/P.O. Box › Willy-Brandt-Platz 2 Postal Code/City › 12529 Schönefeld Country › Germany Contact Person › Dr. Johanna Holldack (CEO), Angelika Leppert (CFO) Telephone › +49-30-5200586020 Email › contact@kupando.com Website › www.kupando.com Social Media › I Number of Employees › 4 plus extended network of consultants Founded (year) › 2018 (operational since 2022) Areas of Activity › oncology; solid tumours; immuno therapy; infectious diseases; AMR; pathogen-agnostic treatment and prevention; trained innate immunity External › | University of Bochum (oncology); Collaborations | Undisclosed Partner (innovative vaccine research) | BMFTR-funded pathogen-agnostic therapy and prophylaxis against AMR Request for › Kupando is pioneering a new era in Further Collaborations cancer and infectious disease prevention and treatment through the power of innate immune activation and trained innate immunity. The innovative dual TLR agonist approach has the potential to transform the way of fighting these diseases. We’re seeking partners who share our vision for transforming patient care. We are currently open to codevelopment partnerships for solid tumors, either as single agent or combination therapies. Partner with Kupando and help us develop innovative therapies for cancer and infectious diseases.
Member of
KUPANDO is a pioneering biotech company developing disruptive therapies to address critical unmet medical needs with significant market potential in cancer and infectious diseases. Kupando’s disruptive approach harnesses the power of innate immune stimulation and induction of trained innate immunity by dual Toll-Like Receptor (TLR) agonists. Our lead candidate, KUP101, is a differentiated and competitive dual TLR agonist with a robust preclinical profile, advancing into the clinic with a pipeline of multiple programmes targeting oncology and infectious disease indications.
Drug candiates: TLR4/7 agonists Toll-Like Receptors (TLRs) are key components of the immune system responsible for detection of cancer and infection signature molecules. When they detect a threat, such as a virus or a tumour cell, they activate the immune system to fight back. TLR4 and TLR7 are two important TLRs, each with unique roles in recognising and responding to different threats. Kupando develops innovative drug candidates which activate both TLR4 and TLR7 simultaneously, unleashing a powerful immune response, both harnessing innate immunity and inducing trained immunity.
A unique tool to fight cancer and infectious diseases Our proprietary drug candidates are ideally suited for the systemic treatment of solid tumours (tissue agnostic), and the prevention and treatment of infectious diseases. Kupando is focusing on critical unmet medical needs, such as treatment-resistant cancers and antimicrobial-resistant infections.
A game-changer Kupando’s drug candidates are first-in-class, differentiated and competitive small molecules with the potential to transform the management of cancer and infectious diseases. The innate immune system is highly conserved. As such, its efficacy treating cancer or treating/ preventing infections is tumour/ pathogen agnostic.
KUPANDO
Hope for cancer patients facing difficult-to-treat conditions In cancer, Kupando’s lead drug candidate, KUP101 may extend therapeutic options for those who do not respond to checkpoint inhibitors.
Promising new approach to combat infectious diseases As a host-directed agent – unlike antibiotics – KUP101 has the potential for highly effective therapeutic as well as prophylactic applications, while mitigating the risk of pathogen resistance; especially in antimicrobialresistant infections.
Advantageous features › TLR4 and TLR7 are validated targets › High specificity for target › No relevant off-targets › Fast intracellular uptake, leading to improved safety › Combines both TLR4 and TLR7 agonist › Advantageous administration route (formulated for systemic administration) › Tumor agnostic, pathogen agnostic (broad immune response including epitope spreading) › Effective as single agent or in combination (synergistic in combination with checkpoint inhibitors) › Host-directed agent, no induction of drug resistance when used to treat or prevent infectious diseases
Management With over 100 drug development projects and a huge variety of transactions under its belt, our team brings extensive expertise in business and drug development including in manufacturing, non-clinical and clinical development of vaccines and drugs, as well as regulatory pathways in Europe, the US and Asia.
Partnering Proposition We are currently open to co-development partnerships in solid tumors (clinical stage), either as single agent or combination therapies.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
84 | 85
Name › Lipotype Address/P.O. Box › Blasewitzer Str. 58 Postal Code/City › 01307 Dresden Country › Germany Contact Person › Marta Vicini Telephone › +49-351-25-989-50 Email › service@lipotype.com Website › www.lipotype.com Social Media › I Number of Employees › 42 Founded (year) › 2012 Areas of Activity › Lipidomics
Lipotype: A leader in modern lipidomics Lipids are essential molecules of living organisms, yet most routine analyses still overlook the vast majority of lipids. For example, while standard human blood tests capture only a few lipid parameters, more than 99% of the lipid spectrum remains unmeasured. This limits progress in understanding metabolism, inflammation, ageing, and the molecular foundations of disease. Lipotype GmbH, founded in Dresden in 2012, addresses this gap by offering advanced, comprehensive lipidomics services to academic and industry partners worldwide.
Extensive lipid coverage and high analytical precision Lipotype provides access to over 7,000 individual lipids across more than 100 lipid classes, representing the broadest lipidomics coverage available today. Its mass spectrometry-based platforms deliver quantitative, reproducible lipid profiles across a wide variety of sample types, including blood, tissues, cells, model organisms, food products, and cosmetic formulations. Automated workflows, rigorous quality controls, and robust data processing ensure reliable, comparable, and publication-ready datasets.
Fast turnaround and clear biological interpretation A major advantage of Lipotype’s offering is that the service goes far beyond raw data. Customers receive reports with data visualisations, statistical analyses, and biological interpretation when requested, allowing them to quickly understand lipid changes and their functional relevance. Turnaround times of about six weeks make the platform ideal for fast paced research projects, biomarker identification, clinical screenings, and product development cycles.
Member of
LIPOT YPE
A multidisciplinary team with deep expertise Lipotype’s scientific foundation is rooted in decades of lipid research led by Prof. Dr. Kai Simons, a globally recognised pioneer in cell membrane biology and the lipid raft concept. The company’s team brings together molecular biologists, clinicians, mass spectrometry specialists, biostatisticians, and bioinformatics experts. This interdisciplinary expertise ensures high quality analyses and meaningful data interpretation for clients across the life sciences, biotech, pharma, food, and cosmetics sectors.
Supporting research across diverse fields Lipidomics plays an increasingly important role in under standing metabolic disorders, cardiovascular risk, neurodegeneration, and immune regulation. It also supports innovations in nutrition, dermatology, and personalised medicine. Lipotype enables these advances by providing detailed lipid profiles that help identify disease relevant lipid signatures, track intervention responses, or characterise the lipid composition of products and biological systems.
Enabling the future of lipid based research and innovation As the importance of lipid metabolism becomes more widely recognised, reliable and comprehensive lipidomics data are essential for uncovering new biomarkers and mechanisms. With its broad coverage, rapid delivery, and scientific depth, Lipotype helps researchers transform complex lipidomes into clear, actionable insights, bringing lipid science closer to practical biomedical and industrial impact.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
86 | 87
Name › Maiwald Intellectual Property Address/P.O. Box › Elisenstraße 3, Elisenhof Postal Code/City › 80335 Munich Country › Germany Contact Person › Dr Eva Dörner Telephone › +49-89-747266-0 Fax › +49-89-776424 Email › info@maiwald.eu Website › www.maiwald.eu Social Media › I Q Number of Employees › 270 Founded (year) › 1995 Type of Company › Law Firm Areas of Activity › Sectors: | Pharma & Biotech | Organic Chemistry & Polymers | Inorganic & Construction Materials | Food & Agriculture | Electrical & Mechanical Engineering | Communication & Information Technology | Mobility & Energy | Displays & Light | Measuring & Process Technology | Medical Technology & Imaging | Artificial Intelligence & Digitalization | Defence and security technology/ Defence Engineering Legal Areas: | Patents & Utility Models | Supplementary Protection Certificates | Trademarks & Designs | Copyright | Competition & Antitrust Law | Compliance | Contract Law | Employee Invention Law | Pharmaceutical Law | Data Protection | Plant Variety Protection | UPC Strategy: | IP Search | IP Consulting
As one of Germany’s largest and best-known firms in the field of intellectual property, Maiwald’s foremost aim is to achieve the best possible solution for each client in each particular case. Maiwald employs about 270 people working out of Munich and Düsseldorf. The interdisciplinary teams work closely with each other and with foreign associates, always with an eye to the client’s particular needs, whether start-up, medium-sized firm, or large corporation, across all industrial sectors. Maiwald’s team does its utmost to ensure that all IP matters are handled with competence and care, irrespective of the client’s physical location, whether in Germany, Europe, or beyond. Client-oriented solutions and personal consultation are at the heart of Maiwald’s professional approach. Our teams comprising 110 highly qualified patent attorneys, attorneys-at-law and technical experts, including search specialists, devote their extensive skills and experience to providing clients with optimal customized IP solutions on a daily basis. Teams of paralegals with client-specific competencies address individual administrative needs. Client satisfaction is evidenced by the long-standing business relationships with many prestigious corporations.
Main areas of practice Maiwald advises and represents domestic and international clients from all technical fields across the entire spectrum of intellectual property law. When appropriate, an interdisciplinary exchange of information and expertise can take place between various teams, ensuring that the optimal solution is achieved in each particular case.
Maiwald’s patent attorneys Maiwald’s team of patent attorneys combine their expertise across various technical fields and advise and represent clients across a wide range of industries. Maiwald’s patent attorneys have extensive experience in the management of international patent portfolios.
MAIWALD
Helping you shape the future.
egal
Engineering Legal
Research
Services include drafting and filing patent applications and coordinating worldwide prosecution as well as Engineering defending, enforcing, and contesting IP rights. Patent attorneys also prepare freedom-to-operate (FTO) opinions based on thorough research and analysis to establish whether existing IP rights of third parties could potentially stand in the way of a client’s particular product or manufacturing process. Clients also benefit from the exceptional expertise in opposition and appeal proceedings before the German and European Patent Office as well as in infringement and nullity proceedings before the national courts.
Life Science
Maiwald’s attorneys-at-law Maiwald’s team of attorneys-at-law can boast many
arch
Life Science years of experience in trademark, design, copyright, and contract law as well as patent infringement litigation, particularly in the conduct and coordination of international litigation proceedings.
Close cooperation between patent attorneys and attorneys-at-law is especially important in patent infringement litigation, since this type of proceedings generally calls for a comprehensive overview of the various national regulations as well as a thorough grasp of the particular technology. The interdisciplinary teams provide a comprehensive package of services to guarantee the successful conduct of legal proceedings in an international arena, also in cases where speed is of the essence, such as in preliminary injunction proceedings or border seizure procedures. However, Maiwald’s attorneys-at-law would be the first to acknowledge that litigation is not always the best solution. They are skilled advocates in arbitration and mediation proceedings and are trusted experts when it comes to negotiating licensing contracts
maiwald.eu Member of 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
88 | 89
Name › Microcoat Biotechnologie GmbH Address/P.O. Box › Am Neuland 3 Postal Code/City › 82347 Bernried Country › Germany Contact Person › Dr. Ingrid Wanninger (Business Development) Dr. Michael Kroder (Business Development) Telephone › +49-8158-9981-0 Fax › +49-8158-9981-10 Email › info@microcoat.de Website › www.microcoat.de Social Media › I Number of Employees › > 200 Founded (year) › 1992 Type of Laboratory › S1/S2, GLP, GCP, GMP, ISO 9001, EN ISO 13485 ISO 14001 Areas of Activity › | Contract manufacturing | Custom development | Laboratory services | Endotoxin and pyrogen testing service External › Business-to-business with industrial Collaborations partners in the pharmaceutical industry, diagnostic industry and life science industry Request for › Microcoat seeks joint projects and Further Collaborations service partnership with pharmaceutical, biotech and diagnostic companies, as well as with players in the field of food safety testing, crop science and instrumentation (medical devices).
Member of
Company profile Microcoat offers a wide range of individual and specialised services for the diagnostic and pharmaceutical industry. In close cooperation with our customers, we aim for best performance, building on a complete range of advanced technologies and uncompromised quality standards. For pharmaceutical companies, we leverage our profound expertise in in-vitro diagnostics and assay development in order to become a preferred partner in early development, pre-clinical and clinical phases of drug development and patient sample testing. For food safety, environmental testing and other specialised diagnostic fields, Microcoat aims to be the preferred OEM-partner for the development and manufacturing of reliable test components and kits.
Contract manufacturing diagnostics Microcoat is an approved original equipment manufacturer (OEM) for diagnostic test kits, bulk and finished components. We manufacture according to ISO and IVD standards. Since all critical test components are produced and modified in house, we are able to control quality at all stages of the production process. Production technologies: › Fermentation (30 litre scale) › Downstream processing › Protein chemistry › Microplate and particle coating › Dispensing/filling/labelling › Freeze-drying › Kit assembly Product categories: › Coated microplates › Lateral flow test strips › Recombinant proteins/antigens › Antibody/protein conjugates › Liquid components › Dried/lyophilized components › Diagnostic kits
MIRCOCOAT
Custom development diagnostics Microcoat offers unique expertise in diagnostic assay and product development. A broad spectrum of methods, skilled staff and intensive communication with the customer are the cornerstones of successful project execution. Development projects are based on detailed milestone plans and follow standardised development guidelines through the five project phases (feasibility, development, verification, validation and manufacturing). We develop for you: › Immunological assays › Molecular assays › Sample and matrix preparation protocols › Depletion protocols
Functional Service Provider Laboratory services
B2B Diagnostics
In our certified facilities, we conduct a broad spectrum of GLP/GCP services to support drug development starting from early discovery to post-marketing surveillance. As an independent contract research organisation and preferred provider we serve pharma and life science industries worldwide. Based on long lasting experience in endotoxin and pyrogen testing, Microcoat offers a set of proprietary methods and skilled scientific personnel for GMP release testing as well as non-routine projects. Services are run as flexible customer-specified projects including the search for root causes, exploration of realization alternatives, development of product-specific adaptions and GMP compliant validation of newly established methods. Our services include: › Assay development and validation › Biomarker testing › Immunogenicity/PK assays › Endotoxin and pyrogen testing
Business model Microcoat is focused on business-to-business with industry customers, seeking a reliable and long-lasting partnership for outsourcing projects such as contract manufacturing (OEM), assay and product development, and bioanalytical testing in the context of pre-clinical and clinical studies.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
90 | 91
Name › Microsynth AG Subsidiaries › Microsynth Seqlab GmbH Microsynth France SAS Microsynth Austria GmbH Ecogenics GmbH Address/P.O. Box › Schützenstrasse 15 Postal Code/City › 9436 Balgach Country › Switzerland Contact Person › Dr. Markus Schmid, Christof Wunderlin (Co-CEOs) Johanna Brändli (Head of Quality Management) Telephone › +41-71-722-83-33 Email › info@microsynth.ch Website › www.microsynth.com www.ecogenics.ch Founded (year) › 1989 Type of Laboratory › S1/S2, GMP/GLP Key Certifcates › | ISO 9001:2015 | ISO 13485:2016 | EN ISO 17025:2017 | GMP certified (Swissmedic) for testing of TpP/TP/GMO
The Company Microsynth is a trusted partner for nucleic acid synthesis and analysis, serving customers in research, diagnostics, and the biopharmaceutical industry worldwide, with a strong focus on Europe. For more than 35 years, we have followed one simple principle: delivering highquality results fast, with personal support and an excellent price-performance ratio. With sites in Switzerland, Germany, France, and Austria, and more than 130 employees, Microsynth provides local access, consistent standards, and dependable execution across Europe.
Oligo Synthesis Microsynth offers a comprehensive oligo portfolio covering four specialised areas tailored to distinct applications: › Research Oligos: Oligos for PCR, sequencing, cloning, and routine molecular biology applications. › Diagnostic Oligos: Primers and an extensive probe portfolio for molecular diagnostic assays and kit development. › Therapeutic Oligos: ASOs, siRNAs, aptamers, and CpG oligos, supporting projects from early screening to preclinical development. › Custom Oligos: Tailored oligos and specialised building blocks beyond standard offerings. Across all four areas, our success is driven by optimised synthesis platforms, advanced purification, and expert scientists. Automated production, rigorous quality control, and advanced analytics ensure exceptional quality, consistency, and reliability of our oligo products.
DNA/RNA Analysis Microsynth is a leading European provider of DNA sequencing services. Our strategically located Express laboratories ensure efficient sample logistics and rapid turnaround times, including overnight results for key services: › Economy Run: Best-in-class Sanger sequencing in tubes or plates for routine samples as well as challenging PCR products and plasmids.
MICROSYNTH
Oligonucleotide Synthesis • • • •
Oligos for daily research Diagnostic oligos Therapeutic oligos (ASOs, siRNAs, etc.) Tailored oligos beyond standard needs
DNA and RNA Analysis • • • • •
Sanger sequencing Illumina and ONT sequencing PCR, qPCR, and digital PCR Genotyping Mycoplasma testing
Contract Research • • • • •
Assay development Assay validation (ICH guidelines) GxP analysis of customer test items Process outsourcing Genomics research
› E. coli NightSeq®: An innovative Sanger sequencing service enabling direct sequencing of plasmids from E. coli and other host strains – saving up to one full working day. › Full PlasmidSeq: A long-read Oxford Nanopore (ONT) sequencing service for plasmids, PCR products, BACs, and other constructs up to 300 kb. Beyond Express sequencing, Microsynth offers a broad portfolio of additional DNA/RNA sequencing solutions. Standardised and custom workflows based on Oxford Nanopore and Illumina technologies support applications ranging from targeted sequencing to complex genomic projects. While our NGS CORE services provide predefined, off-the-shelf solutions with fast turnaround times and an excellent price-performance ratio, NGS CUSTOM services deliver fully tailored solutions to meet specific project requirements. Additional services include DNA/RNA isolation, PCR and qPCR, digital PCR, fragment length analysis, cell line authentication, and mycoplasma testing.
Contract Research Microsynth provides contract research services focused on nucleic acid-based analytical methods in regulated environments. We support assay development, qualification, validation, and sample testing for advanced therapies, including gene, cell, and RNA products. Combining scientific expertise with GMP-compliant execution, we help customers reach key development milestones efficiently through integrated analytical platforms and clear communication.
Quality and Compliance Quality is an integral part of all Microsynth processes. The company operates certified quality management systems and supports projects under ISO and GMP requirements. Our laboratories are accredited according to ISO/IEC 17025, ISO 13485, and ISO 9001, and genetic analysis platforms are certified by Swissmedic for GMPcompliant quality control of medicinal products.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
92 | 93
Name › Navigo Proteins GmbH Business Unit: Navigo Precision Address/P.O. Box › Heinrich-Damerow-Straße 1 Postal Code/City › 06120 Halle/Saale Country › Germany Contact Person › Michael Hamm (Head of Business Development Navigo Precision) Telephone › +49 345 27996-330 Email › info@navigo-proteins.com Website › www.navigo-proteins.com www.navigo-precision.com Social Media › I Number of Employees › 80-90 Founded (year) › 2017 Type of Laboratory S1 Areas of Activity › Precision Medicine, Oncology, Ophthalmology Biological Patents › Extensive patent portfolio in proprietary affinity ligand technology External › ITM, GAIASO Theranostics, Veraxa, Collaborations SCK CEN, AI-DT, University of Leipzig
Pioneering the Next Generation of Precision Medicine Navigo Precision, part of the Navigo Proteins Group, is a German, fast-growing, near-clinical stage, bio pharmaceutical company developing next-generation targeted therapies for Precision Medicine. We have a proprietary AI-driven platform with strong IP-protection for therapeutic proteins called Affilins ®. These are a novel class of target-binding therapeutic proteins, combining the advantages of antibodies and peptides by a smaller size, better tumour penetration, excellent stability and a robust, scalable production process. We have a growing portfolio of targets directly available for partnering and have existing collaborations in the pharmaceuticalindustry with strong players like ITM, SCK CEN or GAIASO Theranostics for the development of targeted therapies in oncology.
Our Mission By leveraging the unique features of Affilin® technology, Navigo Precision is redefining targeted therapeutics, advancing these innovations from the laboratory to clinical development, and ultimately delivering transformative therapies to patients worldwide.
AI-Driven Innovation and Advanced Collaborations Navigo Precision is at the forefront of integrating artificial intelligence with wet-lab capabilities, dramatically enhancing the accuracy and applicability of our research. Collaborations with partners such as AI-DT, Nostrum and the University of Leipzig further accelerate innovation and discovery.
Targeted Therapeutics Powered by Affilin® Target-Binding Proteins Precision medicine is built on the ability to accurately target specific molecular structures, such as TumourAssociated Antigens (TAAs) and checkpoint signalling pathways. At Navigo Precision, we combine deep expertise in protein engineering and drug design with an unwavering commitment to developing innovative targeted therapeutics and diagnostics. Member of
NAVIGO PROTEINS
The Power of Affilin® Design Affilins® can be precisely customised as mono-, bi-, or multi-specific ligands, allowing for tailored therapeutic strategies. They can be seamlessly conjugated with functional moieties, such as cytotoxic payloads or radioactive isotopes, to create highly targeted and potent anti-cancer therapeutics. These therapies address both Tumour-Associated Antigens and immuno-oncology (I/O) targets, offering a versatile platform for advanced cancer treatment. Our expanding portfolio of Affilin® assets demonstrates exceptional pre-clinical results, tackling key challenges in targeted therapy, such as: › Optimising biodistribution for maximal efficacy. › Effectively targeting low- or medium-expressing tumours with high and sustained tumour-specific accumulation, outperforming current benchmarks. Through these innovations, Navigo Precision is driving the development of best-in-class therapies designed to meet unmet medical needs and improve patient outcomes.
Expanding Partnerships for Breakthrough Research To advance cutting-edge science, Navigo Precision is rapidly expanding its network of partnerships. These include collaborations with other leading innovators such as Veraxa and research institutions like SCK CEN, both of which are dedicated to highly innovative, nextgeneration cancer research. A key strength of our platform is its application in radiotheranostics, a field where we have co-founded a new venture, GAIASO Theranostics, focused on developing next-generation therapies for female cancers, which remain among the most pressing areas of unmet medical need in oncology.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
94 | 95
Name › Navigo Proteins GmbH Business Unit: Navigo Pure Address/P.O. Box › Heinrich-Damerow-Straße 1 Postal Code/City › 06120 Halle/Saale Country › Germany Contact Person › Joséphine Hammerlindl (Business Development Manager Navigo Pure) Florian Settele (Head of Business Unit Navigo Pure) Telephone › +49-345-27996-330 Email › info@navigo-pure.com Website › www.navigo-pure.com Social Media › I Number of Employees › 80-90 Founded (year) › 2017 Type of Laboratory S1 Areas of Activity › Downstream processing Custom affinity ligand & resin development Biological Patents › Extensive patent portfolio around proprietary affinity ligand technology
Reinventing purification for biologics Precision Capturing ® is Navigo Proteins’ pioneering affinity chromatography platform within the Navigo Pure business unit that redefines the way biologics are purified. Traditional downstream processing often requires multiple sequential chromatography steps, each of which adds time, cost, and complexity to biologics manufacturing. Precision Capturing® addresses these challenges by consolidating purification into a single, highly efficient capture step. This streamlined approach significantly accelerates process development, improves product quality, and enhances manufacturing efficiency across a wide spectrum of biologics. At the heart of the platform are proprietary engineered scaffold ligands, derived from artificial Protein A scaffolds. These ligands are small, robust, and highly specific, designed to selectively bind even the most challenging biologic molecules. Unlike conventional technologies that are often limited to antibodies with Fc regions, Precision Capturing® enables purification of a diverse range of therapeutic modalities, including antibodies, enzymes, blood factors, vaccines, viral vectors, and non-Fc proteins. This flexibility makes it a truly universal solution for next-generation bioprocessing.
Navigo Pure: from innovation to implementation Precision Capturing ® ligands and resins are already a pplied in EMA- and FDA-approved bioprocesses, proving their regulatory acceptance and industrial reliability. These products are used throughout the entire value chain, from preclinical development to clinical supply and large-scale commercial manufacturing.
Member of
NAVIGO PURE
To bring this platform to market on an industrial scale, Navigo has established Navigo Pure, the dedicated business unit focused on delivering custom ligands and resins for use under GMP standards. Navigo Pure ensures that customers benefit from: › Simplicity & Speed: Fewer purification steps mean shorter timelines, reduced process complexity, and accelerated time-to-market for novel therapies. › Robustness & Yield: The high specificity of Navigo’s ligands enables excellent product quality, improved yields, and more predictable performance under industrial conditions. › Scalability & Regulatory Readiness: With GMPcompliant production and extensive regulatory expertise, solutions are designed to seamlessly support clinical and commercial manufacturing. › Cutting-edge Ligands & Resins: Advanced affinity tools are created for drug classes most in need of efficient chromatographic processes, helping overcome current bottlenecks in biologics production.
25+ years of experience Backed by over 25 years of experience in bioprocessing innovation, Navigo Proteins has become a trusted global partner for affinity purification. Today, the company proudly supports more than 40 organisations, from fast-moving biotech start-ups to established Top-10 global pharmaceutical leaders, in developing and commercialising life-changing therapies. With the Navigo Pure business unit, Navigo Proteins is shaping the future of biologics manufacturing by delivering smarter, faster, and more reliable purification solutions.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
96 | 97
Name › Neovii Biotech GmbH Address/P.O. Box › Am Haag 6+7 Postal Code/City › 82166 Gräfelfing Country › Germany Contact Person › Sebastian Hofmann Telephone › +49-89-898888-0 Fax › +49-89-898888-16 Email › info.germany@neovii.com Website › www.neovii.com Number of Employees › 150 Founded (year) › 2003 Type of Laboratory › BioStoffV S3** cGMP certified production facilities, EU (Annex 1 EU-MP guideline) up to grade A respectively ISO5 (according to EN-ISO 14644-1) Areas of Activity › | Transplantation Medicine | Haematological Oncology External › Academic research institutions and Collaborations other companies
The company The company Neovii Biotech GmbH – as part of the Neovii Group – is dedicated to delivering targeted bio pharmaceutical treatment options in transplantation medicine and haematological oncology. The focus of its activities is the development and commercialisation of immunologically active biopharmaceutical therapeutics based on innovative antibody technologies. All the manufacturing activities are located in Gräfelfing/ Germany. Neovii has a presence in more than 40 countries worldwide. For further details please visit: www.neovii.com
Research and Development Neovii supports research and development activities in the fields of solid organ transplantation, stem cell transplantation, and immune and haemato-oncological disorders. Neovii actively seeks in-licensing and acquisitions opportunities. We are looking to expand our portfolio of products with novel life-transforming therapies that address severe unmet medical needs, in particular in the areas of transplantation, haemato-oncology, and immune disorders.
Areas of interest Since its inauguration Neovii Biotech has been manufacturing and commercialising a medicinal product for the prevention of graft-versus-host-disease after stem cell transplantation and prevention/treatment of acute organ rejection following solid organ transplantation.
Member of
NEOVII
The main fields of our operations are: › Stem Cell Transplantation › Solid Organ Transplantation › Aplastic Anaemia › Autoimmune Diseases Transplantation: ATLGs (Anti-human T-lymphocyte immunoglobulins) – polyclonal antibodies ATLGs are antibody-based medicines for the targeted suppression of immune responses (immunosuppressants). They suppress immune responses by multiple mechanisms, such as immune cell depletion, inhibition of T-cell function, and induction of regulatory immune cells. Their immunosuppressive properties are used mainly in solid organ transplantation and stem cell transplantation. In stem cell transplantation (SCT) polyclonal antibodies are indicated for the prevention of graft-versus-hostdisease (GVHD). GVHD is recognised as a severe complication following SCT that negatively impacts on the patient’s quality of life and is a major cause of morbidity and mortality. In GVHD, transplanted immune cells attack the recipient’s body, causing tissue and organ damage. By suppressing these immune reactions, ATLGs significantly lower the incidence of GVHD (Finke J, et al‚ Lancet Oncot 2009;10(9)1855—64). In solid organ transplantation (SOT), polyclonal antibodies are indicated either for the prevention of organ rejection or to suppress active, acute rejection reactions. The rejection of a transplanted organ is primarily caused by immune cells of the recipient that start attacking the grafted organ, because it is recognised as foreign. By suppressing these immune reactions, ATLGs limit organ damage and prevent graft loss (Kaden J, et al. Ann Transplant. Jan 10 2013;18:9-22). ID-Number: ATM.00003-3.0
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026
98 | 99
Name › New England Biolabs GmbH Address/P.O. Box › Brüningstr. 50 – Geb. B852 Postal Code/City › 65926 Frankfurt am Main Country › Germany Contact Person › Dr. Carsten Lanwert Telephone › +49-69-305-23140 Fax › +49-69-305-23149 Email › info.de@neb.com Website › www.neb-online.de Founded (year) › 1981
NEB – Passion for Science Created by scientists for scientists, New England Biolabs is proud to be a world leader in the discovery and production of enzymes and reagents for molecular biology applications. Since our establishment in 1974, we have remained committed to developing highquality, innovative products that empower not only your research but also our own. Our profits have always funded an extensive research programme, which we believe is critical for staying connected to our customers and helping to drive scientific breakthroughs. From our founding principles to our unique corporate culture, NEB’s philosophy can be distilled down to three core values: passion, humility and being genuine.
Latest Innovation in Enzyme Technology Our outstanding expertise in protein engineering and evolution has led to the creation of unrivaled enzymes and unique workflows in library preparation and target enrichment for the NGS space. These products set the benchmarks for optimal performance and ease of use in modern molecular biology laboratories. Moreover, NEB’s specialised offerings for alternative DNA assembly, isothermal amplification as well as novel reagents for CRISPR/Cas9-based genome editing make us a first-choice supplier for today’s molecular biologists.
Customised Solutions/GMP–grade & Lyophilisation NEB’s customised solutions unit has been delivering tailor-made enzyme formulations and packaging solutions to biotech, pharma and diagnostic customers. Building on an extensive experience, our GMP-grade manufacturing capabilities offer a range of customised products at scale, enabling commercial customers and partners to use NEB’s world-class products in their specific applications and to support them in their efforts to access regulated markets. The recently established subsidiary NEB Lyophilisation Sciences combines expert knowledge in the design, development and manufacture of innovative enzyme solutions for ambient store products to meet our customers small- to large-scale lyophilisation needs.
NEW ENGL AND BIOL ABS
ISO-certified Quality NEB is dedicated to providing research products of the highest quality. Our integrated quality management systems are certified to meet the requirements according to the standards ISO 13485 and ISO 9001.
Social Responsibility & Sustainability
THE BRIDGE TO YOUR SUCCESS Customized Enzymes and Reagents from New England Biolabs Largest selection of enzymes for genomic research Research-grade and GMP-grade production Large to small scale lyophilization capabilities ISO 9001 and ISO 13485 certified Formulations without components such as BSA, detergents or glycerol Enzymes at user defined concentrations Custom aliquoting, kitting, packaging & private label (OEM) www.neb-online.de
While our passion for science helps us to drive discovery, we continue to be guided by our responsibility to each other and our community. We continuously strive to promote ecologically sound practices and environmental sustainability in order to protect our natural resources. As an additional measure, NEB has received ISO 14001 certification, a quality standard for environmental management systems. We also recognise that we must work together to build a more equitable society and improve diversity, equity and inclusion in our workplace.
Basic and Applied Science We believe that basic research and the cultivation of scientific knowledge is critical for us to stay connected with our customers and to drive scientific breakthroughs. At NEB, over 30 labs participate in research projects, which are aided by post-doctoral fellows and students in Masters and PhD programmes. NEB researchers have authored or co-authored over 1,500 publications to date. With a dual focus on basic and applied research, NEB’s culture is both collaborative and academic.
Scientific Customer Service Our support model is unique as it utilises technical support scientists, scientist responsible for product development or manufacturing, and product line experts. As such, customers are supported by scientists and often experts in the product or its application.
New England Biolabs GmbH The NEB subsidiary in Germany represents the service hub for Central Europe. From our location in Frankfurt, we serve scientists and industry customers in Germany and Austria and support our network of distribution partners across Europe. For further information please visit our website at www.neb-online.de. 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 100
| 101
Name › Northway Biotech Address/P.O. Box › Mokslininkᶙ 4 & Melkio 7 Postal Code/City › Vilnius Country › Lithuania Contact Person › Prof. Vladas Algirdas Bumelis (CEO) Telephone › +370-5-210-2247 Email › bd@northwaybiotech.com Website › www.northwaybiotech.com Social Media › I Number of Employees › 180-200 (Vilnius sites) Founded (year) › 2004 Areas of Activity › Biopharmaceuticals, Monoclonal Antibodies, Recombinant Therapeutic Proteins, plasmid DNA, Gene Therapy, Viral Vectors, Contract Development, Contract Manufacture, cGMP Manufacture, Analytical Services/ Testing, Viral Clearance
A Rapidly Expanding End-to-End Biopharmaceutical CDMO Northway Biotech is a contract development and manufacturing organisation (CDMO) specialising in proteinbased biologics and gene therapy, with facilities in the Greater Boston and in Lithuania, an EU member state recognised as an emerging biotechnology hub. The company provides integrated services across the biopharmaceutical value chain, from cell line development to clinical and commercial manufacturing of drug substances and drug products, including antibodies, recombinant therapeutic proteins, plasmid DNA (pDNA), and viral vectors. With 22 years of experience, Northway Biotech has partnered with over 105 clients and completed more than 205 projects. The company is also developing Bio City in Vilnius, a dedicated biotechnology campus with planned long-term investment.
Biologics and Gene Therapy CDMO Services Cell Line Development Capabilities:
External › Northway Biotech cooperates with Collaborations numerous biotech companies and also with some medium-sized companies and three Big Pharma companies.
› Single-cell cloning with analytical confirmation and stability studies for the development of mammalian cell lines › Development of bacterial and yeast strains with stable expression › Full microbial & mammalian cell bank characterisation
Upstream Process Development: › Optimisation of media and feeding strategy at lab scale › Small-scale qualification and process characterisation studies › DOE experiments for yield and quality improvement › Scale-up and confirmation runs (up to 200 L SUB)
Downstream Process Development: › Harvesting (centrifugation, depth-filtration) and cell disruption › Isolation and solubilisation of inclusion bodies followed by refolding of target protein › Protein purification at different scales using various chromatography techniques › Small-scale qualification and process characterisation studies
NORTHWAY BIOTECH
› Rapid technology transfer and scale-up to cGMP manufacturing scale
Viral Clearance Studies: › Early and late-phase VCS meeting FDA/EMA › regulations › Capacity to conduct up to 6 individual studies in › parallel › Available as part of the CDMO services and as standalone service for other CDMOs
Analytical and Formulation Development Capabilities: › Development, qualification, and validation of physicochemical, biochemical, and immunological analytical methods and cell-based bioassays according to ICH guidelines › Characterisation, monitoring, and optimisation of products’ quality attributes across all stages of development › Release and in-process control testing › Formulation development services for liquid and lyo philised drug product in vials and pre-filled syringes › Stability studies
cGMP Manufacturing: › GMP certified facilities › Master and Working Cell Bank (MCB and WCB) manufacturing for microbial and mammalian cell cultures › Microbial fermentation up to 3,000 L working volume in stainless steel reactors › Mammalian cell culture up to 4,000 L working volume in single-use reactors › Viral vectors manufacturing up to 1,000 L working volume in single-use reactors › Plasmid DNA production for gene therapy up to 300 L working volume in single-use reactors › BSL-3 manufacturing capacity up to 200 L › Fill and finish of sterile drug production into vials, pre-filled syringes (PFS) and cartridges › Lyophilisation of aseptic drug product into vials
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 102
| 103
Name › Omicron-Laserage Laserprodukte GmbH Address/P.O. Box › Raiffeisenstrasse 5e Postal Code/City › 63110 Rodgau Country › Germany Contact Person › Natalie Stühler Telephone › +49-6106-8224-0 Email › sales@omicron-laser.de Website › www.omicron-laser.de Social Media › F I I Number of Employees › 99 Founded (year) › 1989 Areas of Activity › Laser, LED, Light Sources, Diode Lasers, Medical Lasers, Medical Systems, CW Light Sources, Customised Laser Systems, Photonics, Laser Development, Laser Solutions, Customised Light Sources, Biotech, Life Sciences, Microscopy, Spectroscopy
Flexible Laser & LED Light Sources for Industry & Science with 36 Months Warranty Omicron-Laser has been developing, manufacturing, and distributing innovative laser and LED light sources since 1989 and is one of the leading manufacturers for demanding applications in biotechnology, microscopy, microlithography, medicine, and many more. Based in Germany, Omicron is specialised in customised solutions in addition to its broad product portfolio. Product development and production comply with European and US guidelines and are conducted according to the ISO9001 and ISO13485 quality standards. Omicron offers CW light sources as well as high-speed modulated systems in the nanosecond and picosecond range, both as single and multi-wavelength solutions.
Important developments based on ISO 9001 and ISO 13485 include: › the LightHUB® laser beam combiner series › the LedHUB® high-power LED light engine › the QuixX® picosecond pulsed diode laser › the PDT medical laser system for cancer treatment › the BrixXLAB multichannel desktop laser for laboratory applications › BrixXHUB Ultra® Highly Integrated Multimode HighPower Light Engine
Highly Integrated Multimode High-Power Light Engine: BrixXHUB Ultra® As the first highly integrated multimode high-power laser light engine on the market, the BrixXHUB Ultra is the perfect fit for applications in widefield laser illumination. The new device is a highly integrated multimode highpower laser light engine with up to 6 high-power BrixX lasers at its core, offering a wide range of wavelengths between 375 and 1550nm at up to more than 5 Watts per wavelength. This, combined with 6 analog and digital modulation inputs, provides unique flexibility to meet dynamic project needs. The system is designed for user-friendly operation and comes fully equipped with all essential accessories, enabling users to promptly
OMICRON-L ASERAGE
start their projects without any delay. In addition, its user-upgradeable design allows for easy customisation, enabling individuals to adapt to evolving project requirements effortlessly.
Flexible Multi-Wavelength Solutions: LightHUB+®, LightHUB Ultra®, LedHUB® Omicron’s innovative LightHUB+® and LightHUB Ultra® laser light engines represent a new form of laser light sources for science, research, and industry based on the ultra-compact LuxX (LuxX+) laser series. The highperformance systems can be equipped with one to six (LightHUB+®) or seven (LightHUB Ultra®) laser modules of different wavelengths from UV to the near IR range and offer rapid analogue intensity modulation with up to 1.5MHz (3MHz and 250MHz digital) and digital full ON/ OFF modulation with a switching time of <1µs for each channel. The individual laser modules can easily be exchanged and added by the user. Hence the systems can be adapted to changing application requirements and are future-proof. The Omicron LedHUB® is a high-power LED light source for biotech, industrial, and analytical applications. With up to 6 different wavelengths between 340 and 940nm it can be used in applications like widefield microscopy, optogenetics, chemical analysis, forensics, and many more. The modular principle of the LedHUB® provides the possibility to start with only one or two wavelengths initially and upgrade by further wavelengths at a later stage. The capability of rapid switching between wavelengths and high-speed analogue modulation of intensity is a key feature for demanding applications.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 104
| 105
Name › Pharmahungary Group Address/P.O. Box › 7 Záhony street, Graphisoft Park Postal Code/City › H-1031 Budapest Country › Hungary Contact Person › Andras Nogradi Telephone › +3630-7900017 Email › businessdevelopment@ pharmahungary.com Website › www.pharmahungary.com Social Media › I Number of Employees › 15+ Founded (year) › 2001 Type of Laboratory › Fully equipped state-of-the-art in vitro, ex vivo, and in vivo laboratories with in vivo imaging capabilities including ultrasound, MRI, CT, fluorescent imager, etc. capabilities. Areas of Activity › Preclinical CRO: | efficacy & safety studies | cardiovascular | infarction | heart failure | renal kidney | musculoskeletal | sarcopenia | inflammation | inflammatory | i n vivo | in vitro, cells | large animals, pigs | extracellular vesicle (exosomes) isolation and characterisation Oligonucleotide discovery and development: | AI-driven miRNA discovery platform | miRNA therapeutics for cardiovascular, oncology, and musculoskeletal indications External › https://www.pharmahungary.com/ partners/ collaborations Biological patents › miRNA patent families: | WO 2013/057527 A2 | WO 2025/003718 A1
More than a CRO, your creative R&D team Pharmahungary Group, a group of innovative R&D companies have a mixed business model: › we provide efficacy and explorative safety studies from cells to large animals focusing on but not limited to cardiovascular, metabolic, renal, inflammation, musculoskeletal, and oncology disease indications › mechanism of action studies including transcriptomics, proteomics, histology, immunohistochemistry, extracellular vesicles isolation and characterization › we discover and develop therapeutic miRNA compounds based on our proprietary AI-driven miRNAmRNA molecular network analysis drug discovery enabling bioinformatics tools
Pharmacology testing platform - from cells to large animals Since 2001 our innovative R&D services include in vitro and in vivo efficacy models with cardiac cells, small and large animal models of cardiovascular, metabolic, renal (myocardial infarction, heart failure, arrhythmias, diabetes, insulin resistance, hyperlipidemia, atherosclerosis, uremia, obesity, etc.), musculoskeletal (e.g. sarcopenia) as well as inflammation, and neuropathy diseases. Customdesigned and cardiovascular co-morbidity models, e.g. myocardial infarction with risk factors and e.g. hyperlipidemia, and diabetes, as well as multicenter studies are also available.
What we offer › innovative preclinical R&D services from in vitro to in vivo efficacy and cardiac safety models including custom-designed co-morbidity, large animal models › extracellular vesicles isolation, and characterization service from any body fluids
What we look for › pharma and biotech companies -> outsource your pharmacology studies to Pharmahungary Group: in vitro and in vivo models of cardiovascular, metabolic, renal, inflammation, musculoskeletal, and oncology diseases from cells to large animals.
PHARMAHUNGARY
Discovery and development of miRNA therapeutics: open for investments and partnering Cardioprotective therapeutic microRNAs Using our miRNA discovery and development platform, we discovered and patented cardioprotective microRNAs (termed protectomiRs) around 4 different miRNA families. The lead candidates (miR-125b* & miR450a) are in small animal proof-of-concept stage. We are seeking co-deve lopment partners and raising capital to further develop the miRNA drug candidates with our 2+ decades of experience as a preclinical R&D service provider that has been involved in more than 350 different drug-development projects. Development in other indications: oncology, inflammation, musculoskeletal, and women’s health.
AI-driven miRNA discovery tool We developed miRNAtarget (www.mirnatarget.com), a bioinformatics tool based on miRNA-mRNA molecular networks analysis, enabling the discovery of therapeutic miRNAs and identify targets and off-targets of miRNA-type oligonucleotides. We offer drug discovery and development partnerships for miRNA development (target and off-target analysis) in various therapeutic indications.
What we offer › IP protected therapeutic miRNA lead compounds for ischemic, oncology, musculoskeletal, and women’s health diseases › bioinformatic tools for the discovery and development of RNA therapeutics
What we look for › co-development partners for miRNA therapeutics (focusing on innovative miRNA chemistry and deli very system) › investors › in-licensing partners
Member of 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 106
| 107
Name › PlasmidFactory GmbH Address/P.O. Box › Meisenstr. 96 Postal Code/City › 33607 Bielefeld Country › Germany Contact Person › Dr. Dirk Winnemöller Dr. Marco Schmeer Telephone › +49-521-2997-350 Fax › +49-521-2997-355 Email › info@plasmidfactory.com Website › www.plasmidfactory.com Social Media › I Number of Employees › 54 Founded (year) › 2000 Areas of Activity › | Customer-specific plasmid and proprietary Minicircle DNA production and amplification – from research to clinical and commercial supply | DNA for Cell & Gene Therapy for Cell & Gene Therapy, including AAV vector manufacturing, gene-modified cell therapy (ex vivo & in vivo), and vaccine development | Minicircle Technology – bacterial backbone-free DNA designed to reduce impurities, enhance safety, and improve functional yields and transfection/transduction performance | Scalable manufacturing capabilities from milligram to gram scale, supporting seamless progression from early development to late-stage supply | In-stock DNA solutions and specialised services, including plasmid linearisation, POLYARESCUE®,
Member of
ITRPROTECT®, ITRRESCUE®, and storage services | Comprehensive quality control and advanced analytics, including CGEbased topology analysis and in-depth characterisation
Custom DNA Manufacturing PlasmidFactory provides customer-specific plasmid and proprietary Minicircle-DNA manufacturing for applications in gene and cell therapy, AAV vector production, vaccination, transfection, drug delivery, and nano-biotechnology. DNA is produced in clearly defined quality grades to support all development stages: Scientific Quality Grade for research and preclinical use, High Quality Grade as starting material for regulated productions (e.g., viral vectors or CAR-T manufacturing), and GMP Quality Grade for clinical and commercial supply.
In-Stock DNA Solutions Selected plasmids and Minicircles are available offthe-shelf for immediate project initiation. These include reporter gene constructs (e.g., GFP, luciferase, lacZ), AAV helper and packaging plasmids (2-PlasmidSystem; pDG/pDP family; multiple serotypes), and S/MARbased vectors such as pEPI/pEpito plasmids.
Specialised Services & Logistics Complementar y ser vices include plasmid DNA l inearisation, POLYARESCUE ®, ITRRESCUE ® and ITRPROTECT®, long-term storage solutions, and coordinated logistics support to ensure secure handling and supply continuity for regulated programmes.
Quality Control & Analytics PlasmidFactory applies comprehensive quality control and advanced analytical methods, including proprietary capillary gel electrophoresis (CGE) for precise characterisation of plasmid topology and structural stability – enabling reliable assessment of DNA integrity, including during storage.
Minicircle Technology Minicircles are circular, supercoiled DNA molecules generated by intramolecular recombination from a parental plasmid. Unlike conventional plasmids, Minicircles do not contain bacterial backbone elements such as origins of replication or antibiotic resistance genes. This backbone-free design improves safety, reduces regulatory complexity, and enhances functional per-
PL ASMIDFACTORY The better way to DNA!
Plasmid & Minicircle DNA
From Research to GMP Grade
formance in therapeutic applications. Minicircles have demonstrated increased transfection efficiency and expression stability, making them a powerful vector system for next-generation gene and cell therapies and beyond. PlasmidFactory holds key intellectual property in this field and provides service manufacturing of these supercoiled monomeric constructs according to customer specifications.
Advanced DNA for Next-Generation Therapeutics
CDMO for customized plasmid & Minicircle DNA DNA up to GMP Grade for cell & gene therapy applications AAV plasmids & Minicircles available off- the-shelf ilable lly ava a b o l • G able n • Scal prove ically n i l C •
PlasmidFactory.com
High-quality plasmid and Minicircle DNA are critical material for advanced therapeutic platforms, including cellular therapies (e.g., CAR-T and other gene-modified cell therapies), AAV vector manufacturing, lentiviral vector production, and nucleic acid-based vaccines. DNA integrity and structural design directly influence safety, expression performance, manufacturability, and regulatory robustness. In cellular therapy applications, Minicircles enhance transfection efficiency and enable stronger, more sustained transgene expression while avoiding bacterial backbone elements that may contribute to cytotoxicity or regulatory concern. Their smaller, supercoiled structure improves gene transfer efficiency, particularly in primary cells, supporting scalable non-viral engineering strategies. In AAV manufacturing, Minicircles eliminate backbone sequences at the source, reducing packaging-related impurities, increasing full capsid rates, and enabling higher functional vector titers with improved transduction performance. Proprietary ITRRESCUE ® and ITRPROTECT® technologies safeguard fragile inverted terminal repeats, while POLYARESCUE® supports stable amplification of challenging polyA sequences for vaccine and nucleic acid applications. Manufacturing is performed in EU-based facilities using scalable, single-use, end-to-end processes that support reliable supply from research through clinical and commercial stages. Beyond Minicircles, PlasmidFactory amplifies virtually any customer-specific DNA construct – including plasmids for lentiviral vectors – with defined quality grades tailored to regulatory requirements.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 108
| 109
Name › ProBioGen AG Address/P.O. Box › Herbert-Bayer-Str. 8 Postal Code/City › 13086 Berlin Country › Germany Contact Person › Dr. Alfred Merz (CEO) Telephone › +49-30-322-935-100 Fax › +49-30-322-935-400 Email › info@probiogen.de cdmo@probiogen.de Website › www.probiogen.de Social Media › I Q Number of Employees › 300 Founded (year) › 1994 Type of Laboratory S1, S2 Areas of Activity › l Biopharmaceutical development and GMP manufacturing l Proprietary technologies to enhance product characteristics and process efficiency l Designer cell lines l Vector platforms Biological Patents › ProBioGen holds numerous international patents on technologies to improve product quality/potency and enhance cellular productivity. External › With many international companies Collaborations and research organisations, e.g. Boehringer Ingelheim, Bayer, Charité, Novartis, etc. Request for › ProBioGen works with biotech and Further Collaborations pharma companies that develop (complex) therapeutic proteins and antibodies or viral vaccines and viral vectors.
Intelligent Biopharmaceutical Solutions ProBioGen is a Berlin based CDMO, specializing in the development and manufacturing of biopharmaceutical active ingredients, viral vectors and vaccines through proprietary technologies to improve product quality and features. Combining state-of-the-art development services and intelligent product-specific technologies results in biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and GMP-compliant manufacturing is performed by a highly skilled and experienced team.
Unique Services Cell line & process development for therapeutic proteins › CHO.RiGHT® expression system › DirectedLuck® transposase for efficient gene delivery & high titers › Proprietary chemically defined (CD) media platform/ multiple suppliers › Robust and economic platform processes › Classic and intensified processes › Reports to support investigational new drug (IND) filing › Modular services and open source concept
(GMP) Manufacturing for therapeutic proteins › Cell banking (MCB/WCB) › Up to 1000 L TOX manufacturing › 2x up to 1000 L GMP manufacturing › Disposable, stirred tank bioreactors
Development services for various viral vectors › Tailor-made solutions for the production of e.g. lentiviral and adenoviral vectors, AAV and MVA › Suitable cell substrates for the propagation of various viral vectors in suspension processes using CD medium › Robust upstream and downstream processing supported by comprehensive analytical tools › Cost-effective non-cGMP production for preclinical development phase
(GMP) Manufacturing for various viral vectors Member of
› Cell banking (MCB, WCB) and virus banking (MSV/WSV) › Up to 200L TOX manufacturing
PROBIOGEN
› Up to 200L GMP manufacturing (up to biosafety level 2) › Aseptic filling of drug product and diluent under GMP conditions
Analytics, bioassays & quality management
Your Biologics. ® Elevated.
› Integrated analytical development › Validation according to bioanalytical guidelines (EMA/FDA) › Stability studies in accordance with ICH Q1 › Wide range of cell based and binding activity assays › Various cell based and instrumental analyses for content and identity testing of viral vectors and vaccines
Innovative Technologies GlymaxX® ADCC enhancement & glyco-engineering › Prevents antibody fucosylation › Boosts ADCC cell-killing activity against tumors and infected cells › Applicable to both novel and existing producer cell lines › Allows adjustment of fucose, galactose, and sialic acid levels in glycoproteins
DirectedLuck® – Transposase system › Proprietary transposase for efficient gene delivery › Generates high-titer clones (up to 8 g/L) › Superior heterodimer rates for bi-specific mAbs
Lenti.RiGHT® packaging and producer cell line › GMP qualified starter cell bank based on HEK 293 › Efficient LV production in CD medium (107-108 TU/ml) › No requirement of GMP-grade plasmid DNA or transfection reagent › Straightforward purification of lentiviral particles for e.g. CAR-T therapies
AGE1.CR® Designer cell line & MVA viral vaccine manufacturing platform › Avian suspension cell line permissive for numerous human and veterinary viral vaccine strains › GMP-compliant chemically defined media and scalable suspension processes › Proprietary MVA strain, transgene expression design, and technology for rapid generation of recombinants
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 110
| 111
Name › ProJect Pharmaceutics GmbH Address/P.O. Box › Fraunhoferstrasse 22 Postal Code/City › 82152 Martinsried Country › Germany Telephone › +49-89-45-22-89-700 Fax › +49-89-45-22-89-717 Email › info@project-pharmaceutics.com Website › www.project-pharmaceutics.com Social Media › I Founded (year) › 2010 Type of Laboratory › Contract research and development (CRO); cytotoxic (≤OEL5); BSL-1; BSL-2; fee-for-service business model; 2-4 weeks start up time; slim and reliable timelines; GLP-like quality standards; submission-compliant documentation Areas of Activity › Analytical characterisation; preformulation screening; formulation development; freeze drying cycle development; lyophilisation process and scale-up; technology transfer Biological Patents › Several patents in freeze drying and formulation External › | Network for seamless development Collaborations from pre-clinic to fill/finish and market. | Formulation specialist for DS and DP CMOs worldwide. | Partnered with Bi-nex for CDMO services on mAb DS (cell line & process development, manufacturing). | Local company representation in APAC and U.S.A. | Credited laboratory for Wyatt Technology in Europe. Request for › | Small biotechnology/mid-size pharma companies, large top players in Further Collaborations pharma/biotechnology. | From DSP development to early and late drug product phases up to life cycle management. | Customised solutions for challenges in formulation, analysis or process.
ProJect Pharmaceutics is a leading independent European CRO specialised in formulation and manufacturing process development for injectables: biologics (rec. proteins, antibodies, fusion proteins), peptides, ADCs, cytotoxics, small molecules, generics, viral therapeutics, ATMPs, VLPs and other nanoparticular drug delivery systems. We apply innovative, quality-by-design based, rational concepts of pharmaceutical development according to ICHQ8 and other guidelines. We support our global customers in developing a consistently high-quality pharmaceutical product that is transferable, scalable and manufacturable under GMP conditions. ProJect Pharmaceutics is managed by experts with >30 years of experience in the pharmaceutical industry. In about 850 m2 we operate special laboratories for biologics, cytotoxics and a BSL-2 unit, equipped with dedicated industrial HOF pilot freeze dryers.
Protein formulation › Predictive formulation analytics: a QbD-based highthroughput approach for accelerated development › Pre-formulation, early state & late phase formulation › Liquid & lyophilised formulation (DoE-based)
High concentration protein formulation › Low viscosity formulation for s.c. application › UF/DF process development › Syringeability evaluation
Cytotoxic small molecules A deep understanding of the challenges when processing highly potent drugs, such as limited solubility in water and rapid degradation, paired with long-lasting experience and comprehensive know-how of lyophilisation from various organic solvents enables us to provide specific solutions for high potency & cytotoxic drugs.
Antibody-drug conjugates (ADCs) › Predictive, high-throughput formulation development › High-end freeze-drying technology By combining protein formulation and process know-how with cytotoxic drug expertise the company holds unique assets to develop ADCs. On top we offer complementary formulation and process development of intermediate antibody & linker-payload bulk.
PROJECT PHARMACEUTICS
Peptide formulation › Formulation and lyophilisation cycle development
Innovative liposome technology › High encapsulation efficiency (hydro- & lipophilic APIs) › GMP-compatible manufacturability with standard equipment
Viral-based therapeutics › Lyophilised formulation and cycle development
In-use stability studies › Evaluation of DP compatibility with IV line equipment
Freeze drying › In vials, dual chamber systems, syringes, cartridges, bulk trays or bags, containers in nest&tub configuration › Out of organic solvents › Rational cycle development (robust, collapse-safe, cost & time efficient, tailored to the formulation) › Bulk lyophilisation (solid or powder) › SEM structural analysis of lyo cake › Time lapse video & IR thermal camera monitoring › Aseptic pre-clinical batch manufacturing › Robustness & design space evaluation › Smooth technology transfer to GMP
Process development and manufacturing › DSP: Smart optimisation of UF/DF & purification steps targeting a common DS/DP formulation › Container closure system compatibility › Forced stress, in-use & accelerated stability studies › Detergent & excipient quantification › Sterile filtration study › Manufacturability assessment › Fill&finish process mock-up › Aseptic pre-clinical batch manufacturing
Fill&finish As state-of-the-art development experts we are teamed up with state-of-the-art contract manufacturing experts to provide high-quality parenterals from pre-clinical to clinical and commercial scale.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 112
| 113
Name › Promega Corporation Address/P.O. Box › 2800 Woods Hollow Road Postal Code/City › Madison, WI 53711 Country › USA Telephone › +1-608-274-4330 Fax › +1-608-277-2516 Website › www.promega.com Social Media › F I I Number of Employees › 2,200+ Founded (year) › 1978 by William A. Linton Areas of Activity › | High quality reagents & kits for all types of DNA, RNA and protein analysis; cell-based & biochemical assays for analysis of cellular processes; MSI diagnostics; cell systems for therapeutic antibodies including LOT release assays. | Integrated Systems including instruments, chemistries and personalized support that simplify the process of automating research in the lab. | Custom manufacturing | Onsite Stocking | Automation Support | Tailored R&D Solutions Annual turnover › $775m USD Biological Patents › Promega holds hundreds of patents in the areas of: | Bioluminescence | Cellular Analysis | Cell biology | Drug Discovery
Fuelled by curiosity. Powered by exploration. Promega Corporation is a global leader in biotechnology, biochemistry, and cellular and molecular biology, developing innovative technologies for the Life Sciences. Based on bioluminescent technology innovations, Promega offers a broad portfolio of functional reporter bioassays, primary cell-killing assays, and immuno assays, used for R&D or QC batch release of therapeutic antibodies and cell/gene therapies. Promega’s services are designed to accelerate your biologics drug discovery and development workflows.
Discover Promega The company’s portfolio of over 4,000 products supports a range of life sciences work across areas such as cell biology; DNA, RNA, and protein analysis; drug development; human identification; and molecular diagnostics. For over 40 years, Promega’s products have been used in labs for academic/government research, forensics, drug discovery, clinical diagnostics, as well as agricultural and environmental testing.
Let’s work together to power ideas for tomorrow and the next 100 years. Promega supports research and development worldwide with innovative products, technical advice, and service. As a partner of pharmaceutical and biotechnology companies, Promega offers special fillings and formulations of enzymes as well as the production of specialised materials such as reporter cell lines, e.g. CRISPR-modified cell lines based on luminescent Promega technologies. From simple changes in product size or packaging to the development of custom assays and high-throughput solutions, Promega’s custom offerings cover a breadth of capabilities in manufacturing, technology development, assay automation, and inventory management. (www.promega.com/custom-solutions/)
Corporate Responsibility Since 2008, Promega has reported on its commitment to and progress regarding sustainability. In addition, Promega has been an active participant in the UN Global Compact for almost a decade. Sustainability is a core value across the entire company, from the way Promega
PROMEGA
designs its buildings and develops its products, to how Promega cultivates its vision of meaningful business. (www.promega.com/corporate-responsibility-csr/) Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors, serving over 100 countries.
Our Branches in Europe: Promega GmbH, Walldorf, Germany (covering Germany, Austria, Poland, and Eastern-Europe) Tel: + 49-6227-6906-0 Email: de_custserv@promega.com Promega Biotech Iberica SL, Madrid, Spain (covering Spain and Portugal) Tel: +34-916621126 Email: esp_custserv@promega.com Promega Italia S.R.L., Milan, Italy Tel: +39-2-54-05-01-94 Email : marketing.it@promega.com Promega UK Limited, Southampton, UK Tel: +44-23-8076-0225 Email: ukmarketing@promega.com Promega AG, Dübendorf, Switzerland (covering Switzerland and Liechtenstein) Tel: +41-44-878-90-00 Email: ch_custserv@promega.com Promega Benelux, Leiden, Netherlands (covering Benelux and Rwanda) Tel: +31-71-532-42-44 Email: benelux@promega.com Promega Nordic, Nacka, Sweden (covering Nordic countries and Estonia) Tel: +46-8-452-24-50 Email: sweorder@promega.com Promega France, Charbonnières-les-Bains, France Tel: +33-800-488-000 Email: FR.support@promega.com 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 114
| 115
Name › PSM GmbH Address/P.O. Box › Am Nusskopf 39 Postal Code/City › 66578 Schiffweiler Country › Germany Contact Person › Thorsten Haefner Telephone › +49 6821 2959 60 Email › service@psm-saar.de Website › www.psm-saar.de Social Media › I F I Q Number of Employees › ~ 110 Founded (year) › 2020 Type of Laboratory › Contract Development Manufacturing Services (CDMO) for biopharmaceuticals including monoclonal antibodies, biosimilars, small molecules and diluents. Capabilities to process pre-fillable syringes (PFS), vials, and cartridges. Areas of Activity › Our End-to-End CDMO Services | Analytical services | Method and process development | Cold-chain logistics, including lowtemperature handling down to –70 °C | Compounding | Aseptic filling or filling with terminal sterilisation | Visual inspection and secondary packaging | GMP storage and GDP transport
Your Pharma CDMO for Aseptic Filland-Finish Services PSM GmbH is a family-run German company that operates as a Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry, located in Schiffweiler in the state of Saarland in Germany.
From Clinical Development to Commercial Manufacturing As an end-to-end CDMO, we provide services for the entire implementation process and lifecycle of your drug, from clinical phases to commercial GMP manufacturing. Our portfolio includes method and process development, in-house analytical services, aseptic fill-andfinish services, visual inspection with CCIT, secondary packaging with serialisation, as well as GMP storage and GDP transport.
State-of-the-Art EU GMP Annex 1 Approved Facility With our state-of-the-art facility, we are proud to be one of the first European CDMOs to have passed the inspection by the local authorities under the new EU GMP Annex 1. Our facility has been inspected and approved by the local regulatory authorities in 2024. All the equipment, from fill and finish to secondary packaging, is designed to process all common ready-to-use primary packaging containers, including pre-fillable syringes up to 10 mL, vials up to 50 ml, and cartridges up to 10 mL, made of glass or polymer. This flexibility enables us to offer fill-and-finish services for biopharmaceutical drugs like monoclonal antibodies, biosimilars, small molecules and diluents (e.g. WFI). Our current processes can accommodate batch sizes of up to 600 litres.
Highest Product Yields for Orphan Drugs For very high-value biological drugs like monoclonal antibodies, we use the most sophisticated human-free robotic fill-and-finish technologies with isolator tech-
PSM
nology to minimise product loss throughout the entire processing cycle for batch sizes of up to 100 litres. Our services include the handling of low-temperature drugs of -70° C and the controlled thawing process of frozen API.
Your Benefits in Working with Us Fast Decision-Making Processes: Flat hierarchies in our family-owned business ensure fast decision-making processes, making your project a success within the agreed timeline. Focused Collaboration and Customised Solutions: We are approachable, easy to work with, and offer customised solutions to integrate your project requirements into our processes and equipment. Agility and Flexibility: Changing requirements during a project are embraced rather than rejected. Reliability and Transparency: We want to be your reliable partner and ensure the highest level of transparency in all processes relevant to your product. Relationship-Based Decision-Making: We base our decisions not simply on short-term commercial aspects, but also on your product’s long-term success.
Our Mission In order to support patients and improve their quality of life, we put passion into our daily work, focus on pharmaceutical excellence and use the latest fill-andfinish technologies and processes. We offer the most advanced, agile and, above all, GMP-compliant endto-end solutions for aseptic contract manufacturing. psm-saar.de
Watch our video showcasing biopharmaceutical fill-and-finish processes.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 116
| 117
Name › QUANTRO Therapeutics GmbH Address/P.O. Box › Helmut-Qualtinger-Gasse 2 Postal Code/City › 1030 Vienna Country › Austria Contact Person › Dr Michael Bauer Telephone › +43-122-66001 Email › contactus@quantro-tx.com Website › www.quantro-tx.com Social Media › I Number of Employees › 16 Founded (year) › 2019 Type of Laboratory Research and Discovery Areas of Activity › | Time resolved transcriptomics | Measure transcriptional dynamics | R&D pipeline and discovery platform | Drugging previously undruggable transcription factors External › | Boehringer Ingelheim Oncology Collaborations | Institute for Molecular Pathology IMP, Vienna, Austria
QUANTRO Makes Transcription Factors Druggable QUANTRO Therapeutics’ proprietary technology, the precise and time-resolved, direct quantitative measure of transcriptional dynamics at any point in time, is defining a new state of the art in transcriptomic drug discovery. We have successfully established a pioneering transcriptomic drug discovery platform technology, which unleashes the potential of drugging previously undruggable transcription factor targets. Our platform has been validated on >10 different oncology and inflammation targets, is currently running at a capacity of approx. 100´000 compounds tested in our high-throughput dual target screening. Taking drug discovery to a next level we established the first 10-target multiplex assay, moving from individual target screening to compound library profiling for multiple targets simultaneously. QUANTRO’s technology has been successfully used in several HTS campaigns and created functionally validated and proprietary hit libraries against several key oncogenic transcription factors, thereby successfully building an innovative drug discovery pipeline for our own drug development programmes and our strategic partner Boehringer Ingelheim Oncology.
The Transcription Factor Challenge Due to the complexity of protein-protein-DNA interactions, the investigation of transcription factors requires cell-based assays. Many of these targets are intrinsically disordered proteins, thereby escape traditional discovery or rational design approaches, hence they have been and still are largely considered undruggable. Consequently, the discovery of transcription factor targeting drugs has been difficult and transcription factor related therapies remain an unmet medical need for patients, representing untapped opportunity for innovative drug discovery. Member of
QUANTRO THERAPEUTICS
QUANTRO Defines a New State of the Art in Transcriptomic Drug Discovery RNAseq based methods have been used for transcriptomic discovery; however, this technology is limited to quantification of mRNA abundance in absence of understanding transcriptional dynamics. Changes of transcriptional dynamics occur within minutes; therefore, primary transcriptional effects and their molecular targets remain invisible to RNAseq based methods. Reporter assays using green flourescent protein are also too slow and only cover a mixture of primary, secondary and distant pathway effects.
3D visual © Biolution GmbH
Contrary to these limitations, QUANTRO’s transcriptomic technology precisely measures time-resolved changes of transcriptional dynamics, at any point in time. We capture direct primary on-target effects and differentiate these from downstream signalling-pathway effects. By matching transcriptional “fingerprints” derived from acute degradation of transcription factor proteins with corresponding “fingerprints” triggered by small m olecules, we successfully identify drugs targeting previously undruggable transcription factors. Our first-in-class oncology pipeline focuses on “undruggable” targets using our time-resolved functional transcriptomics discovery platform to identify modulators, activators, and inhibitors of gene transcription with unmatched precision. We are successfully building our proprietary R&D pipeline and continue advancing our strategic collaboration with Boehringer Ingelheim. Backed by Boehringer Ingelheim Venture Fund (BIVF) and Evotec as SEED investors, QUANTRO pursues a dual strategy of venture financing and strategic partnering to advance our innovative first-in-class pipeline towards clinical development. QUANTRO is currently fundraising for SERIES A to take the company to clinical stage. In parallel we are open for strategic partnering with leading pharma companies to broaden the target space in oncology and additional indications. 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 118
| 119
Name › Rentschler Biopharma SE Address/P.O. Box › Erwin-Rentschler-Str. 21 Postal Code/City › 88471 Laupheim Country › Germany Contact Person › Dr. Latika Bhonsle-Deeng, Global Head of Communications Telephone › +49-7392-701-0 Fax › +49-7392-701-300 Email › communications@ rentschler-biopharma.com Website › www.rentschler-biopharma.com Social Media › I I Number of Employees › 1,400 Founded (year) › 1872 Type of Laboratory › S1 Areas of Activity › Contract development and manufacturing organization (CDMO) for biopharmaceuticals, including complex therapeutic proteins External › Strategic collaboration with Vetter, Collaborations headquartered in Ravensburg, Germany, for high quality aseptic filling and secondary packaging Request for › Rentschler Biopharma offers Further Collaborations bioprocess development and cGMP manufacturing solutions from concept to market for pharma and biotech companies in long-term collaborations and strategic collaboration settings.
Member of
A world-class biopharmaceutical CDMO Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, and operations in Milford, MA, USA. In 2024, the company joined the United Nations Global Compact, emphasizing Rentschler Biopharma’s focus on sustainability.
Your trusted partner to commercialisation and beyond The company offers process development and manufacturing of biopharmaceuticals, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma is highly experienced in the development and cGMP manufacturing of monoclonal antibodies, designer proteins, and other therapeutic biotherapeutics in compliance with international standards (EMA/ FDA). Working collaboratively with its clients, Rentschler Biopharma provides customised solutions with customised work packages for each development stage. State-of-the-art cGMP facilities and cell culture processes are leveraged for manufacturing for both, clinical studies and commercial supply. Consistent monitoring of the international regulatory landscape and in-depth understanding of the necessary regulatory documentation (CMC), ensures that each project is properly documented in accordance with international regulatory requirements. The company works in a strategic collaboration with Vetter for aseptic manufacturing & packaging. The desired goal of the collaboration with Vetter is the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.
RENTSCHLER BIOPHARMA
Bioprocess development › Fast and efficient supply for multiple candidate screening › Fed batch, n-1 perfusion and continuous processes › Robust and scalable CHO cell line development platform › Flexible purification platform for any protein format › Well-established analytical methods
cGMP biomanufacturing › Multiple stainless steel bioreactor lines, including a twin system with 2x 3,000 L › Flexible single-use bioreactor lines up to 2,000 L › State-of-the-art purification processes › Guaranteed product quality and purity in accordance with cGMP guidelines › For clinical and commercial supply
Rentschler Development Services The company provides tailored service offerings for best-fit solutions for client projects. “Velocity” offers fast-track development for Phase I/II, “Flexibility” is for fully customized projects, “Liberty” offers standalone activities and work packages.
Dual-site approach in Europe and the USA From its headquarters in Germany, and its site in Milford, MA, USA, the company offers end-to-end solutions that address clients’ clinical and commercial needs right in their target market. Rentschler Biopharma’s state-of-the-art Milford, MA site primarily focuses on the production of highly complex molecules for international clients and and boasts 22,000 square feet of manufacturing cleanroom space and four 2,000 L single-use bioreactors. As a world-class solution provider, we ensure optimum time-to-clinic and time-to-market by accelerating timelines to create competitive advantage for our clients. For seamless market approval, we consult and assist clients with regulatory queries, develop optimised strategies, and generate complete documentation for approval of clinical studies and market launch. 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 120
| 121
Name › Richter BioLogics Address/P.O. Box › Suhrenkamp 59 Postal Code/City › 22335 Hamburg Country › Germany Contact Person › Dr Thilo Kamphausen Telephone › +49-40-55290-451 Fax › +49-40-55290-888 Email › BusinessDevelopment@ richterbiologics.eu Social Media › I Number of Employees › > 400 Founded (year) › 1987 Areas of Activity › Contract development and manufacturing organisation (CDMO) Biological Patents › Several patents on manufacture of proteins and pDNA (pART process) External › Biotech and Pharma companies Collaborations worldwide Request for › Richter BioLogics offers CDMO Further Collaborations services from gene to finished product. Our teams provide top level solutions to bring your product to market. Contact us for more details.
High class GMP-compliant microbial production of biopharmaceuticals – Plasmid DNA and Proteins Richter BioLogics is a leading and expanding Germanybased contract development and manufacturing organisation (CDMO) specialised in a broad range of products derived from bacteria and yeasts. With over 35 years experience in GMP manufacturing, Richter BioLogics provides its clients with a unique knowledge base in process and analytical validation, process performance qualification (PPQ) procedures, commercial production of therapeutic proteins, antibody-like scaffolds (e.g., VHH/ Nanobodies, Fab-fragments), bacterial vaccines, and plasmid DNA (pDNA) products.
Your product – our competence and dedication Our focus is on our customers, their needs, timelines and quality requirements. Our seasoned, highly educated, and motivated teams support the global pharmaceutical and biotechnological industries with one-stop-shop services ranging from strain/process development to analytical development, manufacturing, QC testing and filling of finished product. In addition to our headquarters, we operate three GMP compliant facilities with biorector capacities of 2x 1,500L and 2x 300L to provide manufacturing solutions for large and commercial scales. Further space and connections exist to install more capacity as needed by the customer.
Quality is our DNA
Member of
Richter BioLogics consistently works to the highest standards of pharmaceutical quality as verified by major regulatory bodies including but not limited to EMA, FDA, PMDA, ANVISA, MFDS, and more, as well as by numerous customer audits. Throughout the company teams have excellent expertise in the development and cGMP-compliant production of biopharmaceuticals. To ensure efficient, timely and transparent work, we apply professional project management methods and an integrated Quality Management System. The quality system
RICHTER BIOLOGICS
at Richter BioLogics meets the strictest standards of quality in biopharmaceutical production.
Products and services Our process development team possesses extensive experience in developing and optimising fermentation and purification processes. For initial strain development, a variety of proprietary E. coli expression systems are available to support strain selection. Small-scale models of existing processes provide helpful tools for trouble shooting, process characterisation, and validation and ensure a smooth scale-up to large-scale cGMPcompliant manufacture. Additionally, our in-house QC testing covers development and validation of a variety of analytical methods (incl. biological assays), performance of stability studies, and characterisation of reference standards.
Richter BioLogics offers a full range of biopharmaceutical manufacturing services: › Establishment of cell banks (MCB/WCB) › In-house QC testing and release › Stability studies according to ICH guidelines › Strain and process development › pART proprietar y process– pDNA for different purposes at scales needed › cGMP manufacturing for clinical phases I to III › Commercial cGMP manufacturing › Process validation and PPQ procedures Thanks to the broad knowledge of Richter BioLogics’s experts and many decades of experience gained from different kinds of projects, Richter BioLogics works out tailor-made solutions for its customers worldwide, which include large pharmaceutical companies as well as advanced biotech companies. We manage each of our customer projects individually and with the utmost dedication and flexibility - a guarantee for a successful and ongoing partnership.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 122
| 123
Name › SciRhom GmbH Address/P.O. Box › Am Klopferspitz 19 (IZB) Postal Code/City › 82152 Martinsried Country › Germany Contact Person › Dr. Jan Poth Telephone › +49-89-614241230 Email › info@scirhom.com Website › www.scirhom.com Social Media › I Number of Employees › 9 Founded (year) › 2016 Areas of Activity › Preclinical and early clinical development of therapeutics with novel mode of action, treatment of autoimmune and inflammatory diseases, key inflammation pathways, iRhom2/TACE signal transduction biology Biological patent › Comprehensive international patent portfolio External › Hospital for Special Surgery, New York, collaborations expert academic collaborators, highly reputable Contract Research Organisations
SciRhom and its Vision SciRhom is a pioneering biotech enterprise with the vision to translate advanced scientific findings into game-changing therapies for the treatment of autoimmune and inflammatory diseases. Based on a decade of ground-breaking research by Prof. Carl Blobel, M.D., Ph.D., co-founder of SciRhom and Director of the Arthritis and Tissue Degeneration Program at Hospital for Special Surgery, New York, SciRhom is developing first-in-class antibodies against the cellular target protein iRhom2 for the selective inhibition of the inflammatory master switch TACE.
SciRhom’s Approach TACE (TNFα converting enzyme or ADAM17) controls several major signalling pathways in health and disease, including TNFα, IL-6R, and EGFR signalling, and has therefore been considered a highly attractive target to block pro-inflammatory pathways. However, direct inhibition of TACE causes severe side effects, such as skin and intestinal lesions, since it leads to the blockade also of physiologically important and protective pathways. Very recently, iRhom2 (inactive Rhomboid 2, RHBDF2) was discovered as the exclusive key regulator of TACE for the disease-associated release of TNFα, IL-6R, and HB-EGF from immune cells. In contrast, the activation of TGFα as a crucial mediator of skin and intestinal barrier function is supported by both iRhom2 and its closely related family member iRhom1. SciRhom’s highly specific antibodies against only iRhom2 open the exciting opportunity to selectively and simultaneously target the iRhom2-mediated pro-inflammatory activities of TACE, while preserving its iRhom1-supported protective functions important for normal physiology. This new mode of action allows for a highly efficacious but safe treatment of various disorders, including major debilitating autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and lupus glomerulonephritis.
SCIRHOM
SciRhom’s Asset
The Innovation & Gründerzentrum Biotechnologie (IZB) in Martinsried near Munich, home of a number of biotech companies (© IZB)
Illustration of iRhom1/TACE and iRhom2/TACE complexes and their role in driving inflammatory processes (iRhom2/TACE) as well as protecting the skin & intestinal barrier (iRhom1/TACE and iRhom2/TACE)
SciRhom’s key asset is a series of first-in-class humanised monoclonal antibodies (mAbs) against iRhom2 with excellent physicochemical, pharmacokinetic, and pharmacological properties. Reflecting the simultaneous blockade of several disease-driving pathways and the restoration of immune-balancing mechanisms, our antibodies have proven superior efficacy over the current standard of care single pathway inhibitors Humira, Remicade, RoActemra, and Skyrizi in various disease mouse models. Further to the unique mode of action, our anti-iRhom2 antibodies promise a better tolerability and a real disease-modifying effect. The CMC development of the clinical candidate SR-878 and its toxicological assessment were successfully completed. Based on the previous series A financing round, SciRhom has entered SR-878 into clinical development with the goal to ultimately demonstrate clinical proof-of-concept in two indications. SciRhom’s antibodies are protected by four strong patent families that cover the antibodies themselves, their iRhom2 target epitopes, as well as their therapeutic use until 2039.
SciRhom’s Management Our management team unites several decades of biotech and big pharma experience in advancing therapeutics into early clinical development and beyond, and consists of › Jan Poth, Ph.D., Managing Director & CEO › Jens Ruhe, Ph.D., Co-Founder, Managing Director & COO › Matthias Schneider, Ph.D., Co-Founder & CSO › Jürgen Reeß, M.D., Ph.D., CMO
Inhibiting iRhom2/TACE complexes by binding our antibody to iRhom2 simultaneously blocks a number of pathways driving inflammation, while the physiological effects, such as skin & intestinal barrier protection, are preserved through the activity of unaffected iRhom1/TACE complexes
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 124
| 125
Name › Valicare GmbH
Valicare – Partner for strategic life cycle management in the GMP industry
Address/P.O. Box › Eschborner Landstrasse 130-132 Postal Code/City › 60489 Frankfurt on the Main Country › Germany Contact Person › Dr. E. Sons-Brinkmann Telephone › +49-69-153-293-700/709 Email › info@valicare.com Website › www.valicare.com Social Media › I Number of Employees › > 100 Founded (year) › 2002
GMP regulations become more and more complex, challenging and time consuming. Lack of actual regulatory knowledge, human resources and short timelines are only some of the hurdles.
Areas of Activity › GMP Services for Pharma and Biotech with a special focus on Cell and Gene Therapies.
Valicare is not only a GMP service supplier but also a partner for strategic life cycle management in the GMP industry. Knowing the business inside out, we support you efficiently from R&D to manufacturing of sterile medicinal products and cell and gene therapies, compliant to EU-GMP and Annex 1. We enable seamless processes and offer sustainable solutions for any step of your GMP process from advice and guidance to practical on-site support.
About the company: Valicare GmbH is headquartered in Frankfurt/Main since 2002 and a subsidiary of Syntegon Technology GmbH, a leading supplier of process and packaging technology and life cycle management. Valicare is ISO 9001:2015 certified and has a subsidiary (joint venture) in Turna, Slovakia. Around 120 experts work in GMP projects worldwide. Multidisciplinary teams of engineers and scientists, experienced project managers, and senior GMP consultants support customers in the pharma, biotech, and medical device industries and manufacturers of cell and gene therapy products. More than 5000 GMP projects have been successfully completed worldwide. Our approaches are always riskbased, and as efficient as possible.
Our services: High-level GMP (and GxP) consulting support: › GMP, GAP, and target-performance analyses for every GxP topic and for quality systems according to DIN EN ISO 9001 and DIN EN ISO 13485 › Implementation or adaptation of GMP QA systems
VALICARE
› Structuring and moderation of workshops (risk analysis, risk assessment) › Design and planning of GMP-compliant project workflows › Definition of high-level process or project specifications (URS) › GMP concepts for risk, change, or deviation management or validation strategies › GMP for new and rebuild projects › Documentation services (basic and demanding)
Risk-based, integrated qualification and validation support in compliance with GMP, especially Annex 15. Our services include, but are not limited to: › Design review, plant-specific technical and process risk analyses › Qualification of equipment from laboratory to large machines and (clean) rooms, FAT, SAT, AFT › Preparation of qualification documentation and definition of test conditions › Calibration and requalification after modernisation, HMI upgrades after format change › Qualification and validation of biodecontamination processes in isolators as well as of inspection systems › Validation of manufacturing processes, cleaning processes, analytical methods, and computer systems
Our passion: Accelerating GMP for cell and gene therapies › Expert advice on the development, transfer, and implementation of straight and GMP-compliant ATMP manufacturing processes › Our turnkey manufacturing concepts (valicare.tainer; cult.tainer), consisting of fully equipped GMP- and Annex 1 compliant cleanroom modules, enable aseptic process development and manufacturing of ATMPs, accompanied and supported in all GMP issues by our experts on-site.
COCREATE & COSUCCEED to reduce time to market.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 126
| 127
Name › Vetter Pharma International GmbH Address/P.O. Box › Eywiesenstrasse 5 Postal Code/City › 88212 Ravensburg Country › Germany Contact Person › Lars Hahn Telephone › +49-751-3700-0 Email › EU and other international inquiries: info@vetter-pharma.com US inquiries: infoUS@vetter-pharma.com Asia Pacific inquiries: info@vetter-pharma.com Website › www.vetter-pharma.com Number of Employees › 7,300 Founded (year) › 1950 Areas of Activity › Drug product development, aseptic clinical and commercial fill and finish, device assembly and packaging, analytical services, regulatory support, logistic services
We place heightened focus on your success as your strategic partner We produce aseptically prefilled syringes, cartridges, vials and dual-chamber systems as a globally operating CDMO partner. We are a family-owned, independent company rooted in 75+ years of history. We do not manufacture our own drugs – we focus on providing highly skilled support and state-of-the-art manufacturing resources. We support our customers from the initial phases of clinical drug product development and filling to commercial manufacturing, device assembly and packaging, and lifecycle management. Over 80% of our active projects are biologics.
We are a reliable, responsive, and progressive partner Our portfolio of services includes dedicated resources for clinical development and commercial manufacturing as well as assembly and packaging, and more. We provide tailored solutions to meet your product’s specific market needs.
Services › Drug Product Development Support in navigating key early decisions in your product’s evolution with scalability, quality and efficiency in mind. › Aseptic Filling & Visual Inspection Comprehensive expertise in manufacturing injectable drug products and related visual inspection systems. › Device Assembly & Packaging Strategic, technical and packaging support for patient-friendly combination products. › Analytical Services Robust, customizable testing methods for drug products including evaluation and quality verification. › Regulatory Support Support to achieve milestones related to compliance during clinical development, market authorization and beyond. › Logistic Services Cutting-edge solutions that maximize efficiency, transparency and precision of a vital supply chain.
VETTER PHARMA INTERNATIONAL
Fast facts: Vetter-at-a-glance › Headquartered in Ravensburg, Germany › Commercial production sites in Ravensburg and Langenargen, Germany › Dedicated clinical production facilities in Rankweil, Austria, and Chicago, USA › Branch offices for Asia Pacific in Singapore, Japan, South Korea, and China › More than 7,300 employees worldwide › A leading specialist in the development, aseptic production, assembly and secondary packaging of prefilled drug delivery systems › International expertise with regulatory authorities including FDA, EMA, PMDA (Japan), and RP (Germany) › Service offerings for pharma and biotech firms of all sizes and locations › Numerous patents including technologies for protection against tampering and counterfeiting › Lyophilization (freeze-drying) and siliconization specialist
For more information, please scan the QR code.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 128
| 129
Name › X-act Cologne Clinical Research GmbH Address/P.O. Box › Rudi-Conin-Strasse 4 Postal Code/City › 50829 Cologne Country › Germany Contact Person › Olivia F. Hoffmann, Sales & Marketing Manager Jasmin Atarodi, Managing Director Andreas Fichtner, Head Biostatistical Services Ilka Strehlau, Head Clinical Data Management Telephone › +49-221-337716-0 Fax › +49-221-337716-33 Email › business@x-act-cologne.com Website › x-act-cologne.com Social Media › I Number of Employees › 35+ Founded (year) › 1994 Areas of Activity › Clinical Data Management Biostatistical Services Medical Writing
Your Trusted Partner in Clinical Data Management, Biostatistics and Medical Writing From study planning to regulatory submission, we provide comprehensive support to ensure top quality and compliance. Our expert team offers tailored, efficient services that optimise processes, easing our clients’ workload. Committed to excellence and reliability, we support our clients in advancing medical research to deliver groundbreaking therapies globally. Let’s shape the future of healthcare together.
Company Overview Type: Owner-managed CRO Founded: 1994 Location: Cologne, Germany Experience: 500+ successful studies (interventional Phase I – IV, non-interventional, medical device) Team: 35 + seasoned and technology proficient team members contribute to the success of your project.
Biostatistical Services › Consulting: Answering scientific questions with expert statistical advice › Study Design: Sample size determination, inclusion of statistical input in protocols › Randomisation: Customised randomisation plans and implementation › Analysis Plans: Statistical Analysis Plans (SAP) with focused programming › Statistical Programming: SAS Programming of individualized tables, figures, and listings › Data Mapping: SDTM and ADaM standards for study submission support › Reporting: Comprehensive biostatistical reports for studies, publications, or dossiers
X-ACT COLOGNE
Clinical Data Management › Consulting: Providing strategic, tailor-made eClinical solutions › CRF Design and Implementation: Aligning with CDISC | CDASH standards › Documentation: Creating essential data management documents for project success › Best Practices: Implementing Good Clinical Data Management Practices › Procedures: Supported by robust and harmonised SOPs › Collaboration: Work closely with the clinical team and medical experts to review and clean data › Reporting: Offering comprehensive status updates for clarity and transparency
Medical Writing › Protocol Development: Implementation of expert input › Interpretation: Digesting the results of the statistical analysis. Aligning the outcome with the study objectives. Discussing the outcomes with key stakeholders. › Study Report: Comprehensive authoring and logically structured presentation.
Interested in our Services? Contact us at: business@x-act-cologne.com
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 130
| 131
Name › YMC Europe GmbH Address/P.O. Box › Schöttmannshof 19 Postal Code/City › 46539 Dinslaken Country › Germany Contact Person › Dr. Carsten Weber Telephone › +49-2064-427-0 Fax › +49-2064-427-222 Email › info@ymc.eu Website › www.ymc.eu Social Media › I Q Number of Employees › 50 (Europe) 485 (worldwide) Founded (year) › 1993 Areas of Activity › | Glass Columns for Lab and Pilot Scale | Prepacked Glass Columns | Laboratory Services | Preparative Liquid Chromatography | Analytical Liquid Chromatography
Your resource for chromatography As a research-driven chromatography specialist, YMC provides chromatographic solutions for compounds such as peptides and proteins, mAbs, and ADCs, as well as oligonucleotides from R&D scale through scale-up to production and final quality control in your lab. We supply innovative bio-chromatography resins and columns for preparative processes, as well as highly reproducible BioLC-(U)HPLC-columns for SEC, IEX, RP, & HIC. Furthermore, YMC glass columns in laboratory as well as pilot scale are designed to meet bio-chromatographers’ demands. You can choose them empty as well as prepacked according to your requirements by YMC’s inhouse packing service. In addition, you can make use of on-demand services for application support, screening, analytical, or preparative method development. Trainings on different chromatographic topics complement the products and services.
Innovations The most recent and interesting developments include: › The new standard for columns for bio-purification suitable for self-packing: YMC PilotPLUS › Macro-porous AEX resin for the purification of large biomolecules: MacroSep IEX Q › Innovative solutions for BioLC: YMC-Triart Bio (U) HPLC columns, also available in bioinert hardware The broad and continuously growing portfolio of stationary phases especially designed for the separation of biomolecules provides high flexibility for the chromatographer and ensures successful lab results, day after day. Additionally, the availability of particle sizes from analytical to preparative scale guarantees smooth and easy scale-up processes.
YMC EUROPE
Worldwide availability and support YMC products are available worldwide through a dedicated support network that guarantees qualified and meaningful practical assistance with regard to method development, method transfer, method validation, purification services, and custom column packing – locally, personally, and efficiently. It is not only product specifications that represent YMC quality, but also the positive energy and dynamics of our employees, who provide competent and consistent performance together with pronounced reliability even for the most difficult and demanding separations. The YMC network consists of highly focused product specialist teams to provide active support for chromatographers.
Regulatory Support Since all YMC processes and working procedures are thoroughly monitored and documented, YMC resins and glass columns are fully compliant with requirements. Full technical documentation is available to show compliance with all applicable regulations.
16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 132
| 133
Name › YUMAB GmbH Science Campus Braunschweig-Süd Address/P.O. Box › Inhoffenstr. 7 Postal Code/City › 38124 Braunschweig Country › Germany Contact Person › Dr. Inga Hochnadel Telephone › +49-531-481170-0 Email › info@yumab.com Website › www.yumab.com Social Media › I Number of Employees › 30 Founded (year) › 2012 Type of Laboratory › S1, S2 Areas of Activity › | Fully human antibody discovery & lead development | Antibody Libraries | Engineering & Humanization | R&D services (CRO) | Partnered innovation Request for › YUMAB seeks clients & partners for Further Collaborations human antibody development in the biopharma, biotech, & diagnostic industries.
Accelerating Biotherapeutic Innovation YUMAB is a German biotech company offering contract and partnered research for the development of therapeutic antibodies from target to optimised lead candidates. The company was founded in 2012 with the aim of providing state-of-the-art and next-generation recombinant antibody technologies to researchers from early start-ups to biotech and biopharma industry, helping them to bridge the gap between research innovation and therapeutic application. Since then, the company has evolved into a global player advancing biomedicine by accelerating the development of next-generation biotherapeutics.
Translating Innovation by Technologies The YUMAB ® antibody platform provides access to challenging targets, supports all antibody drug modalities and accelerates the development of biotherapeutics by addressing the needs of manufacturing and clinical development through advanced protein engineering and lead optimisation technologies. The company delivers fully human and humanised therapeutic antibody candidates that are the closest to the natural human antibody repertoire. Our highly diverse, fully human antibody libraries contain >1011 natural antibody sequences and specificities to all types of antigens. In addition, YUMAB can also access very broad immune repertoires from different immunised animal species (mouse, rat, rabbit, chicken, llama …), maximising epitope and functional diversity to identify the optimal drug candidate for each target and any modality. Our powerful in-vitro discovery technologies are efficient for rare and difficult target antigens and allow for the pre-design of functional and biophysical properties. Antibody candidates are identified rapidly within weeks. They are highly developable into all antibody drug formats including full-length IgG, Fab, scFv, bi- and multispecific, CAR, fusion proteins, and ADCs. Our advanced protein engineering technologies include in silico and experimental platforms that deliver lead candidates with desirable biophysical properties and lowest immunogenicity optimal for manufacturing and clinical development.
YUMAB
Proven Success
Therapeutic antibody discovery & development
From Target to Lead
Our antibody platform has been proven in over 400 projects with more than 140 customers and partners worldwide, and by several drug candidates in clinical development. In 2020, YUMAB spun out CORAT Therapeutics to bring its proprietary COVID-19 antibody drug into the clinic in just 11 months. The virus-neutralising antibody COR-101 is uniquely designed to treat patients with high viral loads by not inducing unwanted immune responses. In addition, YUMAB is involved in numerous collaborations to develop novel technologies such as AI-assisted discovery and development, target discovery on tumour samples, mammalian display or TCR-like antibodies (TCRm).
Trusted and Collaborative Partner YUMAB offers customised service and partnering con cepts to accelerate the translation of your research innovation into drug development, with affordable entry costs, flexible licensing options, and no additional thirdparty obligations. Our team of experts is committed to close communication with clients and partners, providing advice and guidance throughout the antibody discovery and early development process.
YUMAB at a Glance Therapeutic antibody platform › Fully human libraries for low immunogenicity › Broad immune repertoires of different species including close to human germline humanisation › Canine & feline antibody libraries for animal health › Optimised in vitro selection for difficult targets › Rapid discovery within weeks
Direct link to lead development › Advanced antibody lead development & optimisation › All antibody modalities, all disease areas › Robust, adjustable process, high success rates
YUMAB® platform › Fully integrated discovery & development platform from target to optimised lead › Modular projects with flexible entry & exit points
Flexible services, collaborations & partnering › Fee-for-service & flexible licensing options › No technology access fee › Collaborative development 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 134
| 135
Start ups
LOOPL AB
Name › LoopLab Bio GmbH Address/P.O. Box › Muthgasse 11 Postal Code/City › 1190 Vienna Country › Austria Contact Person › Mag. Simona Neubauer, MBA Jochen Stritzker, PhD Telephone › +43-676-84-34-96-771 Email › Simona.neubauer@looplab.bio Website › www.looplab.bio Social Media › I Number of Employees › 19 Founded (year) › 2023 Type of Laboratory Biotechnology research and development laboratory Areas of Activity › Immunology-driven drug discovery, Fc-Engager fusion proteins, autoimmune disease treatment
LoopLab Bio is a Vienna-based biotechnology startup developing a novel class of Fc-Engager fusion proteins to induce antigen-specific immune tolerance. Built on a proprietary platform, its technology selectively targets inhibitory Fcγ receptors to reprogram pathogenic immune responses, enabling precise modulation without broad immunosuppression. The modular platform supports applications in autoimmune and allergic diseases, as well as prevention of anti-drug antibody (ADA) responses, aiming to deliver durable therapeutic benefit rather than chronic symptom control.
Facility – Vienna, Austria LoopLab Bio’s Vienna research facility serves as the central hub for its immune tolerance platform. The site supports molecular biology, protein engineering, and immunology research across discovery and preclinical programs. An interdisciplinary team with expertise in immune modulation, Fc biology, and biologics development enables rapid design, optimization, and evaluation of Fc-Engager candidates. Flexible laboratory infrastructure allows multiple programs to progress in parallel.
Overall Goals
Member of
LoopLab Bio aims to transform treatment of immune-mediated diseases by restoring antigen-specific tolerance instead of broadly suppressing immunity. Its first-in-class Fc-Engager fusion proteins engage disease-relevant antigens and inhibitory Fcγ receptors to selectively silence pathogenic pathways while preserving protective immunity. Through multiple preclinical programs, the company seeks to replace lifelong therapies with short-course or one-time treatments that durably restore immune balance, reduce patient burden, and lower longterm healthcare costs. 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 136
| 137
OPST
Name › OPST GmbH Address/P.O. Box › Wettersteinstr. 1 Postal Code/City › 82024 Taufkirchen Country › Germany Contact Person › Marc Niwar Telephone › +49-1514-491-77-30 Email › info@opst.solutions Website › www.opst.solutions Social Media › I Number of Employees › 5 Founded (year) › 2023 Areas of Activity › | AKTA service and support | chromatography / purification systems (new and refurbished) | synthesizers and liquid handling equipment (new and refurbished) | refurbishment and resale of laboratory systems | service, maintenance and repair support | spare parts supply | synthesis building blocks and reagents | user training and project support
Synthesis & purification: equipment, service, reagents Who we are OPST GmbH (Oligo Peptide Service Technology) supports laboratories and production environments with reliable equipment and practical service concepts to keep systems available and processes efficient. We combine technical know-how with hands-on workflow understanding and clear communication. With 30+ years of combined experience in oligo/peptide production and lab equipment service, we take a pragmatic, solution-driven approach.
What we do OPST provides service, maintenance, repair support, and spare parts for laboratory systems, with a strong focus on AKTA chromatography systems and purification workflows. We refurbish used systems for resale in line with defined technical specifications and also supply laboratory equipment (new and refurbished) for synthesis, purification and related workflows. In addition, we provide building blocks and reagents (e.g. special phosphoramidites and supports, dyes/labels, clickchemistry reagents). We assist with on-site implementation, offer user training on the equipment and advise on device selection and process setup for new or expanding production environments.
RIANA THERAPEUTICS
Address/P.O. Box › Veterinaerplatz 1 Postal Code/City › 1210 Vienna Country › Austria Contact Person › Anna Orlova, PhD Email › office@rianatx.com Website › www.rianatx.com Social Media › I Number of Employees › 5 Founded (year) › 2023 Areas of Activity › | Oncology therapeutics | Acute myeloid leukaemia (AML) | Protein-protein interaction inhibitors | STAT5 signalling & transcription factors | Small-molecule drug discovery | Precision oncology
© Thomas Suchanek
Name › RIANA Therapeutics
Patient-centred innovation targeting STAT5 to overcome AML resistance RIANA Therapeutics is a female-led, Vienna-based biotech startup developing first-in-class small molecule therapies for patients with acute myeloid leukemia (AML) and other STAT5-driven cancers. Our mission is to address urgent unmet needs by targeting mechanisms that current treatments fail to control, including FLT3positive AML, where relapse rates remain high despite targeted therapies. RIANA focuses on STAT5, a key driver of disease progression and therapy resistance in AML. Although STAT5 is a central resistance node, it has long been considered undruggable due to challenging protein–protein interaction interfaces. Our approach selectively disrupts STAT5 oligomerization, which is essential for its oncogenic activity, while preserving physiological function. By targeting resistance at its molecular root, we aim to complement existing therapies such as FLT3 and BCL-2 inhibitors and improve patient outcomes.
Member of
With a lean structure and strong external expertise, RIANA is advancing from validated hits toward lead identification and preclinical development, preparing for its first seed round in 2026. 16TH EUROPEAN BIOTECHNOLOGY GUIDE 2026 138
| 139
Become partner of the next edition 2027! Media Contact:
Andreas Macht Sales & Marketing Tel. +49-30-264921-54 andreas.macht@knowb.io
VOLUME 16
2026 978-3-928383-98-1
16th European Biotechnology Guide
Proven Expertise and Customized End-To-End Solutions for Your Products Clinical & Commercial
Over 100 years of trusted Drug Substance Cell Culture / Microbial: 200L – 800L – 2000L and Fill-Finish Solutions • •
• •
Oncolytic Viruses
Drug Substance Manufacturing
Drug Product Manufacturing
Recombinant Proteins Monoclonal Antibodies
Process Development
Vaccines
• •
Gene & Immune Therapeutics
Science & Industry
Biosimilars
Labeling & Packaging
European Biotechnology Guide
Quality Control & Analytics
Seamless project integration and a reliable supply chain – powered by our expert transfer team. Contact us
IDT Biologika Dessau-Rosslau, Germany
www.idt-biologika.com
2026
Proud to be part of the SK bioscience family.
Publication Partners